1,3,4-Oxadiazolinone compounds and drugs

By developing 1,3,4-oxadiazolinone compounds as PIM kinase inhibitors, the problem of difficulty in inhibiting PIM kinase in the prior art has been solved, and effective treatment for a variety of diseases has been achieved.

CN113302184BActive Publication Date: 2024-11-22NIPPON SHINYAKU CO LTD
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
CN201980089037.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-11-15
Filing Date
2019-11-14
Publication Date
2024-11-22
Estimated Expiration
2039-11-14

AI Technical Summary

Technical Problem

Existing technologies are difficult to effectively inhibit PIM kinase, making it difficult to treat a variety of diseases it is involved in, such as multiple sclerosis, cancer and infectious diseases.

Method used

A class of 1,3,4-oxadiazolinone compounds or pharmaceutically acceptable salts or solvates thereof have PIM kinase inhibitory effects for use as inhibitors of PIM kinases.

Benefits of technology

These compounds can effectively inhibit PIM kinase, thus showing therapeutic effects in the treatment of diseases involving PIM kinases such as systemic lupus erythematosus, lupus nephritis, etc.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113302184B_ABST
    Figure CN113302184B_ABST
Patent Text Reader

Abstract

The object of the present invention is to provide a compound having PIM inhibitory activity. As the present invention, for example, a 1,3,4-oxadiazolinone compound or a pharmaceutically acceptable salt or a solvate thereof represented by the following formula [1] can be cited. The compound of the present invention has PIM inhibitory activity. In addition, since the compound of the present invention has PIM inhibitory activity, it is useful as a therapeutic agent for systemic lupus erythematosus, lupus nephritis, etc. [Chemical Formula 1] #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to 1,3,4-oxadiazolinone compounds and drugs. Background Art

[0002] Protein kinases are enzymes that phosphorylate proteins, which control various biological functions such as cell proliferation, survival, differentiation, and organ formation. The PIM kinase family is a protein kinase that phosphorylates serine and threonine groups, including PIM1, PIM2, and PIM3. PIM1, PIM2, and PIM3 each recognize substrate proteins and have repeated functions, but there are differences in expression tissues. It is known that the functions of PIM kinases are involved in transcription and translation, and control cell proliferation and survival (for example, see non-patent document 1). In addition, for activation, unlike other kinases that require phosphorylation, PIM kinases have the characteristic of being constantly activated. It is known that the expression of PIM kinases is induced by cytokines and proliferation factors, and the induction mediated by cytokines is mediated by the JAK / STAT pathway. Other PI3K / AKT pathways related to cell survival are also known to share substrates such as BAD and 4EBP1 (for example, see non-patent document 2). As described above, it is believed that PIM kinases act downstream of the JAK / STAT pathway and share substrates with the PI3K / AKT pathway, and therefore PIM inhibitors have similar efficacy to inhibitors of the above two pathways.

[0003] According to studies on gene-deficient mice, it was reported that mice with triple gene deficient PIM1, PIM2, and PIM3 were confirmed to have reduced body size but survived (for example, see Non-Patent Document 3). Therefore, it is presumed that PIM inhibitors have a good safety profile. In addition, it is known that PIM kinases are involved in immune responses and inflammatory responses, and based on the safety profile of PIM inhibitors, effectiveness against immune abnormalities and inflammatory diseases can be expected. Specifically, it is believed to be effective for the following diseases: multiple sclerosis (for example, see Patent Document 1), rheumatoid arthritis (for example, see Non-Patent Document 4), food allergy (for example, see Non-Patent Document 5), asthma (for example, see Non-Patent Document 6), systemic lupus erythematosus (for example, see Patent Document 1 and Non-Patent Document 4), lupus nephritis (for example, see Patent Document 1 and Non-Patent Document 4), inflammatory bowel disease (for example, see Non-Patent Document 7), ulcerative colitis (for example, see Non-Patent Document 8), atopic dermatitis (for example, see Non-Patent Document 9), autoimmune lymphoproliferative syndrome (for example, see Patent Document 1), chronic obstructive pulmonary disease (for example, Non-Patent Document 10), allergic respiratory disease (for example, Non-Patent Document 11), eosinophilic granulomatosis with polyangiitis (for example, Non-Patent Document 9), eosinophilic syndrome (for example, Non-Patent Document 9), chorioamnionitis (for example, Non-Patent Document 12), ankylosing spondylitis (for example, Non-Patent Document 4), myasthenia gravis (for example, Non-Patent Document 13), and psoriasis (for example, Non-Patent Document 14).

[0004] It has been reported that PIM kinases are highly expressed in a wide range of blood cancers and solid cancers and are involved in the development of pathological conditions. For example, prostate cancer (e.g., see non-patent document 15), colorectal cancer (e.g., see non-patent documents 16 and 17), esophageal cancer (e.g., see non-patent documents 18 and 19), ovarian cancer (e.g., see non-patent document 20), uterine cancer (e.g., see non-patent document 21, 22, and 23), kidney cancer (e.g., see non-patent document 24), liver cancer (e.g., see non-patent document 25), pancreatic cancer (e.g., see non-patent document 26), gastric cancer (e.g., see non-patent document 27), breast cancer (e.g., see non-patent document 28), lung cancer (e.g., see non-patent documents 29 and 30), head and neck cancer (e.g., see non-patent document 31), glioma (e.g., see non-patent documents 32 and 33), osteosarcoma (e.g., see non-patent documents 34, 35, and 36), bladder cancer (e.g., see non-patent document 37), acute lymphocytic leukemia (e.g., see non-patent document 38), acute myeloid leukemia (e.g., see non-patent document 39), chronic lymphocytic leukemia (e.g., see non-patent document 40), and leukemia (e.g., see non-patent document 41). For example, see Non-Patent Document 40), chronic myeloid leukemia (see Non-Patent Document 41), B-cell lymphoma (see Non-Patent Documents 42, 43, 44), multiple myeloma (see Non-Patent Documents 45, 46), T-cell lymphoma (see Non-Patent Document 47), skin cancer (see Non-Patent Document 48), Kaposi's sarcoma (see Non-Patent Document 49), Hodgkin's lymphoma (see Non-Patent Document 50), myeloproliferative neoplasms (see Non-Patent Document 51), adenoid cystic carcinoma (e.g., Non-Patent Document 52), Ewing's sarcoma (e.g., Non-Patent Document 53), adult T-cell leukemia (e.g., Non-Patent Document 54), mesothelioma (e.g., Non-Patent Document 55), acute promyelocytic leukemia (e.g., Non-Patent Document 56), choriocarcinoma (e.g., Non-Patent Document 57), liposarcoma (e.g., Non-Patent Document 58), neuroblastoma (e.g., Non-Patent Document 59), seminoma (e.g., Non-Patent Document 60), lymphoblastic lymphoma (e.g., Non-Patent Document 46), etc. Based on the above, PIM inhibitors are useful in the treatment of these cancers.

[0005] In addition, since PIM kinase is located downstream of the JAK / STAT pathway, it is expected to be effective even for diseases in which the JAK / STAT pathway is considered to be abnormal, such as Crohn's disease, irritable bowel syndrome, pancreatitis, diverticular disease, Graves' disease, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, vasculitis, autoimmune thyroiditis, dermatitis, scleroderma, vitiligo, graft-versus-host disease, Sjogren's syndrome, and glomerulonephritis.

[0006] PIM kinases are also involved in infectious diseases. For example, there are Epstein-Barr virus infection or hemophagocytic syndrome in which Epstein-Barr virus is known to be involved (for example, see Non-Patent Document 61), influenza (for example, Non-Patent Document 62), hepatitis C (for example, Non-Patent Document 63), Salmonella infection (for example, Non-Patent Document 64), herpes virus infection (for example, Non-Patent Document 65), Trichomonas vaginalis infection (for example, Non-Patent Document 66), human granulocytic ehrlichiosis (for example, Non-Patent Document 67), etc. In addition, for aplastic anemia (for example, see Non-Patent Document 68), atherosclerosis (for example, see Non-Patent Documents 69 and 70), pulmonary hypertension (for example, see Non-Patent Document 71), diabetes (for example, Non-Patent Documents 69 and 70), prostatic hypertrophy (for example, Non-Patent Document 72), and Alzheimer's disease (for example, Non-Patent Document 73), it has been reported that PIM kinases contribute to the pathological conditions, suggesting the usefulness of PIM inhibitors.

[0007] PIM kinase has been reported to have an inhibitory effect on the production of autoantibodies (see, for example, Patent Document 1). Therefore, effectiveness can be expected even for nephrotic syndrome, polymyositis, dermatomyositis, mixed connective tissue disease, dilated cardiomyopathy, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, pemphigus, pemphigoid, and neuromyelitis optica in which autoantibodies are involved.

[0008] Prior art literature

[0009] Patent Literature

[0010] Patent Document 1: International Publication No. 2010 / 022076

[0011] Non-patent literature

[0012] Non-patent literature 1: Nawijn et al., Nat. Rev. Cancer, 2011, 11, 23-34.

[0013] Non-patent document 2: Mondello et al., J. Hematol. Oncol., 2014, 7, 95.

[0014] Non-patent document 3: Mikkers et al., Mol. Cell. Biol., 2004, 24, 6104-6115.

[0015] Non-patent document 4: Lin et al., Int. Immunopharmacol., 2015, 28, 859-865.

[0016] Non-patent document 5: Wang et al., J. Allergy Clin. Immunol., 2012, 130, 932-944.

[0017] Non-patent document 6: Vries et al., Eur. Respir. J., 2016, 47, 783-791.

[0018] Non-patent document 7: Jackson et al., Cell Immunol., 2012, 272, 200-213.

[0019] Non-patent document 8: Shen et al., Dig. Dis. Sci., 2012, 57, 1822-1831.

[0020] Non-patent literature 9: Andina et al., J. Allergy. Clin. Immunol., 2009, 123, 603-611.

[0021] Non-patent document 10: Yang et al., Pathol. Res. Pract., 2017, 213, 322-326.

[0022] Non-patent document 11: Shin et al., Am. J. Respir. Cell Mol. Biol., 2012, 46, 488-497.

[0023] Non-patent document 12: Lim et al., Mol. Hum. Reprod., 2017, 23, 428-440.

[0024] Non-patent document 13: Egli et al., PLoS One, 2015, 10, e0142741.

[0025] Non-patent document 14: Perera et al., Sci. Transl. Med., 2014, 6, 223ra22.

[0026] Non-patent document 15: Kirschner et al., J. Natl. Cancer. Inst., 2014, 107, dju407.

[0027] Non-patent literature 16: Weirauch et al., Neoplasia, 2013, 15, 783-794.

[0028] Non-patent literature 17: Peng et al., PLoS One, 2013, 8, e76693.

[0029] Non-patent document 18: Li et al., Oncol. Rep., 2010, 24, 997-1004.

[0030] Non-patent literature 19: Liu et al., J. Surg. Oncol., 2010, 102, 683-688.

[0031] Non-patent literature 20: Xie et al., Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2014, 39, 649-657.

[0032] Non-patent document 21: Rimon et al., Int. J. Oncol., 2004, 24, 1325-1338.

[0033] Non-patent literature 22: Jimenez-Garcia et al., Oncotarget, 2017, 8, 58872-58886.

[0034] Non-patent literature 23: Liu et al., Oncotarget, 2015, 6, 8019-8035.

[0035] Non-patent document 24: Mahalingam et al., Br. J. Cancer, 2011, 105, 1563-1573.

[0036] Non-patent document 25: Fujii et al., Int. J. Cancer, 2005, 114, 209-218.

[0037] Non-patent document 26: Li et al., Cancer Res., 2006, 66, 6741-6747.

[0038] Non-patent document 27: Warnecke-Eberz et al., Anticancer Res., 2009, 29, 4451-4455. Non-patent document 28: Braso-Maristany et al., Nat. Med., 2016, 22, 1303-1313.

[0039] Non-patent document 29: Kim et al., Pharmacol. Res., 2013, 70, 90-101.

[0040] Non-patent document 30: Jin et al., PLoS One, 2012, 7, e48575.

[0041] Non-patent document 31: Peltola et al., Neoplasia, 2009, 11, 629-636.

[0042] Non-patent literature 32: Herzog et al., Neuro-Oncol., 2015, 17, 223-242.

[0043] Non-patent literature 33: Iqbal et al., Oncotarget, 2016, 7, 33192-33201.

[0044] Non-patent document 34: Mou et al., Int. J. Oncol., 2016, 49, 2116-2126.

[0045] Non-patent document 35: Liao et al., J. Orthop. Res., 2016, 34, 1185-1194.

[0046] Non-patent document 36: Narlik-Grassow et al., Carcinogenesis., 2012, 33, 1479-1486. ​​Non-patent document 37: Foulks et al., Neoplasia, 2014, 16, 403-412.

[0047] Non-patent document 38: Padi et al., Oncotarget, 2017, 8, 30199-30216.

[0048] Non-patent document 39: Burger et al., J. Med. Chem., 2015, 58, 8373-8386.

[0049] Non-patent document 40: Chen et al., Blood, 2009, 114, 4150-4157.

[0050] Non-patent document 41: Fan et al., Mol. Med. Rep., 2017, 16, 4603-4612.

[0051] Non-patent document 42: Kuo et al., Am. J. Cancer Res., 2016, 6, 2489-2501.

[0052] Non-patent document 43: Yang et al., Blood, 2012, 120, 3491-3500.

[0053] Non-patent document 44: Hsi et al., Leuk. Lymphoma, 2008, 49, 2081-2090.

[0054] Non-patent document 45: Keane et al., Blood Cancer J., 2015, 5, e325.

[0055] Non-patent document 46: Paino et al., Clin. Cancer Res., 2017, 23, 225-238.

[0056] Non-patent document 47: Martin-Sanchez et al., PLoS One, 2014, 9, e112148.

[0057] Non-patent literature 48: Shannan et al., Oncotarget, 2016, 7, 54897-54912.

[0058] Non-patent document 49: Bajaj et al., Virology, 2006, 351, 18-28.

[0059] Non-patent document 50: Szydlowski et al., Blood, 2017, 130, 1418-1429.

[0060] Non-patent literature 51: Mazzacurati et al., Oncotarget, 2015, 6, 40141-40157.

[0061] Non-patent literature 52: Xu et al., Cancer Cell Int., 2018, 18, 22.

[0062] Non-patent document 53: Mukaida et al., Cancer Sci., 2011, 102, 1437-1442.

[0063] Non-patent document 54: Bellon et al., Blood, 2016, 127, 2439-2450.

[0064] Non-patent literature 55: Mawas et al., Int. J. Oncol., 2017, 50, 1029-1034.

[0065] Non-patent literature 56: Zhang et al., Pharmacol. Rep., 2017, 69, 1270-1281.

[0066] Non-patent document 57: Mary Photini et al., Exp. Cell Res., 2017, 359, 275-283.

[0067] Non-patent document 58: Nga et al., Int. J. Exp. Pathol., 2010, 91, 34-43.

[0068] Non-patent literature 59: Brunen et al., Mol. Cancer Ther., 2018, 17, 849-857.

[0069] Non-patent document 60: Jimenez-Garcia et al., Sci. Rep., 2016, 6, 38079.

[0070] Non-patent document 61: Rainio et al., Virology, 2005, 333, 201-206.

[0071] Non-patent document 62: de Vries et al., Eur. Respir. J., 2015, 45, 1745-1748.

[0072] Non-patent document 63: Park et al., J. Virol., 2015, 89, 10073-10086.

[0073] Non-patent document 64: Rogers et al., Sci. Signal., 2011, 4, rs9.

[0074] Non-patent document 65: Cheng et al., PLoS Pathog., 2009, 5, e1000324.

[0075] Non-patent document 66: Sutcliffe et al., PLoS Pathog., 2012, 8, e1002801.

[0076] Non-patent literature 67: Lee et al., Genomics, 2006, 88, 496-503.

[0077] Non-patent literature 68: Chiocchetti et al., Haematologica, 2005, 90, 1453-1462.

[0078] Non-patent literature 69: Wang et al., Oncotarget, 2017, 8, 88320-88331.

[0079] Non-patent document 70: Kaneto et al., Mediators Inflamm., 2010, 2010, 453892.

[0080] Non-patent literature 71: Paulin et al., Circulation, 2011, 123, 1205-1215.

[0081] Non-patent literature 72: He et al., Med. Oncol., 2009, 26, 303-308.

[0082] Non-patent document 73: Velazquez et al., Mol. Neurodegener., 2016, 11, 52. Summary of the invention

[0083] Problems to be solved by the invention

[0084] The object of the present invention is to provide compounds having PIM kinase inhibitory activity.

[0085] Solutions to Solve Problems

[0086] The present inventors have made intensive studies and have found that a 1,3,4-oxadiazolinone compound represented by the following general formula [1] or a pharmaceutically acceptable salt thereof or a solvate thereof (sometimes referred to as the compound of the present invention in the specification) has a PIM kinase inhibitory effect, thereby completing the present invention.

[0087] That is, the present invention can include the following inventions (Item 1) to (Item 14).

[0088] (Item 1) a 1,3,4-oxadiazolinone compound of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof,

[0089] [Chemical formula 1]

[0090]

[0091] [Wherein,

[0092] X 1 is a carbon atom or a nitrogen atom,

[0093] X 1 When it is a carbon atom, R 1 is a hydrogen atom, a halogen atom, an alkyl group, an alkenyl group, a non-aromatic carbocyclic group, a dihaloalkyl group, a trihaloalkyl group, an alkoxy group, a dihaloalkoxy group, a trihaloalkoxy group, an alkylsulfonyl group, a cyano group, an aromatic carbocyclic group, or an aromatic heterocyclic group,

[0094] X 1 When it is a nitrogen atom, R 1 does not exist,

[0095] R 2 is a hydrogen atom, a halogen atom, an alkyl group, a non-aromatic carbocyclic group, a trihaloalkyl group, a pentafluorosulfanyl group (SF5), a cyano group, an amino group, or a nitro group,

[0096] R 1 and R 2 Together with adjacent atoms, they can form an indazole ring.

[0097] R 3 is a hydrogen atom, a halogen atom, or an alkyl group,

[0098] X 4 is a carbon atom or a nitrogen atom,

[0099] X 4 When it is a carbon atom, R 4 is a hydrogen atom, a halogen atom, or an alkyl group,

[0100] X 4 When it is a nitrogen atom, R 4 does not exist,

[0101] Among them, X 1 and X 4 These two are not nitrogen atoms.

[0102] L is a linking bond, an alkylene group, an alkenylene group, an alkynylene group, or a group represented by the following L-1, L-2, L-3, or L-4,

[0103] [Chemical formula 2]

[0104]

[0105] (The left-side connecting bond of each group is connected to A of formula [1], and the right-side connecting bond is connected to ring B of formula [1]. R 11 , R 13 , and R 14 are hydrogen atoms or alkyl groups, R 12 is a hydrogen atom, an alkyl group, a monohaloalkyl group, a dihaloalkyl group, or a trihaloalkyl group, R 13 is a hydrogen atom, an alkyl group, and Y is O, S, or -NR 15 -(where R 15 is a hydrogen atom or an alkyl group), m is 0, 1 or 2), R 1 and R 15 (L is L-2, Y is -NR 15 -) together with the adjacent atoms, is a group represented by the following z-1, z-2, z-3,

[0106] [Chemical formula 3]

[0107]

[0108] (R 21 is a hydrogen atom, an oxo group (=O), or an alkoxyimino group (=NOR 23 ), n is 1 or 2, R 22 is a hydrogen atom or an alkyl group. ),

[0109] A represents an aminoalkylamino group, a non-aromatic heterocyclic group, a non-aromatic carbocyclic group, an aromatic carbocyclic group, an aromatic heterocyclic group, or a 1,3-dioxane-2-yl group,

[0110] The non-aromatic heterocyclic group involved in A may be substituted by one or two groups selected from the following (1) to (7):

[0111] (1) Amino group (-NH2),

[0112] (2) Alkyl,

[0113] (3) aminoalkyl,

[0114] (4) alkyl substituted with amino and hydroxyl groups,

[0115] (5) Halogen,

[0116] (6) alkylcarbonyl,

[0117] (7) alkoxycarbonyl,

[0118] The non-aromatic carbocyclic group involved in A may be substituted by 1 to 3 groups selected from the following (1) to (15):

[0119] (1) Amino group,

[0120] (2) Alkyl,

[0121] (3) Alkylamino groups substituted by non-aromatic carbocyclic groups

[0122] (4) Trihaloalkylamino

[0123] (5) Hydroxyalkyl,

[0124] (6) aminoalkyl,

[0125] (7) Hydroxyl

[0126] (8) Monoalkylamino

[0127] (9) Hydroxyalkylamino

[0128] (10) Alkoxycarbonyl

[0129] (11) Carboxyl

[0130] (12) Carbamoyl

[0131] (13) Acetylamino (Me-C(=O)-NH-)

[0132] (14) Piperazine

[0133] (15) Alkylamino

[0134] The aromatic carbocyclic group referred to as A may be substituted by one group selected from the following (1) to (4): (1) aminoalkyl,

[0135] (2) aminoalkoxy,

[0136] (3) Alkoxy substituted by piperidinyl

[0137] (4) Alkoxycarbonylaminoalkyl

[0138] The aromatic heterocyclic group involved in A may be substituted by a piperazinyl group,

[0139] A and L are selected from any of the following (a) to (h),

[0140] (a) When L is a connecting key

[0141] A is aminoalkylamino, non-aromatic heterocyclic, aromatic carbocyclic, or aromatic heterocyclic, and (b) L is alkylene

[0142] A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group,

[0143] (c) When L is alkenylene

[0144] A is a non-aromatic heterocyclic group,

[0145] (d) When L is an alkynylene group

[0146] A is a non-aromatic heterocyclic group,

[0147] (e) When L is L-1

[0148] A is a non-aromatic heterocyclic group, a non-aromatic carbocyclic group, or an aromatic carbocyclic group,

[0149] (f) When L is L-2

[0150] A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group,

[0151] (g) When L is L-3

[0152] A is a non-aromatic heterocyclic group,

[0153] (h) When L is L-4

[0154] A is a non-aromatic heterocyclic group.

[0155] (Item 2) The 1,3,4-oxadiazolinone compound according to (Item 1) or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein X 1 is a carbon atom, X 2 For carbon atoms.

[0156] (Item 3)

[0157] The 1,3,4-oxadiazolinone compound according to (item 1) or (item 2), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein L is a linking bond, an alkylene group, an alkenylene group, an alkynylene group, L-1, or L-2.

[0158] (Item 4) The 1,3,4-oxadiazolinone compound or its pharmaceutically acceptable salt, or its solvate according to any one of (Item 1) to (Item 3), wherein A is an aminoalkylamino group, a non-aromatic heterocyclic group, a non-aromatic carbocyclic group, an aromatic carbocyclic group, or an aromatic heterocyclic group.

[0159] (Item 5) The 1,3,4-oxadiazolinone compound according to (Item 1) to (Item 4), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein L is a linking bond, L-1, or L-2.

[0160] (Item 6) The 1,3,4-oxadiazolinone compound according to any one of (Item 1) to (Item 5), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein A and L are any of the following groups (aa), (ee), and (ff),

[0161] (aa) when L is a linking bond, A is an aminoalkylamino group, a non-aromatic heterocyclic group, an aromatic carbocyclic group, or an aromatic heterocyclic group,

[0162] (ee) when L is L-1, A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group; or (ff) when L is L-2, A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group.

[0163] (Item 7) The 1,3,4-oxadiazolinone compound or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of (Item 1) to (Item 5), wherein L is L-2, and A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group.

[0164] (Item 8) The 1,3,4-oxadiazolinone compound according to (Item 7) or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein L is L-2, m is 0, and Y is -NR 15 -, A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group.

[0165] (Item 9) The 1,3,4-oxadiazolinone compound according to any one of (Item 1) to (Item 8), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the non-aromatic heterocyclic group involved in A is piperidinyl, piperazinyl, pyrrolidinyl, azepanyl, azocanyl, 1,3-dioxanyl, tetrahydrofuranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonan-7-yl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, or 2-azaspiro[3.3]heptane-6-yl,

[0166] The non-aromatic carbocyclic group related to A is cyclohexyl, cyclopentyl, cyclobutenyl, bicyclo[2.2.1]heptyl, bicyclo[1.1.1]pentyl, cuban-1-yl, or 2-azaspiro[3.3]heptyl,

[0167] The aromatic carbocyclic group of A is phenyl,

[0168] The aromatic heterocyclic group referred to as A is pyridyl.

[0169] (Item 10) The 1,3,4-oxadiazolinone compound according to (Item 1) or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein:

[0170] X 1 is a carbon atom,

[0171] R 1 is a halogen atom, a dihaloalkyl group, a trihaloalkyl group, a dihaloalkoxy group, or a trihaloalkoxy group,

[0172] R 2 is a halogen atom or a trihaloalkyl group,

[0173] R 3 is a hydrogen atom,

[0174] X 4 is a carbon atom,

[0175] R 4 is a hydrogen atom,

[0176] L is L-2,

[0177] m is 0,

[0178] Y is NR 15 ,

[0179] R 12 is a hydrogen atom or an alkyl group,

[0180] A is piperidinyl, piperazinyl, pyrrolidinyl, azepanyl, azacyclooctanyl, 1,3-dioxanyl, tetrahydrofuranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonan-7-yl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, or 2-azaspiro[3.3]heptan-6-yl.

[0181] (Item 11) The 1,3,4-oxadiazolinone compound or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of (Item 1) to (Item 9), wherein the 1,3,4-oxadiazolinone compound is a compound described in any one of the following (1) to (254),

[0182] (1) 5-{3-[(4-aminobutyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0183] (2) 5-{3-[(3-aminopropyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0184] (3) 5-{3-[(5-aminopentyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0185] (4) 5-{3-[(6-aminohexyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0186] (5) 5-{3-[(6-aminohexane-2-yl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (6) 5-{3-[4-(aminomethyl)piperidin-1-yl]-4-chlorophenyl}-1,3,4-oxadiazol-2(3H)-one,

[0187] (7) tert-butyl 4-[2-chloro-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]piperazine-1-carboxylate,

[0188] (8) 5-[4-chloro-3-(piperazin-1-yl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0189] (9) 5-[3-(4-aminopiperidin-1-yl)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0190] (10) 5-{3-[4-(2-aminoethyl)piperidin-1-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0191] (11) 5-{3-[3-(2-aminoethyl)piperidin-1-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0192] (12) 5-{4-[4-(2-aminoethyl)piperidin-1-yl]-1H-indazol-6-yl}-1,3,4-oxadiazol-2(3H)-one,

[0193] (13) 5-{3-[4-(1-amino-2-methylpropane-2-yl)piperidin-1-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0194] (14) 5-{3-[4-(2-amino-1-hydroxyethyl)piperidin-1-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0195] (15) 5-[3-(3,9-diazaspiro[5.5]undecane-3-yl)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0196] (16) 5-[3-(2,7-diazaspiro[3.5]nonan-7-yl)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0197] (17) tert-butyl {[2'-chloro-5'-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-3-yl]methyl}carbamate,

[0198] (18) 5-[3'-(aminomethyl)-6-chloro[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one,

[0199] (19) tert-butyl {[5'-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl}carbamate,

[0200] (20) 5-[4'-(aminomethyl)-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one,

[0201] (21) 5-[3'-(aminomethyl)-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one,

[0202] (22) 5-[4'-(2-aminoethyl)-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one,

[0203] (23) 5-{4'-[(piperidin-4-yl)methoxy]-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl}-1,3,4-oxadiazol-2(3H)-one,

[0204] (24) 5-[4'-{[(2S)-1-aminopropane-2-yl]oxy}-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one,

[0205] (25) 5-{3-[5-(piperazin-1-yl)pyridin-3-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0206] (26) 5-{3-[2-(piperidin-4-yl)ethyl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0207] (27) 5-[3-{2-[(1r,4s)-4-aminocyclohexyl]ethyl}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0208] (28) 5-[3-{2-[(2r,5r)-5-amino-1,3-dioxane-2-yl]ethyl}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0209] (29) 5-{3-[(piperidin-4-yl)ethynyl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0210] (30) 5-{3-[(E)-2-(piperidin-4-yl)vinyl]-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0211] (31) 5-{4-chloro-3-[(piperidin-4-yl)amino]phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0212] (32) 5-(3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one,

[0213] (33) 5-(3-{[(1s,4s)-4-aminocyclohexyl]amino}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one,

[0214] (34) 5-[3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0215] (35) 5-(3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-bromophenyl)-1,3,4-oxadiazol-2(3H)-one,

[0216] (36) 5-[3-{[(1r,4r)-4-aminocyclohexyl]amino}-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0217] (37) 5-[3-{[(1r,4r)-4-(aminomethyl)cyclohexyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0218] (38) 5-[3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0219] (39) 5-[3-{[(1r,4r)-4-(1-aminoethyl)cyclohexyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0220] (40) 5-(3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-chloro-5-fluorophenyl)-1,3,4-oxadiazol-2(3H)-one, (41) 5-{3-[4-(aminomethyl)anilino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0221] (42) 5-{3-[(6-azaspiro[2.5]octan-1-yl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0222] (43) 5-{3-[(6-aminospiro[3.3]heptane-2-yl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0223] (44) 5-[3-{[(1r,4r)-4-(2-aminoethyl)cyclohexyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0224] (45) 5-[3-{[(1S)-7-azaspiro[3.5]nonan-1-yl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0225] (46) 5-[3-{[(1R)-7-azaspiro[3.5]nonan-1-yl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0226] (47) 5-(4-chloro-3-{[(piperidin-4-yl)methyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0227] (48) 5-[3-{[(piperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0228] (49) 5-[4-chloro-3-({[(3R)-pyrrolidin-3-yl]methyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one, (50) 5-(4-bromo-3-{[(piperidin-4-yl)methyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0229] (51) 5-[3-{methyl[(piperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0230] (52) 5-[3-{[1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0231] (53) 5-[3-({[(3S)-piperidin-3-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0232] (54) 5-[3-({[(3R)-piperidin-3-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0233] (55) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0234] (56) 5-[3-{[1-(piperidin-4-yl)propyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0235] (57) 5-[3-{[(4-methylpiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0236] (58) 5-[3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0237] (59) 5-[3-{[(1R)-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0238] (60) 5-[3-{[2-(piperidin-3-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0239] (61) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0240] (62) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0241] (63) 5-[3-({1-[(1r,4r)-4-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0242] (64) 5-[3-{[2-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0243] (65) 5-[3-{[2-(piperazin-1-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0244] (66) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0245] (67) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-methylphenyl]-1,3,4-oxadiazol-2(3H)-one,

[0246] (68) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-bromophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0247] (69) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0248] (70) 5-[3-{[2-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0249] (71) 5-[2-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)[1,1'-biphenyl]-4-yl]-1,3,4-oxadiazol-2(3H)-one,

[0250] (72) 5-[3-({2-[(3R)-3-aminopiperidin-1-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0251] (73) 5-[3-({2-[(3S)-3-aminopiperidin-1-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0252] (74) 5-[3-({[(1s,4s)-4-aminocyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0253] (75) 5-[3-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0254] (76) 5-(4-chloro-3-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0255] (77) 5-(4-chloro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0256] (78) 5-(4-bromo-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0257] (79) 5-(3,4-dichloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0258] (80) 5-(4-fluoro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0259] (81) 5-[3-{[1-(piperidin-4-yl)propan-2-yl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0260] (82) 5-(4-methoxy-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0261] (83) 5-(4-bromo-3-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0262] (84) 5-(4-chloro-3-methyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0263] (85) 4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-{[(1S)-1-(piperidin-4-yl)ethyl]amino}benzonitrile,

[0264] (86) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-chloro-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0265] (87) 5-(4,5-dichloro-2-fluoro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0266] (88) 5-(4-chloro-2,5-difluoro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0267] (89) 5-(3,4-difluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0268] (90) 5-[4-(difluoromethyl)-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0269] (91) 5-(4-chloro-3-nitro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0270] (92) 5-(3-amino-4-chloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0271] (93) 5-(4,5-dichloro-2-methyl-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0272] (94) 5-(4-chloro-2-methyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0273] (95) 5-(4-chloro-2-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0274] (96) 5-(2,4-dichloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0275] (97) 5-(3-bromo-4-chloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0276] (98) 5-(3-chloro-4-methyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0277] (99) 5-(3-fluoro-4-methyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0278] (100) 5-(4-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-1H-indazol-6-yl)-1,3,4-oxadiazol-2(3H)-one,

[0279] (101) 5-[4-chloro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-5-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0280] (102) 5-(4-chloro-3-cyclopropyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0281] (103) 5-(3-chloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-4-[(propan-2-yl)oxy]phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0282] (104) 5-(3-chloro-4-methoxy-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0283] (105) 5-(3-chloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0284] (106) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0285] (107)5-[3-(pentafluoro-λ 6 -sulfanyl)-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0286] (108) 5-[3-{[(4-fluoropiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0287] (109) 5-[3-{[(3-fluoropiperidin-3-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0288] (110) 2-chloro-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}benzonitrile,

[0289] (111) 5-[3-({(1R)-1-[(1r,4R)-4-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0290] (112) 5-(2-{[(1S)-1-(piperidin-4-yl)ethyl]amino}pyridin-4-yl)-1,3,4-oxadiazol-2(3H)-one,

[0291] (113) 5-[3-{[(1R)-2,2-difluoro-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0292] (114) 5-[6-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2(3H)-one,

[0293] (115) 5-[3-{[1-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0294] (116) 5-(4-{[(4-fluoropiperidin-4-yl)methyl]amino}-1H-indazol-6-yl)-1,3,4-oxadiazol-2(3H)-one,

[0295] (117) 5-[3-({2-[(1r,4r)-4-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0296] (118) (1r,4r)-4-{[5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)anilino]methyl}cyclohexane-1-carboxylic acid tert-butyl ester,

[0297] (119) (1r,4r)-4-{[5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)anilino]methyl}cyclohexane-1-carboxylic acid,

[0298] (120) 5-[3-({[(1r,4r)-4-(hydroxymethyl)cyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0299] (121) (1r, 4r)-4-{[5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)anilino]methyl}cyclohexane-1-carboxamide,

[0300] (122) 5-[3-{[(4-ethylpiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0301] (123) 5-(4-chloro-3-fluoro-5-{[(4-fluoropiperidin-4-yl)methyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0302] (124) 5-{4-bromo-1-[(piperidin-4-yl)methyl]-1H-indazol-6-yl}-1,3,4-oxadiazol-2(3H)-one,

[0303] (125) 5-[3-{[(1S)-1-(4-fluoropiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0304] (126) 5-[3-({[(3S,4R)-3-fluoropiperidin-4-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0305] (127) 5-[3-({[(3S,4S)-3-fluoropiperidin-4-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0306] (128) 5-[4-(methylsulfonyl)-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0307] (129) 5-[3-fluoro-5-{[(4-fluoropiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0308] (130) 5-{3-[{[(1r,4r)-4-aminocyclohexyl]methyl}(methyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0309] (131) 5-[3-({[(1r,4r)-4-(methylamino)cyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0310] (132) 5-[3-(methyl{[(1r,4r)-4-(methylamino)cyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0311] (133) 5-[3-{[(3-azabicyclo[3.2.1]octan-8-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0312] (134) 5-[3-({1-[(3S)-pyrrolidin-3-yl]propan-2-yl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0313] (135) 5-[3-({[(1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0314] (136) 5-[3-({1-[(3R)-pyrrolidin-3-yl]propan-2-yl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0315] (137) 5-[3-({(1S)-1-[(1R,3S)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0316] (138) 5-[3-{[(1S)-1-(piperidin-4-yl)propyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one

[0317] (139) 5-(4-chloro-3-fluoro-5-{[(1S)-1-(piperidin-4-yl)propyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0318] (140) 5-[3-{[(1R)-2,2-difluoro-1-(4-fluoropiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0319] (141) 5-[3-({[(3R,4R)3-methylpiperidin-4-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0320] (142) 5-[3-{[(1S)-1-(7-azaspiro[3.5]nonan-2-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0321] (143) 5-[3-{[(2-methylpiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0322] (144) 5-[3-{[(1S)-1-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0323] (145) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0324] (146) 5-[4-(trifluoromethyl)-3-{[(1R)-2,2,2-trifluoro-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0325] (147) 5-[4-(trifluoromethyl)-3-{[(1S)-2,2,2-trifluoro-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0326] (148) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0327] (149) 5-[3-{[(1S)-1-(2-azaspiro[3.3]heptane-6-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0328] (150) 5-[3-({(1S)-1-[(1R,3S)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0329] (151) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0330] (152) 5-[3-{[(1R)-2-fluoro-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0331] (153) 5-[3-({(1S)-1-[(1S,3R)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0332] (154) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-bromophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0333] (155) 5-[3-({(1S)-1-[(1R,5S,8r)-3-azabicyclo[3.2.1]octan-8-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0334] (156) 5-[3-({(1S)-1-[(1R,5S,8s)-3-azabicyclo[3.2.1]octan-8-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0335] (157) 5-[3-{[(1S)-1-(azepan-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0336] (158) 5-[3-({(1S)-1-[(1R,3S)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0337] (159) 5-[3-fluoro-5-{[(1S)-1-(4-fluoropiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0338] (160) 5-[3-fluoro-5-{[(1R)-2-fluoro-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0339] (161) 5-[3-{2-[(2r,5r)-5-amino-1,3-dioxane-2-yl]cyclopropyl}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0340] (162) 5-[3-{[(1S)-1-(azoctan-5-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0341] (163) 5-[3-{[(1R)-2,2-difluoro-1-(4-fluoropiperidin-4-yl)ethyl]amino}-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0342] (164) 5-[3-({(1S)-1-[(1S,3R)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0343] (165) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0344] (166) 5-[3-({[(1R,3S)-3-amino-2,2-dimethylcyclobutyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0345] (167) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-methoxyphenyl]-1,3,4-oxadiazol-2(3H)-one,

[0346] (168) 5-[3-({(1S)-1-[(1S,3R)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0347] (169) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-chloro-2,5-difluorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0348] (170) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0349] (171) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-bromo-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0350] (172) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-methylphenyl]-1,3,4-oxadiazol-2(3H)-one,

[0351] (173) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-ethoxy-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0352] (174) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4,5-dichlorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0353] (175) 5-{3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-[(propan-2-yl)oxy]phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0354] (176) 5-[3-({[(1S,3R)-3-amino-2,2-dimethylcyclobutyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0355] (177) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-chloro-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0356] (178) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-4-chloro-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0357] (179) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-4,5-dichlorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0358] (180) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-5-fluoro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0359] (181) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]propyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0360] (182) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-5-bromo-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0361] (183) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-4-chloro-5-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0362] (184) N-[(1S,3R)-2,2-dimethyl-3-{[5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)anilino]methyl}cyclobutyl]acetamide,

[0363] (185) 5-[3-{[(1S)-1-(3-aminobicyclo[1.1.1]pentan-1-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0364] (186) 5-[3-({(1S)-1-[(2S,3R)-4-aminocuban-1-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0365] (187) 5-[3-{[(1S)-1-(4-aminobicyclo[2.2.1]heptane-1-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0366] (188) 5-[3-({(S)-1-[(2S,5R)-5-aminotetrahydro-2H-pyran-2-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0367] (189) 5-[3-({(1S)-1-[(1r,4S)-4-(methylamino)cyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0368] (190) 5-[3-fluoro-5-({(1S)-1-[(1r,4S)-4-(methylamino)cyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0369] (191) 5-[3-({(1S)-1-[(1R,3S)-3-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0370] (192) 5-[3-({(1S)-1-[(1s,3R)-3-(methylamino)cyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0371] (193) 5-[3-({(1S)-1-[(1r,4S)-4-(ethylamino)cyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0372] (194) 5-[3-({(1S)-1-[(1S,3R)-3-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0373] (195) 5-[3-({(1S)-1-[(1s,3R)-3-(ethylamino)cyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0374] (196) 5-[3-{[(1S)-1-{(1s,3R)-3-[(cyclopropylmethyl)amino]cyclobutyl}ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0375] (197) 5-[3-{[(1S)-1-{(1r,4S)-4-[(2,2,2-trifluoroethyl)amino]cyclohexyl}ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0376] (198) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]propyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0377] (199) 5-[3-({(1S)-1-[(1S,3R)-3-aminocyclopentyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0378] (200) 5-[3-({(1S)-1-[(1R,3S)-3-aminocyclopentyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0379] (201) 5-[3-{[(1S)-1-{(1r,4S)-4-[(2-hydroxyethyl)amino]cyclohexyl}ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0380] (202) 5-[3-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0381] (203) 5-[3-fluoro-5-({(1S)-1-[(1s,3R)-3-(methylamino)cyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0382] (204) 5-[3-fluoro-5-({(1S)-1-[(1r,4S)-4-(methylamino)cyclohexyl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0383] (205) 5-(4-chloro-3-{[methyl(piperidin-4-yl)amino]methyl}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0384] (206) 5-[3-fluoro-5-{[(1S)-1-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0385] (207) 5-[3-fluoro-5-{[(1S)-1-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0386] (208) 5-[3-fluoro-5-({(1S)-1-[(1s,3R)-3-(methylamino)cyclobutyl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0387] (209) 5-[3-{[(1S)-2-fluoro-1-(4-fluoropiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0388] (210) 5-[3-fluoro-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0389] (211) 5-[3-fluoro-5-({(1S)-1-[(3R,4R)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0390] (212) 5-[4-(difluoromethoxy)-3-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0391] (213) 5-[4-(difluoromethoxy)-3-fluoro-5-{[(1S)-1-(4-methylpiperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0392] (214) 5-[4-(difluoromethoxy)-3-fluoro-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0393] (215) 5-(3-{[(1-acetylpiperidin-4-yl)(methyl)amino]methyl}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one,

[0394] (216) 5-[4-(difluoromethoxy)-3-fluoro-5-({(1S)-1-[(2R,4R)-2-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0395] (217) 5-[3-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0396] (218) 5-[3-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0397] (219) 5-[3-fluoro-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0398] (220) 5-[4-(difluoromethoxy)-3-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl-1,3,4-oxadiazol-2(3H)-one,

[0399] (221) 5-[4-chloro-3-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0400] (222) 5-[4-chloro-3-fluoro-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0401] (223) 5-[3-fluoro-5-({(1S)-1-[(3S,4R)-3-fluoropiperidin-4-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0402] (224) 5-[3-fluoro-5-({(1S)-1-[(3S,4R)-3-fluoropiperidin-4-yl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0403] (225) 5-[3-({(1S)-1-[(3S,4S)-3-ethylpiperidin-4-yl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0404] (226) 5-[3-({(1S)-1-[(3R,4R)-3-ethylpiperidin-4-yl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0405] (227) 5-[3-fluoro-5-({(1S)-1-[(3S,4R)-3-fluoropiperidin-4-yl]ethyl}amino)-4-methylphenyl]-1,3,4-oxadiazol-2(3H)-one,

[0406] (228) 5-[3-fluoro-4-methyl-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0407] (229) 5-[3-({(1S)-1-[(3S,4S)-3-ethylpiperidin-4-yl]ethyl}amino)-5-fluoro-4-methylphenyl]-1,3,4-oxadiazol-2(3H)-one,

[0408] (230) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-cyclopropyl-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0409] (231) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-ethyl-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one,

[0410] (232) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-(prop-1-en-2-yl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0411] (233) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-(propan-2-yl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0412] (234) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}sulfanyl)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0413] (235) 5-{4-bromo-3-[(piperidin-4-yl)methoxy]phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0414] (236) 5-{4-bromo-3-[1-(piperidin-4-yl)ethoxy]phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0415] (237) 5-(3-{1-[(1r,4r)-4-aminocyclohexyl]ethoxy}-4-bromophenyl)-1,3,4-oxadiazol-2(3H)-one,

[0416] (238) 5-(3-{[(1r,4r)-4-aminocyclohexyl]methoxy}-4-bromophenyl)-1,3,4-oxadiazol-2(3H)-one,

[0417] (239) 5-{3-[1-(piperidin-4-yl)ethoxy]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one,

[0418] (240) 5-[3-{[(1r,4r)-4-aminocyclohexyl]methoxy}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one,

[0419] (241) 5-(3-{[(1r,4r)-4-aminocyclohexyl]methoxy}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one,

[0420] (242) 5-(4-chloro-3-{[(1s,3s)-3-(piperazin-1-yl)cyclobutyl]methoxy}phenyl)-1,3,4-oxadiazol-2(3H)-one,

[0421] (243) 5-(3-{[(1s,4s)-4-aminocyclohexyl]methoxy}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one,

[0422] (244) 5-(1-{[(1r,4r)-4-aminocyclohexyl]methyl}-1,2,3,4-tetrahydroquinolin-7-yl)-1,3,4-oxadiazol-2(3H)-one,

[0423] (245) 5-fluoro-1-{(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}-7-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2,3-dihydroquinolin-4(1H)-one,

[0424] (246) 5-[(4E)-5-fluoro-4-(methoxyimino)-1-{(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}-1,2,3,4-tetrahydroquinolin-7-yl]-1,3,4-oxadiazol-2(3H)-one,

[0425] (247) 5-(4-{(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3,4-oxadiazol-2(3H)-one,

[0426] (248) 5-{8-fluoro-4-[(1S)-1-(piperidin-4-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl}-1,3,4-oxadiazol-2(3H)-one,

[0427] (249) 5-(4-{(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}-8-fluoro-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3,4-oxadiazol-2(3H)-one,

[0428] (250) 5-{(2R)-8-fluoro-2-methyl-4-[(1S)-1-(piperidin-4-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl}-1,3,4-oxadiazol-2(3H)-one,

[0429] (251) 5-{(2S)-8-fluoro-2-methyl-4-[(1S)-1-(piperidin-4-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl}-1,3,4-oxadiazol-2(3H)-one,

[0430] (252) 5-[(2S)-4-{(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}-8-fluoro-2-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-1,3,4-oxadiazol-2(3H)-one,

[0431] (253) 5-[(2R)-4-{(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}-8-fluoro-2-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-1,3,4-oxadiazol-2(3H)-one,

[0432] (254) 5-{9-fluoro-5-[(1S)-1-(piperidin-4-yl)ethyl]-2,3,4,5-tetrahydro-1,5-benzoxazepine -7-yl}-1,3,4-oxadiazol-2(3H)-one.

[0433] (Item 12) A pharmaceutical composition comprising the 1,3,4-oxadiazolinone compound or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of (Item 1) to (Item 9) as an active ingredient.

[0434] (Item 13) A PIM kinase inhibitor comprising the 1,3,4-oxadiazolinone compound or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of (Item 1) to (Item 9) as an active ingredient.

[0435] (Item 14) PIM kinases involved in multiple sclerosis, rheumatoid arthritis, food allergies, asthma, systemic lupus erythematosus, lupus nephritis, inflammatory bowel disease, ulcerative colitis, atopic dermatitis, autoimmune lymphoproliferative syndrome, chronic obstructive pulmonary disease, allergic respiratory disease, eosinophilic granulomatosis with polyangiitis, eosinophilic syndrome, chorioamnionitis, ankylosing spondylitis, myasthenia gravis, psoriasis, prostate cancer, colorectal cancer, esophageal cancer, ovarian cancer, uterine cancer, kidney cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, glioma, osteosarcoma, bladder cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, B-cell lymphoma, multiple myeloma, T-cell lymphoma, skin cancer, Kaposi's A therapeutic agent for Hodgkin's sarcoma, Hodgkin's lymphoma, myeloproliferative neoplasms, adenoid cystic carcinoma, Ewing's sarcoma, adult T-cell leukemia, mesothelioma, acute promyelocytic leukemia, choriocarcinoma, liposarcoma, neuroblastoma, seminoma, lymphoblastic lymphoma, Epstein-Barr virus infection or hemophagocytic syndrome in which Epstein-Barr virus involvement is known, influenza, hepatitis C, Salmonella infection, herpes virus infection, vaginal Trichomonas infection, human granulocytic ehrlichiosis, aplastic anemia, atherosclerosis, pulmonary hypertension, diabetes, prostatic hypertrophy or Alzheimer's disease, comprising the 1,3,4-oxadiazolinone compound or a pharmaceutically acceptable salt thereof, or a solvate thereof according to any one of (1) to (11) as an active ingredient.

[0436] [Effects of the Invention]

[0437] The compound of formula [1] or a pharmaceutically acceptable salt or solvate thereof has a PIM kinase inhibitory effect and is therefore useful as a therapeutic agent for diseases in which PIM kinase is involved (eg, systemic lupus erythematosus, lupus nephritis, etc.). DETAILED DESCRIPTION

[0438] Hereinafter, the meaning of each term used in this specification will be described. Unless otherwise specified, each term has the same meaning when used alone or in combination with other terms.

[0439] The "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.

[0440] Examples of the "alkyl group" include, for example, linear or branched alkyl groups having 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms. Specifically, examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, 1-ethylpropyl, 1,2-dimethylpropyl, tert-pentyl, 2-methylbutyl, isopentyl, neopentyl, n-hexyl, sec-hexyl, 1-ethylbutyl, isohexyl, neohexyl, 1,1-dimethylbutyl, tert-hexyl, 2-ethylbutyl, 1,2,2-trimethylpropyl, 2,2-dimethylbutyl, n-heptyl, isoheptyl, n-octyl, and isooctyl.

[0441] The "alkenyl group" refers to a linear or branched hydrocarbon group having 2 to 10 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 2 to 6 carbon atoms, and further preferably 2 to 4 carbon atoms, which has one or more double bonds at any position. Specifically, vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, isoprenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl and the like can be cited.

[0442] Examples of the alkyl moiety of the "monoalkylamino group", "alkylsulfonyl group" and "alkylcarbonyl group" include the same "alkyl groups" as mentioned above.

[0443] "Amino" means -NH2.

[0444] The "monoalkylamino group" means a group in which one hydrogen atom connected to the nitrogen atom of the amino group is replaced by the above-mentioned "alkyl group". Specific examples thereof include methylamino, ethylamino, and isopropylamino.

[0445] "Hydroxyalkyl" refers to a group in which a hydrogen atom bonded to a carbon atom of the above-mentioned "alkyl" is replaced by a hydroxyl group. For example, specific examples include hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, and 2-hydroxypropyl.

[0446] "Aminoalkyl" means a group in which a hydrogen atom attached to a carbon atom of the above-mentioned "alkyl" is replaced by an amino group. For example, specifically, aminomethyl, 1-aminoethyl, 2-aminoethyl, 1-aminopropyl, 2-aminopropyl, 3-aminopropyl, etc. can be mentioned.

[0447] The "alkylamino group substituted with a non-aromatic carbocyclic group" refers to a group in which a hydrogen atom bonded to a carbon atom of the alkyl group of the alkylamino group is replaced with the following non-aromatic carbocyclic group, and examples thereof include a methylamino group substituted with a cyclopropyl group.

[0448] The "hydroxyalkylamino group" means a group in which one hydrogen atom bonded to the nitrogen atom of the amino group is substituted with the above-mentioned "hydroxyalkyl group".

[0449] The "alkylcarbonyl group" refers to a group in which the above-mentioned "alkyl group" is connected to a carbonyl group, and examples thereof include methylcarbonyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, tert-butylcarbonyl, isobutylcarbonyl, sec-butylcarbonyl, pentylcarbonyl, isopentylcarbonyl, and hexylcarbonyl.

[0450] The "monohalogenated alkyl group" means a group in which one hydrogen atom of the above-mentioned "alkyl group" is replaced by the above-mentioned "halogen". Specific examples thereof include fluoromethyl, chloromethyl, and fluoroethyl.

[0451] The "dihaloalkyl" group refers to a group in which two hydrogen atoms of the "alkyl" group are replaced by the "halogen" group. Specific examples thereof include difluoromethyl, dichloromethyl, and difluoroethyl.

[0452] The "trihaloalkyl" group refers to a group in which three hydrogen atoms of the above-mentioned "alkyl" group are replaced by the above-mentioned "halogen". Specific examples thereof include trifluoromethyl, trichloromethyl, and trifluoroethyl.

[0453] The "trihaloalkylamino group" means a group obtained by replacing one hydrogen atom bonded to the nitrogen atom of the amino group with the above-mentioned "trihaloalkyl group". Specific examples thereof include trifluoromethylamino and trifluoroethylamino.

[0454] "Alkoxy" means a group in which the above-mentioned "alkyl" is bonded to an oxygen atom. Examples thereof include alkoxy groups having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, in a straight or branched chain. Specifically, examples thereof include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, n-hexyloxy, n-heptyloxy, and n-octyloxy.

[0455] The "aminoalkoxy group" means a group in which a hydrogen atom bonded to a carbon atom of the above-mentioned "alkoxy group" is replaced by an amino group. Specific examples thereof include aminomethyl, 1-aminoethyl, aminomethoxy, 2-aminoethoxy, and 3-aminopropoxy.

[0456] "Alkoxycarbonyl" means a group in which the above-mentioned "alkoxy" is bonded to a carbonyl group, and examples thereof include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, pentyloxycarbonyl, isopentyloxycarbonyl, and hexyloxycarbonyl.

[0457] Examples of the alkoxy moiety of the "alkoxycarbonyl group", "alkoxycarbonylamino group", "alkoxycarbonylaminoalkyl group" and "alkoxyimino group" include the same "alkoxy groups" as mentioned above.

[0458] Examples of the "alkylene group" include alkylene groups having a linear or branched divalent hydrocarbon group having 1 to 6 carbon atoms. Specific examples include methylene, ethylene, and propylene.

[0459] Examples of the "alkenylene group" include alkenylene groups having a linear or branched divalent hydrocarbon group having 2 to 6 carbon atoms, and specific examples thereof include ethenylene, propenylene, butenylene, and pentenylene.

[0460] "Alkynylidene" includes a linear divalent hydrocarbon group having 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms, and more preferably 2 to 4 carbon atoms, having one or more triple bonds at any position. These may further have a double bond at any position. Examples thereof include ethynylene, propynylene, butynylene, pentynylene, and hexynylene.

[0461] "Oxo" means a double-bonded oxygen (=0).

[0462] The "imino group" refers to a divalent atomic group (=NH) obtained by removing two hydrogen atoms from ammonia (NH3).

[0463] The "alkoxyimino group" means a group in which the hydrogen atom of the above-mentioned "imino group" is replaced with the above-mentioned "alkoxy group". Specific examples thereof include methoxyimino, 2-ethoxyimino, and 3-propoxyimino.

[0464] The "carbocyclic group" is a monocyclic to tricyclic group, and examples thereof include saturated hydrocarbon groups having 3 to 20 carbon atoms, and include aromatic carbocyclic groups and non-aromatic carbocyclic groups.

[0465] Examples of the "aromatic carbocyclic group" include monocyclic to tricyclic aromatic hydrocarbon groups having 6 to 14 carbon atoms. Specifically, phenyl, 1-naphthyl, 2-naphthyl, 1-anthryl, 2-anthryl, 9-anthryl, 1-phenanthrenyl, 2-phenanthrenyl, 3-phenanthrenyl, 4-phenanthrenyl, 10-phenanthrenyl, etc. are included. Among them, phenyl is preferred.

[0466] Examples of the "non-aromatic carbocyclic group" include monocyclic to tricyclic non-aromatic hydrocarbon groups, and specific examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0467] The above-mentioned "non-aromatic carbocyclic group" may also be a bridged hydrocarbon group. Examples of the bridged hydrocarbon group include bicyclo[2.2.1]heptyl (e.g., bicyclo[2.2.1]heptane-1-yl, bicyclo[2.2.1]heptane-2-yl, bicyclo[2.2.1]heptane-7-yl),

[0468] Bicyclo[1.1.1]pentyl (e.g., bicyclo[1.1.1]pentan-1-yl, bicyclo[1.1.1]pentan-2-yl),

[0469] Bicyclo[4.1.0]heptyl (e.g., bicyclo[4.1.0]heptan-1-yl, bicyclo[4.1.0]heptan-2-yl, bicyclo[4.1.0]heptan-3-yl, bicyclo[4.1.0]heptan-7-yl),

[0470] Bicyclo[2.2.2]octyl (e.g., bicyclo[2.2.2]octan-1-yl, bicyclo[2.2.2]octan-2-yl,),

[0471] Bicyclo[3.1.1]heptyl (e.g., bicyclo[3.1.1]heptan-1-yl, bicyclo[3.1.1]heptan-2-yl, bicyclo[3.1.1]heptan-3-yl, bicyclo[3.1.1]heptan-6-yl, ) or

[0472] ·Cuban-1-yl.

[0473] The above-mentioned "non-aromatic carbocyclic group" may also be a spirocyclic group. Examples of the spirocyclic group include spiro[3.3]heptyl (e.g., spiro[3.3]heptane-1-yl, spiro[3.3]heptane-2-yl),

[0474] Spiro[4.4]nonyl (e.g., spiro[4.4]nonan-1-yl, spiro[4.4]nonan-2-yl),

[0475] Spiro[5.5]undecyl, (e.g., spiro[5.5]undec-1-yl, spiro[5.5]undec-2-yl, spiro[5.5]undec-3-yl), or

[0476] - Spiro[2.5]octyl (e.g., spiro[2.5]octan-1-yl, spiro[2.5]octan-4-yl, spiro[2.5]octan-5-yl, spiro[2.5]octan-6-yl).

[0477] Examples of the "aromatic heterocyclic group" include monocyclic to tricyclic aromatic rings having 1 to 3 heteroatoms selected from nitrogen atoms, oxygen atoms, and sulfur atoms as constituent atoms and having 6 to 14 carbon atoms. Specifically, examples include

[0478] Furyl (e.g., 2-furyl, 3-furyl),

[0479] · thienyl (e.g., 2-thienyl, 3-thienyl),

[0480] · pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl),

[0481] Imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl),

[0482] · pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl),

[0483] · triazolyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-4-yl),

[0484] Tetrazolyl (e.g., 1-tetrazolyl, 2-tetrazolyl, 5-tetrazolyl),

[0485] Oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl),

[0486] ·Isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl),

[0487] Oxadiazolyl (e.g., 1,3,4-oxadiazol-2-yl),

[0488] · thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl),

[0489] · thiadiazolyl (e.g., 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,3-thiadiazolyl),

[0490] ·Isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl),

[0491] · pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl),

[0492] · pyridazinyl (e.g., 3-pyridazinyl, 4-pyridazinyl),

[0493] · pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl),

[0494] · pyrazinyl (e.g., 2-pyrazinyl),

[0495] Benzothiadiazole (e.g., 1,2,3-benzothiadiazol-4-yl, 1,2,3-benzothiadiazol-5-yl, 2,1,3-benzothiadiazol-4-yl, 2,1,3-benzothiadiazol-5-yl),

[0496] Benzothiazolyl (e.g., benzothiazol-2-yl, benzothiazol-4-yl, benzothiazol-5-yl, benzothiazol-6-yl, benzothiazol-7-yl),

[0497] Indolyl (e.g., indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl),

[0498] benzothiophene (e.g., 1-benzothiophene-2-yl, 1-benzothiophene-3-yl, 1-benzothiophene-4-yl, 1-benzothiophene-5-yl, 1-benzothiophene-6-yl, 1-benzothiophene-7-yl),

[0499] 1,1-dioxo-1-benzothiophene (e.g., 1,1-dioxo-1-benzothiophene-2-yl, 1,1-dioxo-1-benzothiophene-3-yl, 1,1-dioxo-1-benzothiophene-4-yl, 1,1-dioxo-1-benzothiophene-5-yl, 1,1-dioxo-1-benzothiophene-6-yl, 1,1-dioxo-1-benzothiophene-7-yl),

[0500] Quinolinyl (quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl), or

[0501] ·1,3-Benzoxazol-2-yl.

[0502] The “non-aromatic heterocyclic group” includes a non-aromatic cyclic group having one or more heteroatoms selected from nitrogen atoms, oxygen atoms, and sulfur atoms, which are the same or different, and which is monocyclic or bicyclic. Specifically, for example

[0503] Oxetane (e.g., 2-oxetane, 3-oxetane),

[0504] azetidinyl (e.g., 2-azetidinyl, 3-azetidinyl),

[0505] Tetrahydropyranyl (e.g., 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl),

[0506] 1,4-dioxanyl (e.g., 1,4-dioxane-2-yl),

[0507] 1,3-dioxanyl (e.g., 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl),

[0508] Pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl),

[0509] Piperidinyl (e.g., 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl),

[0510] Piperazinyl (e.g., 1-piperazinyl, 2-piperazinyl, 3-piperazinyl),

[0511] azepanyl (e.g., 1-azepanyl, 2-azepanyl, 3-azepanyl, 4-azepanyl),

[0512] Azocanyl (e.g., 1-azocyl, 2-azocyl, 3-azocyl, 4-azocyl, 5-azocyl),

[0513] Homopiperidinyl (e.g., 2-homopiperidinyl, 3-homopiperidinyl, 4-homopiperidinyl),

[0514] Morpholinyl (e.g., 2-morpholinyl, 3-morpholinyl, 4-morpholinyl),

[0515] · thiomorpholinyl (e.g., 2-thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl), or

[0516] ·Tetrahydrofuranyl (2-tetrahydrofuranyl, 3-tetrahydrofuranyl).

[0517] The above-mentioned "non-aromatic heterocyclic group" may also be a bridged ring group. Examples of the bridged ring group include

[0518] 3-azabicyclo[3.2.1]octyl (e.g., 3-azabicyclo[3.2.1]octan-1-yl, 3-azabicyclo[3.2.1]octan-2-yl, 3-azabicyclo[3.2.1]octan-3-yl, 3-azabicyclo[3.2.1]octan-6-yl, 3-azabicyclo[3.2.1]octan-8-yl),

[0519] Quinuclidinyl (e.g., quinuclidin-2-yl, quinuclidin-3-yl, quinuclidin-4-yl), or

[0520] 6-oxa-3-azabicyclo[3.1.1]heptyl (e.g., 6-oxa-3-azabicyclo[3.1.1]heptan-1-yl, 6-oxa-3-azabicyclo[3.1.1]heptan-2-yl, 6-oxa-3-azabicyclo[3.1.1]heptan-3-yl, 6-oxa-3-azabicyclo[3.1.1]heptan-7-yl).

[0521] The above-mentioned "non-aromatic heterocyclic group" may be a spirocyclic group. Examples of the spirocyclic group include

[0522] 6-azaspiro[2.5]octan-1-yl (e.g., 6-azaspiro[2.5]octan-1-yl, 6-azaspiro[2.5]octan-4-yl, 6-azaspiro[2.5]octan-5-yl),

[0523] 3,9-diazaspiro[5.5]undecane-1-yl (e.g., 3,9-diazaspiro[5.5]undecane-1-yl, 3,9-diazaspiro[5.5]undecane-2-yl, 3,9-diazaspiro[5.5]undecane-3-yl),

[0524] 2,7-diazaspiro[3.5]nonan-1-yl (e.g., 2,7-diazaspiro[3.5]nonan-1-yl, 2,7-diazaspiro[3.5]nonan-2-yl, 2,7-diazaspiro[3.5]nonan-5-yl, 2,7-diazaspiro[3.5]nonan-6-yl, 2,7-diazaspiro[3.5]nonan-7-yl),

[0525] 7-azaspiro[3.5]nonyl, (7-azaspiro[3.5]nonan-1-yl, 7-azaspiro[3.5]nonan-2-yl, 7-azaspiro[3.5]nonan-5-yl, 7-azaspiro[3.5]nonan-6-yl), or

[0526] · 2,5-diazabicyclo[2.2.1]heptyl, (2,5-diazabicyclo[2.2.1]heptan-1-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 2,5-diazabicyclo[2.2.1]heptan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-7-yl).

[0527] Hereinafter, each symbol in formula [1] will be described.

[0528] X1 in formula [1] is a carbon atom or a nitrogen atom, preferably a carbon atom.

[0529] When X1 is a carbon atom, R 1 It is a hydrogen atom, a halogen atom, an alkyl group, an alkenyl group, a non-aromatic carbocyclic group, a dihaloalkyl group, a trihaloalkyl group, an alkoxy group, a dihaloalkoxy group, a trihaloalkoxy group, an alkylsulfonyl group, a cyano group, an aromatic carbocyclic group, or an aromatic heterocyclic group. It is preferably a halogen atom, an alkyl group, a dihaloalkyl group, a trihaloalkyl group, an alkoxy group, a dihaloalkoxy group, an alkylsulfonyl group, a cyano group, or a trihaloalkoxy group, more preferably a halogen atom, a trihaloalkyl group, a dihaloalkoxy group, or a trihaloalkoxy group, and further preferably a halogen atom, a trihaloalkyl group, or a trihaloalkoxy group.

[0530] As involving R 1 The "halogen atom" is preferably a chlorine atom, a bromine atom or a fluorine atom, more preferably a chlorine atom or a fluorine atom.

[0531] As involving R 1 The "alkyl group" is preferably an alkyl group having 1 to 6 carbon atoms.

[0532] As involving R 1The "alkenyl group" is preferably an alkenyl group having 2 to 4 carbon atoms.

[0533] As involving R 1 The "non-aromatic carbocyclic group" is preferably a monocyclic non-aromatic carbocyclic group having 3 to 8 carbon atoms.

[0534] As involving R 1 The "dihaloalkyl group" is preferably a dihaloalkyl group having 1 to 6 carbon atoms.

[0535] As involving R 1 The "trihaloalkyl group" is preferably a trihaloalkyl group having 1 to 6 carbon atoms.

[0536] As involving R 1 The "alkoxy group" is preferably an alkoxy group having 1 to 6 carbon atoms.

[0537] As involving R 1 The "dihaloalkoxy group" is preferably a dihaloalkyl group having 1 to 6 carbon atoms.

[0538] As involving R 1 The "trihalogenated alkoxy group" is preferably a trihalogenated alkoxy group having 1 to 6 carbon atoms.

[0539] As involving R 1 The "alkylsulfonyl group" is preferably an alkylsulfonyl group having 1 to 6 carbon atoms.

[0540] As involving R 1 The "aromatic carbocyclic group" is preferably phenyl.

[0541] As involving R 1 The "aromatic heterocyclic group" is preferably pyridyl.

[0542] R 2 It is a hydrogen atom, a halogen atom, an alkyl group, a non-aromatic carbocyclic group, a trihaloalkyl group, a trihaloalkoxy group, a pentafluorosulfanyl group (SF5), a cyano group, an amino group, or a nitro group. It is preferably a hydrogen atom, a halogen atom, an alkyl group, a trihaloalkyl group, a trihaloalkoxy group, an amino group, or a nitro group, and more preferably a hydrogen atom, a halogen atom, or a trihaloalkyl group.

[0543] As involving R 2 The "halogen atom" is preferably a chlorine atom, a bromine atom or a fluorine atom.

[0544] As involving R 2 The "alkyl group" is preferably an alkyl group having 1 to 6 carbon atoms.

[0545] As involving R 2The "non-aromatic carbocyclic group" is preferably a monocyclic non-aromatic carbocyclic group having 3 to 8 carbon atoms.

[0546] As involving R 2 The "trihaloalkyl group" is preferably a trihaloalkyl group having 1 to 6 carbon atoms.

[0547] As involving R 3 The "alkyl group" is preferably an alkyl group having 1 to 6 carbon atoms.

[0548] X4 is a carbon atom or a nitrogen atom.

[0549] When X4 is a carbon atom, R 4 is a hydrogen atom, a halogen atom, or an alkyl group.

[0550] As involving R 4 The "alkyl group" is preferably an alkyl group having 1 to 6 carbon atoms.

[0551] L is a linking bond, an alkylene group, an alkenylene group, an alkynylene group, or a group represented by the following L-1, L-2, L-3, or L-4,

[0552] [Chemical formula 4]

[0553]

[0554] (The left-side connecting bond of each group is connected to A of formula [1], and the right-side connecting bond is connected to ring B of formula [1]. R 11 , R 13 , and R 14 are hydrogen atoms or alkyl groups, R 12 is a hydrogen atom, an alkyl group, a monohaloalkyl group, a dihaloalkyl group, or a trihaloalkyl group, and Y is O, S, or -NR 15 -(where R 15 is a hydrogen atom or an alkyl group, and m is 0, 1, or 2. ).

[0555] The "alkylene group" for L is preferably a linear or branched alkylene group having 1 to 6 carbon atoms.

[0556] The "alkenylene group" for L is preferably a linear or branched alkenylene group having 2 to 6 carbon atoms.

[0557] The "alkynylene group" for L is preferably a linear or branched alkynylene group having 2 to 6 carbon atoms.

[0558] R involving L-1 11 is a hydrogen atom or an alkyl group.

[0559] As involving R 11 The "alkyl group" is preferably an alkyl group having 1 to 6 carbon atoms.

[0560] R involving L-2 12 is a hydrogen atom, an alkyl group, a monohaloalkyl group, a dihaloalkyl group, or a trihaloalkyl group.

[0561] As involving R 12 The "alkyl group" is preferably an alkyl group having 1 to 6 carbon atoms.

[0562] As involving R 12 The "monohalogenated alkyl group" is preferably a monohalogenated alkyl group having 1 to 6 carbon atoms.

[0563] As involving R 12 The "dihaloalkyl group" is preferably a dihaloalkyl group having 1 to 6 carbon atoms.

[0564] As involving R 12 The "trihaloalkyl group" is preferably a trihaloalkyl group having 1 to 6 carbon atoms.

[0565] m in relation to L-2 is 0, 1, or 2. Preferably, it is 0 or 1.

[0566] Y in L-2 is O, S, or -NR 15 -, R 15 is a hydrogen atom or an alkyl group.

[0567] R involving L-3 13 It is a hydrogen atom or an alkyl group.

[0568] R 13 is a hydrogen atom or an alkyl group.

[0569] As involving R 13 The "alkyl group" is preferably an alkyl group having 1 to 6 carbon atoms.

[0570] As involving R 14 The "alkyl group" is preferably an alkyl group having 1 to 6 carbon atoms.

[0571] A is an aminoalkylamino group, a non-aromatic heterocyclic group, a non-aromatic carbocyclic group, an aromatic carbocyclic group, an aromatic heterocyclic group, or a 1,3-dioxan-2-yl group.

[0572] The aminoalkylamino group for A is preferably an aminoalkylamino group having 1 to 8 carbon atoms.

[0573] As the non-aromatic heterocyclic group for A, pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, azocanyl, 1,3-dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl and 2-azaspiro[3.3]heptyl are preferred.

[0574] As the non-aromatic carbocyclic group for A, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[1.1.1]pentyl, cuban-1-yl and spiro[3.3]heptyl are preferred.

[0575] As the aromatic carbocyclic group for A, a phenyl group is preferred.

[0576] As the aromatic heterocyclic group for A, a pyridyl group is preferred.

[0577] The non-aromatic heterocyclic group for A may be substituted by one or two groups selected from the following (1) to (7).

[0578] (1) Amino group,

[0579] (2) Alkyl,

[0580] (3) aminoalkyl,

[0581] (4) alkyl substituted with amino and hydroxyl groups,

[0582] (5) Halogen,

[0583] (6) alkylcarbonyl,

[0584] (7) alkoxycarbonyl,

[0585] As the substituent which may be substituted on the non-aromatic heterocyclic group concerning A, preferably an amino group, an alkyl group having 1 to 6 carbon atoms, an aminoalkyl group having 1 to 6 carbon atoms, an alkyl group having 1 to 6 carbon atoms substituted with an amino group and a hydroxyl group, a halogen group, or a monoalkylamino group having 1 to 6 carbon atoms.

[0586] As the "alkyl group" which may be substituted on the non-aromatic heterocyclic group related to A, an alkyl group having 1 to 6 carbon atoms is preferred.

[0587] The alkyl moiety of the "aminoalkyl group" which may be substituted on the non-aromatic heterocyclic group related to A is preferably an alkyl group having 1 to 6 carbon atoms.

[0588] The alkyl moiety of the "alkyl group substituted with an amino group or a hydroxy group" which may be substituted on the non-aromatic heterocyclic group related to A is preferably an alkyl group having 1 to 6 carbon atoms.

[0589] The alkyl moiety of the "monoalkylamino" group which may be substituted on the non-aromatic heterocyclic group related to A is preferably an alkyl group having 1 to 6 carbon atoms.

[0590] The alkyl moiety of the "alkylcarbonyl group" which may be substituted on the non-aromatic heterocyclic group related to A is preferably an alkyl group having 1 to 6 carbon atoms.

[0591] The alkoxy moiety of the "alkoxycarbonyl" which may be substituted on the non-aromatic heterocyclic group related to A is preferably an alkoxy group having 1 to 6 carbon atoms.

[0592] The non-aromatic carbocyclic group related to A may be substituted by 1 to 3 groups selected from the following (1) to (15).

[0593] (1) Amino group,

[0594] (2) Alkyl,

[0595] (3) Alkylamino groups substituted by non-aromatic carbocyclic groups

[0596] (4) Trihaloalkylamino

[0597] (5) alkyl substituted with hydroxyl group,

[0598] (6) aminoalkyl,

[0599] (7) Hydroxyl

[0600] (8) Monoalkylamino

[0601] (9) Hydroxyalkylamino

[0602] (10) Alkoxycarbonyl

[0603] (11) Carboxyl

[0604] (12) Carbamoyl

[0605] (13) Acetylamino (Me-C(=O)-NH-)

[0606] (14) Piperazine

[0607] (15) Alkylamino

[0608] As the substituent which may be substituted on the non-aromatic carbocyclic group concerning A, an amino group, an alkyl group having 1 to 6 carbon atoms, an aminoalkyl group having 1 to 6 carbon atoms, a hydroxyl group, or a monoalkylamino group having 1 to 6 carbon atoms is preferred.

[0609] As the "alkyl group" which may be substituted on the non-aromatic carbocyclic group related to A, an alkyl group having 1 to 6 carbon atoms is preferred.

[0610] The non-aromatic carbocyclic group as the "alkyl group substituted with a non-aromatic carbocyclic group" which may be substituted on the non-aromatic carbocyclic group for A is preferably a monocyclic non-aromatic carbocyclic group having 3 to 8 carbon atoms.

[0611] The alkyl group of the "trihalogenated alkylamino" which may be substituted on the non-aromatic carbocyclic group related to A is preferably an alkyl group having 1 to 6 carbon atoms.

[0612] The alkyl group of the "alkyl group substituted with a hydroxy group" which may be substituted on the non-aromatic carbocyclic group related to A is preferably an alkyl group having 1 to 6 carbon atoms.

[0613] As the alkyl group of the "aminoalkyl group" which may be substituted on the non-aromatic carbocyclic group related to A, an alkyl group having 1 to 6 carbon atoms is preferred.

[0614] The alkyl group of the "monoalkylamino" which may be substituted on the non-aromatic carbocyclic group related to A is preferably an alkyl group having 1 to 6 carbon atoms.

[0615] As the alkyl group of the "hydroxyalkylamino" which may be substituted on the non-aromatic carbocyclic group related to A, an alkyl group having 1 to 6 carbon atoms is preferred.

[0616] The alkoxy group of the "alkoxycarbonyl group" which may be substituted on the non-aromatic carbocyclic group related to A is preferably an alkoxy group having 1 to 6 carbon atoms.

[0617] The aromatic carbocyclic group related to A may be substituted by one group selected from the following (1) to (4).

[0618] (1) aminoalkyl,

[0619] (2) aminoalkoxy,

[0620] (3) Alkoxy substituted by piperidinyl

[0621] (4) Alkoxycarbonylaminoalkyl

[0622] The alkyl group of the "alkyl group substituted with an amino group" which may be substituted on the aromatic carbocyclic group related to A is preferably an alkyl group having 1 to 6 carbon atoms.

[0623] The alkoxy group of the "alkoxy group substituted with an amino group" which may be substituted on the aromatic carbocyclic group related to A is preferably an alkoxy group having 1 to 6 carbon atoms.

[0624] The alkoxy group of the "piperidinyl-substituted alkoxy group" which may be substituted on the aromatic carbocyclic group related to A is preferably an alkoxy group having 1 to 6 carbon atoms.

[0625] As the alkoxy group of the "alkoxycarbonylaminoalkyl group" which may be substituted on the aromatic carbocyclic group related to A, an alkoxy group having 1 to 6 carbon atoms is preferred.

[0626] As the alkyl group of the "alkoxycarbonylaminoalkyl group" which may be substituted on the aromatic carbocyclic group related to A, an alkyl group having 1 to 6 carbon atoms is preferred.

[0627] A and L are selected from any of the following (a) to (h).

[0628] (a) When L is a connecting key

[0629] A is an aminoalkylamino group, a non-aromatic heterocyclic group, an aromatic carbocyclic group, or an aromatic heterocyclic group.

[0630] (b) When L is an alkylene group

[0631] A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group.

[0632] (c) When L is alkenylene

[0633] A is a non-aromatic heterocyclic group.

[0634] (d) When L is an alkynylene group

[0635] A is a non-aromatic heterocyclic group.

[0636] (e) When L is L-1

[0637] A is a non-aromatic heterocyclic group, a non-aromatic carbocyclic group, or an aromatic carbocyclic group.

[0638] (f) When L is L-2

[0639] A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group.

[0640] (g) When L is L-3

[0641] A is a non-aromatic heterocyclic group.

[0642] (h) When L is L-4

[0643] A is a non-aromatic heterocyclic group substituted with an amino group.

[0644] More specifically, the compounds of the present invention include the compounds shown in Table 1 below.

[0645] [Table 1]

[0646]

[0647] (In the table, X 1 , X 2 , R 1 , R2 , R 3 , R 4 , R 11 , R 12 , R 22 , Y, m, n, have the same meanings as above. A1 is an alkyl group, and as A1, it is synonymous with the alkyl group of the aforementioned "aminoalkylamino". A2 is a non-aromatic heterocyclic group, A3 is a non-aromatic carbocyclic group, A4 is an aromatic heterocyclic group, and A5 is an aromatic carbocyclic group. "A2 or A3" represents a non-aromatic heterocyclic group or a non-aromatic carbocyclic group, "A4 or A5" represents an aromatic heterocyclic group or an aromatic carbocyclic group, and "A2 or A3 or A5" represents a non-aromatic heterocyclic group, a non-aromatic carbocyclic group, or an aromatic carbocyclic group. ).

[0648] In compound 1a-1, the alkyl group of the aminoalkylamino group of A1 is preferably an alkyl group having 1 to 6 carbon atoms, and more preferably aminopropylamino, aminobutylamino, aminopentylamino, aminohexylamino, or aminohexane-2-ylamino. 1 , preferably a carbon atom, as R 1 , preferably a trihaloalkyl group having 1 to 6 carbon atoms. 2 , preferably a halogen atom, a trihaloalkyl group having 1 to 6 carbon atoms, or a trihaloalkoxy group having 1 to 6 carbon atoms, and more preferably a trihaloalkyl group having 1 to 6 carbon atoms. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0649] In compound 1a-2, A2 is preferably a non-aromatic heterocyclic group, and among them, piperidinyl, piperazinyl, 3,9-diazaspiro[5.5]undecane-3-yl, and 2,7-diazaspiro[3.5]nonane-7-yl are preferred. As the group that may substitute on the non-aromatic carbocyclic group related to A2, amino, aminoalkyl having 1 to 6 carbon atoms, hydroxyalkylamino having 1 to 6 carbon atoms, and alkoxycarbonyl having 1 to 6 carbon atoms are preferred. As X 1 , preferably a carbon atom, as R 1 , preferably an alkyl group having 1 to 6 carbon atoms, a halogen group, or a trihaloalkyl group having 1 to 6 carbon atoms. 2 , preferably a hydrogen atom. 1 and R 2 Together with the adjacent atoms, they may form an indazole ring, which is also a preferred embodiment. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4, preferably a hydrogen atom.

[0650] In compound 1a-3, the aromatic carbocyclic group as A5 is preferably phenyl, and the aromatic heterocyclic group as A4 is preferably pyridyl. As the group that can be substituted on the aromatic carbocyclic group related to A4, preferably an aminoalkyl group having 1 to 6 carbon atoms, an aminoalkoxy group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms substituted by a piperidinyl group, an alkyl group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 6 carbon atoms, that is, an alkoxycarbonylaminoalkyl group, and as the group that can be substituted on the aromatic heterocyclic group related to A5, preferably a piperazinyl group. As X 1 , preferably a carbon atom, as R 1 , preferably a halogen or a trihaloalkyl group having 1 to 6 carbon atoms. 2 , preferably a hydrogen atom. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0651] In compound 1b, the non-aromatic heterocyclic group A2 is preferably a piperidinyl group. 1 , preferably a carbon atom, as R 1 , preferably a trihaloalkyl group having 1 to 6 carbon atoms. 2 , preferably a hydrogen atom. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0652] In compound 1c, the non-aromatic heterocyclic group A2 is preferably a piperidinyl group or a 1,3-dioxanyl group, and the non-aromatic carbocyclic group A3 is preferably a 3- to 8-membered monocyclic non-aromatic carbocyclic group, more preferably a cyclohexyl group. 1 , preferably a carbon atom, as R 1 , preferably a trihaloalkyl group having 1 to 6 carbon atoms. 2 , preferably a hydrogen atom. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0653] In compound 1d, the non-aromatic heterocyclic group of A2 is preferably a piperidinyl group. X1 is preferably a carbon atom, and R1 is preferably a trihalogenated alkyl group having 1 to 6 carbon atoms. 2 , preferably a hydrogen atom. 3, preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0654] In compound 1e, the non-aromatic heterocyclic group of A2 is preferably piperidinyl, 6-azaspiro[2.5]octan-1-yl, 7-azaspiro[3.5]nonan-1-yl, and the non-aromatic carbocyclic group of A3 is preferably a 3- to 8-membered monocyclic non-aromatic carbocyclic group, spiro[3.3]heptyl, more preferably cyclohexyl, spiro[3.3]heptyl. The aromatic carbocyclic group of A5 is preferably phenyl.

[0655] In compound 1e, the group which may substitute on the non-aromatic heterocyclic group related to A2 is preferably 1 to 3 groups selected from the group consisting of an amino group, an aminoalkyl group having 1 to 6 carbon atoms, and a hydroxy group.

[0656] In compound 1e, the group which may be substituted on the aromatic carbocyclic group in relation to A5 is preferably an aminoalkyl group having 1 to 6 carbon atoms.

[0657] In compound 1e, as X 1 , preferably a carbon atom, as R 1 , preferably halogen, trihaloalkyl having 1 to 6 carbon atoms, or trihaloalkoxy having 1 to 6 carbon atoms. 2 , preferably a hydrogen atom. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0658] In compound 1f-1, A3 is preferably a 3- to 8-membered monocyclic non-aromatic carbocyclic group. As the substitutable group related to the 3- to 8-membered monocyclic non-aromatic carbocyclic group, an amino group is preferred. 1 , preferably a carbon atom, as R 1 , preferably a trihaloalkyl group having 1 to 6 carbon atoms. 2 , preferably a hydrogen atom. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0659] In compound 1f-2, the non-aromatic heterocyclic group of A2 is preferably pyrrolidinyl, piperidinyl, 3-azabicyclo[3.2.1]octan-8-yl, 7-azaspiro[3.5]nonane-2-yl, 2-azaspiro[3.3]heptane-6-yl, azepanyl, azacyclooctanyl, tetrahydropyranyl, more preferably 3-azabicyclo[3.2.1]octan-8-yl, 2-azaspiro[3.3]heptane-6-yl, pyrrolidinyl, piperidinyl, and further preferably piperidinyl. The non-aromatic carbocyclic group of A3 is preferably a 3- to 8-membered monocyclic non-aromatic carbocyclic group, bicyclo[1.1.1]pentane-1-yl, cubane-1-yl, bicyclo[2.2.1]heptane-1-yl, and more preferably cyclobutyl and cyclohexyl.

[0660] In compound 1f-2, the group which may be substituted on the non-aromatic heterocyclic group related to A2 is preferably a halogen atom or an alkyl group having 1 to 6 carbon atoms.

[0661] In compound 1f-2, the group that may substitute on the non-aromatic carbocyclic group related to A3 is preferably 1 to 3 groups selected from amino, aminoalkyl having 1 to 6 carbon atoms, hydroxyl, and alkyl.

[0662] In compound 1f-2, as X 1 , preferably a carbon atom. 1 , preferably a halogen atom, an alkyl group having 1 to 6 carbon atoms, a dihaloalkyl group having 1 to 6 carbon atoms, a trihaloalkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a dihaloalkoxy group having 1 to 6 carbon atoms, a trihaloalkoxy group having 1 to 6 carbon atoms, or an alkylsulfonyl group having 1 to 6 carbon atoms; more preferably a halogen atom, a dihaloalkyl group having 1 to 6 carbon atoms, a trihaloalkyl group having 1 to 6 carbon atoms, a dihaloalkoxy group having 1 to 6 carbon atoms, or a trihaloalkoxy group having 1 to 6 carbon atoms; further preferably a halogen atom, a trihaloalkyl group having 1 to 6 carbon atoms, or a trihaloalkoxy group having 1 to 6 carbon atoms. 2 , preferably a hydrogen atom or a halogen atom. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom. m is preferably 0 or 1, and more preferably 0. 12 Preferred are hydrogen atoms and alkyl groups having 1 to 6 carbon atoms, more preferred are alkyl groups having 1 to 6 carbon atoms, and still more preferred are alkyl groups having 1 to 3 carbon atoms.

[0663] In compound 1f-3, A3 is preferably a 3- to 8-membered monocyclic non-aromatic carbocyclic group. As the group which may be substituted on the 3- to 8-membered monocyclic non-aromatic carbocyclic group, an amino group is preferred. As X 1 , preferably a carbon atom, as R 1 , preferably a trihaloalkyl group. 2 , preferably a hydrogen atom. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0664] In compound 1f-3, the non-aromatic heterocyclic group A2 is preferably pyrrolidinyl, piperidinyl, or piperazinyl, and more preferably piperidinyl. The non-aromatic carbocyclic group A3 is preferably a 3- to 8-membered monocyclic non-aromatic carbocyclic group. It is more preferably cyclobutyl or cyclohexyl, and even more preferably cyclohexyl.

[0665] In compound 1f-3, the group which may be substituted on the non-aromatic carbocyclic group related to A2 is preferably an amino group or a piperazinyl group.

[0666] In compound 1g, the non-aromatic heterocyclic group of A2 is preferably a piperidinyl group, and the group that may be substituted on the non-aromatic carbocyclic group of A2 is preferably an acetyl group. 2 , preferably a hydrogen atom. 3 , preferably a halogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0667] In compounds 1i-1 and 1i-2, the non-aromatic heterocyclic group of A2 is preferably a piperidinyl group, and the group that may substitute on the non-aromatic carbocyclic group related to A2 is preferably an alkyl group having 1 to 6 carbon atoms. 1 , preferably a carbon atom, as R 1 , preferably a trihaloalkyl group. 2 , preferably a hydrogen atom. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0668] In compound 1i-3, A is preferably a 3- to 8-membered monocyclic non-aromatic carbocyclic group. As the group which may substitute on the 3- to 8-membered monocyclic non-aromatic carbocyclic group, (1) an amino group is preferred. 1 , preferably a carbon atom, as R 1 , preferably a halogen atom. 2, preferably a hydrogen atom. 3 , preferably a hydrogen atom. 4 , preferably a carbon atom, as R 4 , preferably a hydrogen atom.

[0669] The compounds of the present invention can be manufactured from known compounds or easily synthesized intermediates, for example, according to the following methods, the embodiments described later, or known methods. In the manufacture of the compounds of the present invention, when the raw materials have substituents that affect the reaction, the raw materials are generally protected with appropriate protecting groups in advance by known methods and then reacted. The protecting groups can be removed by known methods after the reaction.

[0670] The 1,3,4-oxadiazolinone compound of the present invention can be used directly as a drug, or can be used in the form of a pharmaceutically acceptable salt, solvate, or solvate of a salt by a known method. As pharmaceutically acceptable salts, for example, salts of inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid; salts of organic acids such as acetic acid, malic acid, lactic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluenesulfonic acid, benzenesulfonic acid, and methanesulfonic acid; or salts of alkali metals such as lithium, potassium, and sodium; salts of alkaline earth metals such as magnesium and calcium; and salts of organic bases such as ammonium salts. These salts can be formed by commonly performed methods.

[0671] For example, when the compound of the present invention is a hydrochloride, it can be obtained by dissolving the 1,3,4-oxadiazolinone compound of the present invention in a hydrogen chloride alcohol solution, a hydrogen chloride ethyl acetate solution, a hydrogen chloride 1,4-dioxane solution, a hydrogen chloride cyclopentyl methyl ether solution, or a hydrogen chloride ether solution.

[0672] In the compounds of the present invention, for compounds with asymmetric carbon, each stereoisomer and their mixtures are included in the present invention. Stereoisomers, for example, utilize their alkalinity and use optically active acids (tartaric acid, dibenzoyltartaric acid, mandelic acid, 10-camphorsulfonic acid, etc.) to perform optical resolution from racemates by known methods, or optically active compounds prepared in advance can be used as raw materials to produce. In addition, optical resolution using chiral columns and asymmetric synthesis can also be used to produce.

[0673] The formula [1] in the present invention is not limited to specific isomers, and includes all possible isomers and racemates.

[0674] (Method for producing the compound of the present invention)

[0675] The compound [1] of the present invention and its salt can be produced from a known compound or an intermediate which can be easily produced from a known compound, for example, according to the following method, the examples described later or a known method.

[0676] When the solvent, reagent and raw material used in each step of the following manufacture method are commercially available, commercial products can be directly used. In addition, the compound obtained in each step of the manufacture method described later and the raw material used can form a salt, which can be converted into other types of salts or free forms using a known method. On the contrary, when the compound obtained in each step of the following manufacture method and the raw material used are free forms, a known method can be used to convert the salt as the target. As an example of the salt, the salt identical with the salt used in the aforementioned compounds of the present invention can be cited.

[0677] In the manufacture of the compounds of the present invention, when the raw materials have substituents that can affect the reaction, protective groups can be introduced in advance on these substituents using known methods, and the protective groups can be removed as needed after the reaction to obtain the target compound. Such introduction of protective groups and removal of protective groups can be appropriately selected and used, for example, by Wuts and Greene, "Greene's Protective Groups in Organic Synthesis", 4th edition, John Wiley & Sons Inc., 2006, or PJ Kocienski, "Protecting Groups", 3rd edition, Thieme, 2005.

[0678] The compounds obtained in each step of the following production method can be isolated or purified by conventional methods using solvent extraction, concentration, distillation, sublimation, recrystallization, reprecipitation, chromatography, etc., or can be used in the next step in the form of a reaction mixture or a crude product.

[0679] Unless otherwise specified, the reaction of each step in the following production method can be carried out by appropriately modifying or combining the methods described in known methods, for example, RC Larock, "Comprehensive Organic Transformations: A Guide to Functional Group Preparations 2nd Edition", John Wiley & Sons Inc., 1999, "Experimental Chemistry Lectures", 4th edition, Maruzen, 1992, edited by the Chemical Society of Japan, "Strategies of Organic Synthesis Based on the Relationship between Names", Chemical Journal, 2006, L. Kuerti and B. Czako, supervised and translated by Kiyoshi Tomioka, "The Latest Methods, Designs and Strategies of Organic Synthesis", Chemical Journal, 2009, G. S. Zweifel and M. H. Nantz, translated by Tamejiro Hiyama, or the methods described in the Examples.

[0680] The outline of the production of the compound [1] of the present invention is as follows.

[0681] [Chemical formula 5]

[0682]

[0683] (Where X 1 , X 4 , R 1 , R 2 , R 3 , R 4 , A, and L have the same meanings as above. A' or L' represents a group that is converted to A or L respectively after the reaction. LG is a leaving group, and examples thereof include halogen and trifluoromethanesulfonate. AA is an alkyl group, for example, a methyl group, an ethyl group, etc.

[0684] That is, compound 6, which is an intermediate of the compound of the present invention, is obtained by reacting compound 2 with compound 3 (step 1) or compound 4 with compound 5 (step 1'). Then, the ester portion of compound 6 is converted into hydrazide 7 (step 2) to obtain the target 1,3,4-oxadiazolinone compound [1] (step 3).

[0685] Specifically, the compound [1] of the present invention is composed of the following (a) to (h) depending on the combination of A and L in the formula. Furthermore, depending on the type of L, a fused ring represented by z-1, z-2, and z-3 may be formed, and these compounds are also included.

[0686] (a) When L is a connecting key

[0687] A is an aminoalkylamino group, a non-aromatic heterocyclic group, an aromatic carbocyclic group, or an aromatic heterocyclic group.

[0688] (b) When L is an alkylene group

[0689] A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group.

[0690] (c) When L is alkenylene

[0691] A is a non-aromatic heterocyclic group.

[0692] (d) When L is an alkynylene group

[0693] A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group.

[0694] (e) When L is L-1

[0695] A is a non-aromatic heterocyclic group, a non-aromatic carbocyclic group, or an aromatic carbocyclic group.

[0696] (f) When L is L-2

[0697] A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group.

[0698] (g) When L is L-3

[0699] A is a non-aromatic heterocyclic group.

[0700] (h) When L is L-4

[0701] A is a non-aromatic heterocyclic group substituted by an amino group.

[0702] More specifically, the compounds of the present invention include the compounds shown in Table 1 above.

[0703] Although the production methods of the above compounds (a) to (h) and z-1, z-2, and z-3 are described, the production methods of the compounds of the present invention are not limited to the following examples.

[0704] The following method

[0705] · Preparation method a-1: Preparation method when L is a linking bond and A is an aminoalkylamino group (Compound 1a-1)

[0706] · Preparation method a-2: Preparation method when L is a connecting bond and A is a non-aromatic heterocyclic group (Compound 1a-2)

[0707] · Preparation method a-3: Preparation method when L is a connecting bond and A is an aromatic carbocyclic group or an aromatic heterocyclic group (Compound 1a-3)

[0708] Preparation method b: Preparation method when L is an alkylene group and A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group (Compound 1b)

[0709] Preparation method c: Preparation method when L is alkenylene and A is non-aromatic heterocyclic group (Compound 1c)

[0710] Preparation method d: Preparation method when L is an alkynylene group and A is a non-aromatic heterocyclic group (Compound 1d)

[0711] Preparation method e: Preparation method when L is L-1 and A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group (Compound 1e)

[0712] Preparation method f-1: L is L-2, A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group, and Y is S or -NR 14 - Preparation method of (compound 1f-1 or 1f-2)

[0713] It can be produced by the following method.

[0714] [Chemical formula 6]

[0715]

[0716] (Where X 1 , X 4 , R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 14 , A1, A2, A3, A4, A5, "A2 or A3", or "A4 or A5" have the same meanings as above. LG 1 is a leaving group, and the same groups as those mentioned above for LG can be mentioned. PG 1 is a protecting group, and examples thereof include tert-butoxycarbonyl and benzyloxycarbonyl. AA is an alkyl group, for example, methyl group, ethyl group, etc. BB , and R CC All represent hydroxyl groups, or R BB With R CC Together they form -OC(CH3)2-C(CH3)2-O-, -O-(CH2)3-O-, or O-CH2-C(CH3)2-CH2-O-. )

[0717] [Chemical formula 7]

[0718]

[0719] (Where X 1 , X 4 , R1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 14 , A1, A2, A3, A4, A5, "A2 or A3", "A2 or A3 or A5", LG 1 , R AA Same as above. DD is an alkyl group, for example, a methyl group, an ethyl group, and a n-butyl group can be mentioned.)

[0720] [Chemical formula 8]

[0721]

[0722] (Where X 1 , X 4 , R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 14 , R AA Same meaning as above.)

[0723] Preparation a-1, preparation a-2, preparation a-3, preparation b, preparation c, preparation e and preparation f-1

[0724] Step 1

[0725] This step is a step of coupling compound 2-1 with the following compounds: compound 8 (Preparation method a-1), compound 9 (Preparation method a-2), compound 10 (Preparation method a-3), compound 11 (Preparation method b), compound 12 (Preparation method c), compound 13 (Preparation method e), compound 14a (Preparation method f), or compound 14b (Preparation method f) in the presence of a transition metal such as palladium to obtain compound 6a-1, 6a-2, 6a-3, 6c, 6d, 6e, 6f-1 or 6f-2, respectively.

[0726] This reaction can be carried out under commonly used conditions by a coupling reaction using a transition metal. Examples of the coupling reaction using a transition metal include the Suzuki-Miyaura coupling reaction, the Stille reaction, the Sonogashira coupling reaction, the Heck reaction, and the Buckwald coupling reaction.

[0727] Examples of the Suzuki-Miyaura coupling reaction include reactions described in Suzuki et al., Chem. Rev., 1995, 95, 2457-2483, etc., which can be applied to step 1a-3 of the above-mentioned preparation method a-3.

[0728] Examples of the Stille reaction include reactions described in Stille et al., Angew. Chem. Int. Ed. Engl. 1986, 25, 508-524, Stille et al., Org. Synthesys 1990, 68, 116, etc. These reactions can be applied to step 1c of the above-mentioned preparation method c.

[0729] Examples of the Sonogashira reaction include reactions described in Sonogashira et al., J. Organomet. Chem. 2002, 653, 46-49, Negishi et al., Chem. Rev., 2003, 103, 1979-2017, etc., which can be applied to step 1d of the above-mentioned preparation method b.

[0730] Examples of the Heck reaction include reactions described in Heck et al., Org. Synth. 2005, 81, 63-76, Heck et al., J. Org. Chem. 1972, 37, 2320-2322, Beletskaya et al., Chem. Rev. 2000, 100, 3009-3066, and the like.

[0731] As examples of the coupling reaction of Buckwald et al., there can be listed the reactions in Buckwald et al., J. Am. Chem. Soc. 1994, 116, 7901-7902., Buckwald et al., Org. Synth. 2002, 78, 23-28. Hartwig et al., Acc. Chem. Res. 2008, 41, 1534-1544., etc., which can be applied to step 1a-1 of the above-mentioned preparation a-1, step 1a-2 of preparation a-2, step 1e of preparation e, or step 1f of preparation f.

[0732] The amount of Compound 8 to Compound 13, Compound 14a, or Compound 14b used is appropriately within a range of 0.5 molar equivalent to 3 molar equivalents relative to Compound 2-1.

[0733] The organic metal catalyst used in the present reaction is not particularly limited. Preferred examples of the organic metal catalyst include tris(dibenzylideneacetone)dipalladium·chloroform adduct (hereinafter referred to as "Pd2(dba)3·CHCl3"), tris(dibenzylideneacetone)dipalladium (hereinafter referred to as "Pd2(dba)3"), tetrakis(triphenylphosphine)palladium (hereinafter referred to as "Pd(PPh3)4"), [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II)·dichloromethane adduct (hereinafter referred to as "Pd(dppf)Cl2·CH2Cl2"), bis(triphenylphosphine) Metal catalysts such as palladium (II) dichloride (hereinafter referred to as "PdCl2(PPh3)2"), [1,1'-bis(di-tert-butylphosphino)ferrocene]-palladium (II) dichloride (hereinafter referred to as "Pd(dtbpf)Cl2"), bis(tricyclohexylphosphine)palladium (II) dichloride (hereinafter referred to as "PdCl2(PCy3)2"), palladium (II) acetate (hereinafter referred to as "Pd(OAc)2"), and [1,3-bis(diphenylphosphino)propane]nickel (II), as well as mixtures of these metal catalysts.

[0734] The amount of the transition metal to be used is appropriately within a range of, for example, 0.01 to 0.3 molar equivalents relative to compound 2-1.

[0735] In this step, a base or salt may be used as required. Examples of the base or salt used include potassium carbonate, cesium carbonate, sodium carbonate, sodium bicarbonate, sodium acetate, potassium acetate, trisodium phosphate, tripotassium phosphate, and solutions thereof, as well as triethylamine (hereinafter referred to as "TEA"), N,N-diisopropylethylamine (hereinafter referred to as "DIPEA"), lithium chloride, and copper (I) iodide.

[0736] The amount of the base to be used is appropriately within the range of, for example, 1 to 4 molar equivalents relative to compound 2-1.

[0737] In this step, appropriate ligands can be used as needed. Examples of usable ligands include 1,1'-bis(diphenylphosphino)ferrocene (hereinafter referred to as "dppf"), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (hereinafter referred to as "Xantphos"), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (hereinafter referred to as "XPhos"), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (hereinafter referred to as "BINAP"), 2-dicyclohexylphosphino-2',6'-diisopropylbiphenyl (hereinafter referred to as "RuPhos"), triphenylphosphine (hereinafter referred to as "PPh3"), tricyclohexylphosphine (hereinafter referred to as "PCy3"), etc.

[0738] The amount of the ligand used is appropriately within a range of, for example, 1 to 5 molar equivalents relative to the transition metal used.

[0739] In this step, the solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane, tetrahydrofuran (hereinafter referred to as "THF"), and dimethoxyethane (hereinafter referred to as "DME"), amides such as N,N-dimethylformamide (hereinafter referred to as "DMF"), N,N-dimethylacetamide (hereinafter referred to as "DMA"), and N-methylpyrrolidone (hereinafter referred to as "NMP"), alcohols such as ethanol, 2-propanol, and tert-butanol, water, or a mixed solvent thereof.

[0740] The reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within a range of 20° C. to 200° C. In addition, a microwave reaction apparatus may be used as necessary.

[0741] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.1 hour to 24 hours.

[0742] Step 2

[0743] This step is a reaction for reducing the triple bond of compound 6d to obtain compound 6b.

[0744] This reaction can be carried out by reacting compound 6d in the presence of a metal catalyst and a hydrogen source under a hydrogen pressure of 1 to 20 atmospheres in an inert solvent.

[0745] The reaction is not limited to any metal catalyst that can be used for the reduction of a common unsaturated carbon bond, and examples thereof include heterogeneous catalysts such as palladium-carbon, palladium black, palladium chloride, palladium hydroxide, rhodium-carbon, platinum oxide, platinum black, platinum-palladium, Raney nickel, and palladium-carbon ethylenediamine complexes.

[0746] The amount of the metal catalyst to be used is appropriately within a range of, for example, 0.001 to 1000 equivalents relative to compound 6d.

[0747] Examples of the hydrogen source include hydrogen gas and ammonium formate.

[0748] When ammonium formate is used as the hydrogen source, the amount of ammonium formate used is usually appropriately within a range of 2 to 100 equivalents relative to compound 15d.

[0749] In this step, the inert solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane, THF, and DME, amides such as DMF, DMA, and NMP, alcohols such as ethanol, 2-propanol, and tert-butanol, water, or mixed solvents thereof.

[0750] The reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within the range of 20°C to 200°C.

[0751] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.1 hour to 24 hours.

[0752] Step 3

[0753] This step is a step of converting the ester of compound 6a-1, 6a-2, 6a-3, 6b, 6c, 6d, 6e, 6f-1 or 6f-2 into hydrazide compound 7a-1, 7a-2, 7a-3, 7b, 7c, 7d, 7e, 7f-1, 7f-2 or 7f-3 in the presence of hydrazine or a hydrazine salt.

[0754] Examples of the hydrazine or hydrazine salt to be used include hydrazine monohydrate, hydrazine hydrochloride, and hydrazine sulfate.

[0755] The amount of hydrazine or hydrazine salt used is appropriately within the range of 1 to 100 molar equivalents relative to compound 6a-1, 6a-2, 6a-3, 6b, 6c, 6d, 6e, or 6f-1.

[0756] In this step, the solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane, THF, and DME, amides such as DMF, DMA, and NMP, alcohols such as ethanol, 2-propanol, and tert-butanol, water, or mixed solvents thereof.

[0757] The reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within the range of 20°C to 200°C.

[0758] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.1 hour to 24 hours.

[0759] Step 4

[0760] This step is a step of converting hydrazide compounds 7a-1, 7a-2, 7a-3, 7b, 7c, 7d, 7e, 7f-1, 7f-2, or 7f-3 into 1,3,4-oxadiazolinone compounds 1a-1, 1a-2, 1a-3, 1b, 1c, 1d, 1e, 1f-1, 1f-2, or 1f-3, respectively, in the presence of a base and a carbonyl reagent.

[0761] Examples of the carbonylating agent used include N,N′-carbonyldiimidazole, triphosgene, methyl chlorocarbonate, and ethyl chlorocarbonate.

[0762] The amount of the carbonylating agent used is appropriately within a range of 1 to 10 molar equivalents relative to the hydrazide compound as a raw material.

[0763] Examples of the base include potassium carbonate, cesium carbonate, sodium carbonate, sodium hydrogen carbonate, sodium acetate, potassium acetate, trisodium phosphate, tripotassium phosphate and solutions thereof, as well as TEA, DIPEA, pyridine and 1,8-diazabicyclo[5.4.0]undec-7-ene.

[0764] The amount of the base used is appropriately within a range of 1 to 10 molar equivalents relative to the hydrazide compound as a raw material.

[0765] In this step, the solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane, THF, and DME, amides such as DMF, DMA, and NMP, and mixed solvents thereof.

[0766] The reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within a range of 20° C. to 200° C. In addition, a microwave reaction apparatus may be used as necessary.

[0767] The reaction time varies depending on the type of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.1 hour to 24 hours.

[0768] When a protecting group is introduced as in the following compound 1a'-1, the target compound can be obtained by removing the protecting group as needed as described above. The removal of the protecting group can be carried out, for example, with reference to Wuts and Greene, "Greene's Protective Groups in Organic Synthesis", 4th edition, John Wiley & Sons Inc., 2006, or PJ Kocienski, "Protecting Groups", 3rd edition, Thieme, 2005.

[0769] [Chemical formula 9]

[0770]

[0771] (Where X 1 , X 4 , R 1 , R 2 , R 3 , R 4 , A1, PG 1 Same meaning as above.)

[0772] Preparation method f-1: L is L-2, A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group, and Y is -NR 15 - Preparation method of (compound 1f-2) (Part 2)

[0773] Compound 7f-2 can also be produced by the following method.

[0774] [Chemical formula 10]

[0775]

[0776] (Where X 1 , X 4 , R 1 , R 4 , R 12 , R 14 , A2, A3, "A2 or A3", and m have the same meanings as above. Y' is -NR 15 -, R 14 Same as above. LG 3 is a leaving group, and examples thereof include a bromine atom, an iodine atom, and a trifluoromethanesulfonate group. )

[0777] Step 1

[0778] This step is a step of obtaining 6f-2' by reacting compound 2-2 with compound 14b in the presence of a base in an appropriate solvent.

[0779] Examples of the base used in the present reaction include pyridine, TEA, DIPEA, potassium carbonate and sodium hydrogen carbonate.

[0780] The amount of the base to be used is appropriately within a range of 1 to 10 molar equivalents relative to compound 2-2.

[0781] The solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include alcohols such as isopropanol, 1-butanol, and 2-methoxyethanol, ethers such as THF and 1,4-dioxane, amides such as DMF, DMA, and NMP, hydrocarbons such as benzene and toluene, dimethyl sulfoxide (hereinafter referred to as "DMSO"), acetonitrile, or mixed solvents thereof.

[0782] In this step, the reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within a range of 20° C. to 200° C. In addition, a microwave reaction apparatus may be used as necessary.

[0783] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 1 hour to 24 hours.

[0784] Step 2

[0785] This step is a step of obtaining a cyano compound 6f-2" by reacting a compound 6f-2' in a suitable solvent in the presence of a cyanide and a transition metal such as palladium.

[0786] Examples of the cyanide used include zinc cyanide, copper cyanide, sodium cyanide, and potassium cyanide.

[0787] The amount of the cyanide used is appropriately within a range of 1 to 10 molar equivalents relative to compound 6f-2'.

[0788] Examples of the transition metal to be used include the same transition metals as those listed in step 1 of Preparation a-1, Preparation a-2, Preparation a-3, Preparation b, Preparation c, Preparation e and Preparation f-1.

[0789] The amount of the transition metal to be used is appropriately within a range of, for example, 0.01 to 0.3 molar equivalents relative to compound 6f-2'.

[0790] In this step, a base or salt may be used as required. Examples of the base or salt used include potassium carbonate, cesium carbonate, sodium carbonate, sodium bicarbonate, sodium acetate, potassium acetate, trisodium phosphate, tripotassium phosphate, and solutions thereof, as well as TEA, DIPEA, lithium chloride, and copper (I) iodide.

[0791] The amount of the base to be used is appropriately within a range of, for example, 1 to 4 molar equivalents relative to compound 6f-2'.

[0792] In this step, the solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane, THF, and DME, amides such as DMF, DMA, and NMP, alcohols such as ethanol, 2-propanol, and tert-butanol, water, or mixed solvents thereof.

[0793] The reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within a range of 20° C. to 200° C. In addition, a microwave reaction apparatus may be used as necessary.

[0794] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.1 hour to 24 hours.

[0795] Step 3

[0796] This step is a step of hydrolyzing the nitrile part of compound 6f-2" in the presence of a suitable acid or base to obtain compound 6f-2'".

[0797] In this step, the acid used includes inorganic acids such as hydrochloric acid and sulfuric acid, and organic acids such as trifluoroacetic acid (hereinafter referred to as "TFA"), methanesulfonic acid, and toluenesulfonic acid. The base includes inorganic bases such as sodium hydroxide, potassium hydroxide, and lithium hydroxide.

[0798] In this step, the amount of the acid or base used is appropriately in the range of 1 to 10 molar equivalents relative to compound 6f-2". If necessary, an excess amount of the acid or base may be used relative to compound 6f-2".

[0799] The solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include alcohols such as methanol, ethanol, and 2-propanol, ethers such as THF, diethyl ether, 1,4-dioxane, and DME, nitriles such as acetonitrile and propionitrile, ketones such as acetone, water, and mixed solvents thereof.

[0800] The reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within a range of 20° C. to 200° C. In addition, a microwave reaction apparatus may be used as necessary.

[0801] The reaction time varies depending on the type of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.5 hours to 4 days.

[0802] Preparation method f-2: Preparation method when L is L-2, A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group, and Y is O

[0803] [Chemical formula 11]

[0804]

[0805] (Where X 1 , X 4 , R 1 , R 2 , R 3 , R 4 , R 12 , A2 or A3, m, R AA Same meaning as above.)

[0806] Step 1

[0807] This step is a step of obtaining the ether compound 6f-3 by the Mitsunobu reaction of the compound 2-3 and the compound 14c, and can be carried out according to a known method.

[0808] This step is usually carried out in a suitable solvent in the presence of an azodicarboxylate reagent and a phosphine reagent.

[0809] The amount of compound 14c used is appropriately within a range of 0.5 to 1.5 molar equivalents relative to compound 2-3.

[0810] Examples of the azodicarboxylate reagent to be used include diethyl azodicarboxylate (hereinafter referred to as "DEAD"), diisopropyl azodicarboxylate (hereinafter referred to as "DIAD"), and bis(2-methoxyethyl)azodicarboxylate (hereinafter referred to as "DMEAD").

[0811] Examples of the phosphine reagent to be used include triphenylphosphine and tributylphosphine.

[0812] The amount of the azodicarboxylate reagent to be used is appropriately within a range of 1 to 2 molar equivalents relative to compound 2-3.

[0813] The amount of the phosphine reagent to be used is appropriately within the range of 1 to 2 molar equivalents relative to compound 2-3.

[0814] The solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane, THF, and DME, and mixed solvents thereof.

[0815] In this step, the reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within the range of 0°C to 100°C.

[0816] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.5 to 24 hours.

[0817] Step 2, Step 3

[0818] This step is a step of converting the ester portion of compound 6f-3 to 1,3,4-oxadiazolinone compound 1f-3 via hydrazide compound 7f-3, and can be produced by the same method as steps 2 and 3 of the above-mentioned preparation method 1a.

[0819] Preparation method g: When L is L-3 and A is a non-aromatic heterocyclic group

[0820] [Chemical formula 12]

[0821]

[0822] (Where X 1 , X 4 , R 1 , R 2 , R 3 , R 4 , R AA , and A1 have the same meanings as above. 2 is a leaving group, and examples thereof include a chlorine atom, a bromine atom, a trifluoromethanesulfonate group, a methanesulfonate group, and a p-toluenesulfonate group.)

[0823] Step 1

[0824] This step is a step of obtaining 6 g by reacting compound 4-1 and compound 9 in the presence of a base in an appropriate solvent. It can be produced by the same method as step 1 of production method f-1 (part 2).

[0825] Examples of the base used in the present reaction include pyridine, TEA, DIPEA, potassium carbonate and sodium hydrogen carbonate.

[0826] The amount of the base to be used is appropriately within a range of 1 to 10 molar equivalents relative to compound 4'.

[0827] The solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include alcohols such as isopropanol, 1-butanol, and 2-methoxyethanol, ethers such as THF and 1,4-dioxane, amides such as DMF, DMA, and NMP, hydrocarbons such as benzene and toluene, halogenated hydrocarbons such as DMSO, acetonitrile, and dichloromethane, and mixed solvents thereof.

[0828] In this step, the reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within a range of 20° C. to 200° C. In addition, a microwave reaction apparatus may be used as necessary.

[0829] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 1 hour to 24 hours.

[0830] Step 2, Step 3

[0831] This step is a step of converting the ester portion of compound 6g into 1,3,4-oxadiazolinone compound 1g via hydrazide compound 7g, and can be produced by the same method as steps 2 and 3 of the above-mentioned production method 1a.

[0832] Preparation method h: When L is L-4 and A is 1,3-dioxane-2-yl substituted with amino group

[0833] [Chemical formula 13]

[0834]

[0835] (Where X 1 , X 4 , R 1 , R 2 , R 3 , R 4 , R AA LG 1 PG 1 Same meaning as above.)

[0836] Step 1

[0837] This step is a step of obtaining 16 by coupling reaction of compound 2-1 with compound 15 in the presence of a transition metal such as palladium, and can be produced by the same method as step 1 of the above-mentioned preparation method a-1, preparation method a-2, preparation method a-3, preparation method b, preparation method c, preparation method e and preparation method f-1.

[0838] Step 2

[0839] This step is a step of reducing compound 16 to obtain compound 17 using a reducing agent.

[0840] For example, there can be mentioned a method using, as the reducing agent, a metal hydride complex such as lithium borohydride, a metal hydride such as diisobutylaluminum hydride, diborane, or a substituted borane.

[0841] The amount of the reducing agent to be used is appropriately within a range of 1 to 5 molar equivalents relative to Compound 16.

[0842] In this reaction, an organic acid such as hydrochloric acid, a Lewis acid such as lithium chloride, or boron trifluoride etherate may be used as necessary.

[0843] When an organic acid or a Lewis acid is used, the amount thereof used is appropriately within a range of 1 to 5 molar equivalents relative to compound 16, and is usually used in the same molar amount as the reducing agent.

[0844] The solvent used in this step is not particularly limited as long as it does not participate in the reaction, and examples thereof include alcohols such as methanol and ethanol, ethers such as THF, 1,4-dioxane, and DME, halogenated hydrocarbons such as dichloromethane, water, or mixed solvents thereof.

[0845] The reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within the range of -10°C to 80°C.

[0846] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.1 hour to 24 hours.

[0847] Step 3

[0848] This step is a step of cyclopropanating the double bond portion of compound 17 to obtain compound 18, which can be prepared by referring to, for example, Simmons et al., Org. Synth. 1961, 72-73., Simmons et al., J. Am. Chem. Soc. 1958, 80, 5323-5324., Simmons et al., J. Am. Chem. Soc. 1959, 81, 4256-4264., Hoveyda et al., Chem. Rev. 1993, 93, 1307-1370.

[0849] This step is usually carried out in a suitable solvent in the presence of a zinc carbene prepared from a dihalomethane and zinc.

[0850] The zinc carbene used in this step is prepared from, for example, dihalomethane such as diiodomethane and dibromomethane and zinc.

[0851] In this step, zinc is usually used in the form of an alloy with copper or silver.

[0852] Examples of zinc to be used include metallic zinc, etc. Diethylzinc, samarium, triethylaluminum, etc. may be used instead of zinc.

[0853] The amount of the dihalogenated methane used is appropriately within a range of 1 to 10 molar equivalents relative to Compound 17.

[0854] The amount of metal zinc, diethylzinc, samarium, and triethylaluminum used is appropriately within the range of 0.5 to 10 molar equivalents relative to Compound 17.

[0855] In this step, an organic acid such as trifluoroacetic acid or dibutyl phosphate may be used as necessary.

[0856] The amount of the organic acid to be used is appropriately within the range of, for example, 0.5 to 10 molar equivalents relative to Compound 17.

[0857] The solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane, THF, and DME, and mixed solvents thereof.

[0858] In this step, the reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within the range of -20°C to 100°C.

[0859] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.5 to 24 hours.

[0860] Step 4

[0861] This step is a step of oxidizing the hydroxyl group of compound 18 to obtain compound 19.

[0862] The reaction is not particularly limited as long as it can oxidize a hydroxyl group to an aldehyde. Examples of the oxidation reaction of a hydroxyl group include the following reactions:

[0863] Dess-Martin reaction using Dess-Martin periodinogen reagent (Dess et al., J. Org. Chem. 1983, 48, 4155-4156., Dess et al., Org. Synth. 2000, 77, 141-147.),

[0864] Oxidation using oxalyl chloride and DMSO (Swern et al., J. Org. Chem. 1978, 43, 2480-2482., Swern et al., Tetrahedron 1978, 73, 1651-1660.),

[0865] · Oxidation by Parikh and Doering et al. using sulfur trioxide-pyridine complex and DMSO (Parikh et al., J. Am. Chem. Soc. 1967, 89, 5505-5507.),

[0866] Chromic acid oxidation using pyridinium chlorochromate or pyridinium dichromate (Corey et al., Tetrahedron Lett. 1979, 399-402., Cheng et al., Synthesis 1980, 223-224.), and the production can be carried out with reference to these documents.

[0867] For example, when compound 19 is obtained by the Dess-Martin reaction, compound 18 is reacted in an appropriate solvent in the presence of a base and a Dess-Martin periodinogen reagent (hereinafter referred to as "Dess-Martin reagent").

[0868] The amount of the Dess-Martin reagent to be used is appropriately within a range of, for example, 1 to 3 molar equivalents relative to Compound 18.

[0869] Examples of the base include TEA, DIPEA, pyridine and 2,6-lutidine.

[0870] The amount of the base to be used is appropriately within the range of, for example, 1 to 3 molar equivalents relative to Compound 18.

[0871] In this step, the solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include hydrocarbons such as toluene and xylene, ethers such as 1,4-dioxane, tetrahydrofuran (hereinafter referred to as "THF"), and dimethoxyethane (hereinafter referred to as "DME"), halogenated hydrocarbons such as dichloromethane and dichloroethane, or mixed solvents thereof.

[0872] The reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within the range of -20°C to 40°C.

[0873] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.1 hour to 24 hours.

[0874] Step 5

[0875] This step is a step of reacting the aldehyde of compound 19 with the diol compound 20 to obtain the acetal compound 21, and can be carried out with reference to, for example, Wuts and Greene, “Greene's Protective Groups in Organic Synthesis”, 4th edition, John Wiley & Sons Inc., 2006, or PJ Kocienski, “Protecting Groups”, 3rd edition, Thieme, 2005.

[0876] Step 6

[0877] This step is to crack the phthalimide part of compound 21 to obtain an amine compound, and then introduce a protective group (PG 1 ) can be performed with reference to, for example, Wuts and Greene, “Greene's Protective Groups in Organic Synthesis”, 4th edition, John Wiley & Sons Inc., 2006, or PJ Kocienski, “Protecting Groups”, 3rd edition, Thieme, 2005.

[0878] Step 7, Step 8,

[0879] This step is a step of converting the ester portion of compound 6h into 1,3,4-oxadiazolinone compound 1h' via hydrazide compound 7h, and can be produced by the same method as steps 2 and 3 of the above-mentioned production method 1a.

[0880] Step 9

[0881] This step is to protect the group PG 1 The deprotection step can be carried out with reference to, for example, Wuts and Greene, “Greene's Protective Groups in Organic Synthesis”, 4th edition, John Wiley & Sons Inc., 2006, or PJ Kocienski, “Protecting Groups”, 3rd edition, Thieme, 2005.

[0882] Preparation method i-1: L is L-2, Y is -NR 15 -、R 1 and R 15 When formed with adjacent atoms (in z-1, R 21 is oxo, alkyl oxime)

[0883] [Chemical formula 14]

[0884]

[0885] (Where X 4 , R 2 , R 3 , R 4 , R 12 , R 23 , R AA , A4, m, LG 1 PG 1 Same meaning as above.)

[0886] Step 1

[0887] This step is a step of reacting compound 2-4 with an amino compound 14d to obtain a cyclized compound 6i-1, which can be produced by the same method as step 1 of production method f-1 (part 2).

[0888] Step 2, Step 3

[0889] This step is a step of converting the ester portion of compound 6i into 1,3,4-oxadiazolinone compound 1i-1 via hydrazide compound 7i-1, and can be produced by the same method as steps 2 and 3 of the above-mentioned production method 1a.

[0890] Step 4

[0891] This step is a step of converting the ketone part of compound 7i-1 into oxime compound 7i-2 by reacting O-alkylhydroxylamine in the presence of a base in an appropriate solvent.

[0892] Examples of the O-alkylhydroxyamine to be used include O-methylhydroxyamine and O-ethylhydroxyamine.

[0893] The amount of O-alkylhydroxylamine to be used is appropriately within a range of 1 to 10 molar equivalents relative to compound 7i-1.

[0894] Examples of the base used in the present reaction include pyridine, TEA, DIPEA, potassium carbonate, sodium hydrogen carbonate and the like.

[0895] The amount of the base to be used is appropriately within a range of 1 to 10 molar equivalents relative to compound 7i-1.

[0896] The solvent used is not particularly limited as long as it does not participate in the reaction, and examples thereof include alcohols such as isopropanol, 1-butanol, and 2-methoxyethanol, ethers such as THF and 1,4-dioxane, amides such as DMF, DMA, and NMP, hydrocarbons such as benzene and toluene, dimethyl sulfoxide (hereinafter referred to as "DMSO"), acetonitrile, or mixed solvents thereof.

[0897] In this step, the reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within a range of 20° C. to 200° C. In addition, a microwave reaction apparatus may be used as necessary.

[0898] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 1 hour to 24 hours.

[0899] Step 5

[0900] This step is a step of converting the hydrazide part of compound 7i-2 to 1,3,4-oxadiazolinone 1i-2, which can be produced by the same method as step 3 of the above-mentioned production method 1a.

[0901] Preparation method i-2: L is L-2, Y is -NR 15 -、R 1 and R 15 When formed with adjacent atoms (in z-1, R 21is a hydrogen atom)

[0902] [Chemical formula 15]

[0903]

[0904] (Where X 4 , R 2 , R 3 , R 4 , R 12 , R AA , A2 or A3, m, have the same meaning as above. LG 3 is a leaving group, and examples thereof include a chlorine atom, a bromine atom, a trifluoromethanesulfonate group, a methanesulfonate group, and a p-toluenesulfonate group.)

[0905] Step 1

[0906] This step is a step of obtaining 6i-2 by reacting compound 2-5 and compound 23 in the presence of a base in an appropriate solvent. It can be produced by the same method as step 1 of preparation method g.

[0907] Step 2, Step 3

[0908] This step is a step of converting the ester portion of compound 6i-2 into 1,3,4-oxadiazolinone compound 1i-3 via hydrazide compound 7i-3, and can be produced by the same method as steps 2 and 3 of the above-mentioned production method 1a.

[0909] Preparation method j-1: L is L-2, Y is -NR 15 -、R 1 and R 15 Production method when forming with adjacent atoms (z-2) (Part 1)

[0910] [Chemical formula 16]

[0911]

[0912] (Where X 4 , R 2 , R 3 , R 4 , R 12 , R 22 , R AA , A 2 or A 3 , m, n, and LG 1 , has the same meaning as above. PG 2 is a protecting group, for example, benzyl, p-methoxybenzyl, etc.

[0913] Step 1

[0914] This step is a step of obtaining compound 23 by coupling reaction of compound 2-6 with compound 14d in the presence of a transition metal such as palladium, and can be produced by the same method as step 1 of preparation method f.

[0915] Step 2

[0916] This step is to protect the group PG 2 The deprotection step can be carried out with reference to, for example, Wuts and Greene, “Greene's Protective Groups in Organic Synthesis”, 4th edition, John Wiley & Sons Inc., 2006 or PJ Kocienski, “Protecting Groups”, 3rd edition, Thieme, 2005.

[0917] Step 3

[0918] This step is a step of obtaining compound 6j by using 25 as an alkylating agent on compound 24 in the presence of a base, and can be carried out by a method known per se.

[0919] Examples of the alkylating agent to be used include 1,2-dibromoethane and 1,3-dibromopropane.

[0920] The amount of the alkylating agent to be used is appropriately within the range of 2 to 3 molar equivalents relative to compound 25.

[0921] Examples of the base include sodium hydride, potassium hydride, potassium carbonate, sodium carbonate, cesium carbonate, sodium hydrogen carbonate, sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium tert-butoxide, and DBU.

[0922] The amount of the base to be used is appropriately within the range of 2 to 5 molar equivalents relative to compound 25.

[0923] The reaction solvent is not particularly limited as long as it does not participate in the reaction, and examples thereof include amides such as DMF and DMA, ethers such as THF, nitriles such as acetonitrile, DMSO, and mixed solvents thereof.

[0924] The reaction temperature varies depending on the types of raw materials and reagents used, but is usually appropriately within a range of 20°C to 150°C.

[0925] The reaction time varies depending on the types of raw materials used and the reaction temperature, but is usually appropriately within the range of 0.5 to 24 hours.

[0926] Step 4, Step 5

[0927] This step is a step of converting the ester portion of compound 6j to 1,3,4-oxadiazolinone compound 1j via hydrazide compound 7j, and can be produced by the same method as steps 2 and 3 of the above-mentioned production method 1a.

[0928] The above-mentioned compound 6j can also be produced by the following method.

[0929] Preparation method of compound 6j

[0930] [Chemical formula 17]

[0931]

[0932] (Where X 4 , R 2 , R 3 , R 4 , R 12 , R 22 , R AA , A 2 or A 3 ,m,n,PG 1 , and LG 1 Same meaning as above.)

[0933] Step 1

[0934] This step is a step of obtaining ether compound 27 by reacting compound 2-7 with compound 26, and can be produced by the same method as step 1 of production method f-2.

[0935] Step 2

[0936] This step is to protect the group PG 2 The deprotection step can be carried out with reference to, for example, Wuts and Greene, “Greene's Protective Groups in Organic Synthesis”, 4th edition, John Wiley & Sons Inc., 2006 or PJ Kocienski, “Protecting Groups”, 3rd edition, Thieme, 2005.

[0937] Step 3

[0938] This step is a step of obtaining compound 6j by intramolecular coupling reaction of compound 28 in the presence of a transition metal such as palladium, and can be produced by the same method as step 1 of preparation method f.

[0939] Preparation method k: L is L-2, Y is -NR 15 -、R1 and R 15 When it is formed with adjacent atoms (z-3)

[0940] [Chemical formula 18]

[0941]

[0942] (Where R 2 , R 3 , R 4 , R 12 , R AA , A 2 or A 3 , and m have the same meanings as above.)

[0943] Step 1

[0944] This step is a step of obtaining ether compound 6k by reacting compound 2-8 with compound 29, and can be produced by the same method as step 1 of production method f-2.

[0945] Step 2, Step 3

[0946] This step is a step of converting the ester portion of compound 6k to 1,3,4-oxadiazolinone compound 1k via hydrazide compound 7k, and can be produced by the same method as steps 2 and 3 of the above-mentioned production method 1a.

[0947] The compounds of the present invention have PIM kinase inhibitory activity as shown in the test examples described below. In addition, the compounds of the present invention have anti-immune abnormality, anti-inflammatory action, and anti-cancer action due to their PIM kinase inhibitory activity.

[0948] Therefore, the compound of the present invention or a pharmaceutically acceptable salt thereof can be used as a preventive or therapeutic agent for diseases in which PIM kinase is involved, for example.

[0949] Diseases for which the compounds of the present invention or pharmaceutically acceptable salts thereof are applicable include, for example, multiple sclerosis (see, for example, Patent Document 1), rheumatoid arthritis (see, for example, Non-Patent Document 4), food allergies (see, for example, Non-Patent Document 5), asthma (see, for example, Non-Patent Document 6), systemic lupus erythematosus (see, for example, Patent Document 1 and Non-Patent Document 4), lupus nephritis (see, for example, Patent Document 1 and Non-Patent Document 4), inflammatory bowel disease (see, for example, Non-Patent Document 7), ulcerative colitis (see, for example, Non-Patent Document 8), atopic dermatitis (see, for example, Non-Patent Document 9), autoimmune lymphoproliferative syndrome (see, for example, Patent Document 1), chronic obstructive pulmonary disease (see, for example, Non-Patent Document 10), allergic respiratory syncope (see, for example, Non-Patent Document 11), and inflammatory bowel disease (see, for example, Non-Patent Document 12). diseases (e.g., non-patent document 11), eosinophilic granulomatosis with polyangiitis (e.g., non-patent document 9), eosinophilic syndrome (e.g., non-patent document 9), chorioamnionitis (e.g., non-patent document 12), ankylosing spondylitis (e.g., non-patent document 4), myasthenia gravis (e.g., non-patent document 13), psoriasis (e.g., non-patent document 14), prostate cancer (e.g., see non-patent document 15), colorectal cancer (e.g., see non-patent documents 16 and 17), esophageal cancer (e.g., see non-patent documents 18 and 19), ovarian cancer (e.g., see non-patent document 20), uterine cancer (e.g., see non-patent documents 21, 22, and 23), kidney cancer (e.g., see non-patent document 24), liver cancer (e.g., see non-patent document 25), cancer (for example, see non-patent document 25), pancreatic cancer (for example, see non-patent document 26), gastric cancer (for example, see non-patent document 27), breast cancer (for example, see non-patent document 28), lung cancer (for example, see non-patent documents 29, 30), head and neck cancer (for example, see non-patent document 31), glioma (for example, see non-patent documents 32, 33), osteosarcoma (for example, see non-patent documents 34, 35, 36), bladder cancer (for example, see non-patent document 37), acute lymphocytic leukemia (for example, see non-patent document 38), acute myeloid leukemia (for example, see non-patent document 39), chronic lymphocytic leukemia (for example, see non-patent document 40), chronic myeloid leukemia (for example, see non-patent document 41), For example, non-patent document 41), B-cell lymphoma (for example, see non-patent documents 42, 43, and 44), multiple myeloma (for example, see non-patent documents 45 and 46), T-cell lymphoma (for example, non-patent document 47), skin cancer (for example, non-patent document 48), Kaposi's sarcoma (for example, non-patent document 49), Hodgkin's lymphoma (for example, non-patent document 50), myeloproliferative neoplasms (for example, non-patent document 51), adenoid cystic carcinoma (for example, non-patent document 52), Ewing's sarcoma (for example, non-patent document 53), adult T-cell leukemia (for example, non-patent document 54), mesothelioma (for example, non-patent document 55), acute promyelocytic leukemia (for example, non-patent document 56), choriocarcinoma (for example,Non-patent document 57), liposarcoma (e.g., non-patent document 58), neuroblastoma (e.g., non-patent document 59), seminoma (e.g., non-patent document 60), lymphoblastic lymphoma (e.g., non-patent document 46), Epstein-Barr virus infection or hemophagocytic syndrome known to involve Epstein-Barr virus (e.g., refer to non-patent document 61), influenza (e.g., non-patent document 62), hepatitis C (e.g., non-patent document 63), Salmonella infection (e.g., non-patent document 64), herpes virus infection (e.g., non-patent document 65), Trichomonas vaginalis infection (e.g., non-patent document 66), human granulocytic ehrlichiosis (e.g., non-patent document 67), etc. Other examples include aplastic anemia (see, for example, non-patent document 68), atherosclerosis (see, for example, non-patent documents 69 and 70), pulmonary hypertension (see, for example, non-patent document 71), diabetes (see, for example, non-patent documents 69 and 70), prostate hypertrophy (see, for example, non-patent document 72), and Alzheimer's disease (see, for example, non-patent document 73).

[0950] The compounds of the present invention can be used directly or mixed with pharmacologically acceptable carriers to form pharmaceutical compositions containing, for example, 0.001% to 99.5%, preferably 0.1% to 90%, and can be used as therapeutic agents for the aforementioned various diseases in mammals such as humans, mice, rats, rabbits, dogs, cats, cows, horses, pigs, monkeys, etc.

[0951] The dosage of the drug is preferably adjusted after considering the patient's state such as age, weight, type and degree of the disease, route of administration, type of the compound of the present invention, whether it is a salt, type of salt, etc., and usually for adults, as the active ingredient amount of the compound of the present invention or its pharmaceutically acceptable salt, in the case of oral administration, it is appropriate to be within the range of 0.01mg to 5g / adult per day, preferably within the range of 1mg to 500mg / adult. Depending on the circumstances, sometimes it is sufficient to be below this amount, or on the contrary, the amount above this amount is required. Usually, it can be given once a day or in fractions, or in the case of intravenous administration, it can be given quickly or continuously within 24 hours.

[0952] One or more hydrogen, carbon and / or other atoms of the compounds of the present invention may be replaced with isotopes of hydrogen, carbon and / or other atoms, respectively. Examples of such isotopes include 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P.32 P. 35 S. 18 F. 123 I and 36 Cl, namely hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine. The compounds substituted with the above isotopes can also be used as medicines, including all radioactive labels of the compounds of the present invention.

[0953] Hereinafter, the present invention will be described in further detail with reference to comparative examples, examples, and test examples, but the present invention is not limited to these examples.

[0954] In the examples, the following abbreviations are used.

[0955] TFA: trifluoroacetic acid

[0956] Pd-C: Palladium-Carbon

[0957] Pd2(dba)3: tris(dibenzylideneacetone)dipalladium

[0958] Pd(PPh3)4: Tetrakis(triphenylphosphine)palladium

[0959] PdCl2(PPh3)2: Bis(triphenylphosphine)palladium(II) dichloride

[0960] Pd(OAc)2: Palladium(II) acetate

[0961] Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

[0962] BINAP: 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl

[0963] PPh3: triphenylphosphine

[0964] Boc2O: di-tert-butyl dicarbonate

[0965] HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate

[0966] HBTU: O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate

[0967] THF: Tetrahydrofuran

[0968] DME: dimethoxyethane

[0969] DMF: dimethylformamide

[0970] DMSO: dimethyl sulfoxide

[0971] NMP: N-methylpyrrolidone

[0972] DIPEA: N,N-diisopropylethylamine

[0973] TEA: triethylamine

[0974] BH3-THF: Borane-tetrahydrofuran complex

[0975] CDCl3: deuterated chloroform

[0976] TLC: Thin layer chromatography

[0977] MS: mass spectrometry

[0978] LCMS: High performance liquid chromatography-mass spectrometry

[0979] ESI: Electron Spray Ionization

[0980] M: molar concentration (mol / L)

[0981] MS was measured by LCMS. ESI was used as an ionization method. The observed mass spectrum value was expressed as m / z.

[0982] The measurement conditions of LCMS are as follows.

[0983] Analytical instrument: ACQUITY UPLC MS / PDA system (manufactured by WATERS) Mass spectrometer: Waters 3100MS detector

[0984] Photodiode array detector: ACQUITY PDA detector (UV detection wavelength: 210-400nm)

[0985] Column: Acquity BEH C18, 1.7 μm, 2.1 × 50 mm

[0986] Flow rate: 0.5mL / min

[0987] Column temperature: 40°C

[0988] Solvents;

[0989] Solution A: 0.1% formic acid / H2O (v / v; the same below)

[0990] Solution B: 0.1% formic acid / acetonitrile

[0991] 1H NMR spectra were measured using a JNM-ECS400 nuclear magnetic resonance apparatus (manufactured by JEOL Resonance Co., Ltd.) The observed peaks were expressed as chemical shift values ​​δ (ppm) (s = singlet, d = doublet, t = triplet, q = quartet, brs = broad singlet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets).

[0992] In the microwave experiment, an Initiator 60 (manufactured by Biotage) was used, which can reach a temperature of 40-250°C and a pressure of up to 20 bar.

[0993] The compound names in the present specification are names given using ACD / NAME (registered trademark, Advanced Chemistry Development Inc.), a naming software based on IUPAC rules, or using ChemBioDraw (version 14.0, manufactured by CambridgeSoft) or based on IUPAC nomenclature.

[0994] The r and s (small letters) in the compound names indicate the stereochemistry of pseudoasymmetric carbon atoms according to IUPAC rules.

[0995] Reference Example 1 Tert-butyl [2-methyl-2-(piperidin-4-yl)propyl]carbamate

[0996] [Step 1] Preparation of tert-butyl [2-methyl-2-(pyridin-4-yl)propyl]carbamate

[0997] To a solution of 2-methyl-2-(pyridin-4-yl)propane-1-amine (0.50 g) in dichloromethane (5 mL), TEA (0.51 mL) and Boc2O (0.84 mL) were added and stirred at room temperature. After confirming the disappearance of the raw material by TLC, the reaction solution was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography to obtain the title compound (0.61 g). MS (m / z): 251.3 [M+H] + .

[0998] [Step 2] Preparation of tert-butyl [2-methyl-2-(piperidin-4-yl)propyl]carbamate: To a solution of tert-butyl [2-methyl-2-(pyridin-4-yl)propyl]carbamate (0.60 g) in methanol (9.75 mL) obtained in step 1, after degassing, add 6M hydrochloric acid (0.48 mL) and platinum (IV) oxide (60 mg) while stirring at room temperature under an argon atmosphere. Replace the reaction system with hydrogen and stir at room temperature under a hydrogen atmosphere. After confirming the disappearance of the raw material by TLC, filter the reaction solution with Celite (registered trademark) containing sodium bicarbonate, and distill off the solvent under reduced pressure. After dissolving the residue in ethyl acetate, add hexane, suspend, and filter to obtain the precipitate to obtain the title compound (0.54 g). MS (m / z): 257.3 [M+H] + .

[0999] Reference Example 2 Tert-[2-{[tert-butyl(dimethyl)silyl]oxy}-2-(piperidin-4-yl)ethyl]carbamic acid Butyl Ester

[1000] [Step 1] Preparation of 4-(1-hydroxy-2-nitroethyl)piperidine-1-carboxylic acid benzyl ester

[1001] Nitromethane (0.22 mL) and potassium tert-butoxide (0.23 g) were added to a solution of 4-formylpiperidine-1-carboxylic acid benzyl ester (0.50 g) in THF (6.25 mL) and tert-butanol (6.25 mL) under ice cooling, and the mixture was stirred at room temperature for 30 minutes. Acetic acid was added to the reaction solution, and after diluting with ethyl acetate, the organic layer was washed with water and dried over anhydrous sodium sulfate. After the solvent was distilled off under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (0.59 g).

[1002] [Step 2] Preparation of benzyl 4-(1-{[tert-butyl(dimethyl)silyl]oxy}-2-nitroethyl)piperidine-1-carboxylate To a solution of benzyl 4-(1-hydroxy-2-nitroethyl)piperidine-1-carboxylate (0.25 g) obtained in step 1 in DMF (1.25 mL), imidazole (0.13 g) and tert-butyldimethylsilyl chloride (0.29 g) were added, and the mixture was stirred at room temperature for 3 days. The reaction solution was diluted with a saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (0.25 g).

[1003] [Step 3] Preparation of benzyl 4-(2-amino-1-{[tert-butyl(dimethyl)silyl]oxy}ethyl)piperidine-1-carboxylate To a solution of benzyl 4-(1-{[tert-butyl(dimethyl)silyl]oxy}-2-nitroethyl)piperidine-1-carboxylate (0.25 g) obtained in step 2 in ethanol (0.25 mL) and water (0.5 mL), ammonium chloride (16 mg) and iron powder (0.33 g) were added, and the mixture was stirred at 80° C. for 3 hours. The insoluble matter was filtered through Celite (registered trademark), and the Celite was washed with ethyl acetate. The filtrate was washed with water and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to obtain the title compound (0.20 g).

[1004] [Step 4] Preparation of benzyl 4-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-5-yl)piperidine-1-carboxylate

[1005] The title compound (0.24 g) was obtained by following the method of Step 1 of Reference Example 1, except that benzyl 4-(2-amino-1-{[tert-butyl(dimethyl)silyl]oxy}ethyl)piperidine-1-carboxylate (0.20 g) obtained in Step 3 was used instead of 2-methyl-2-(pyridin-4-yl)propan-1-amine.

[1006] [Step 5] Production of tert-butyl [2-{[tert-butyl(dimethyl)silyl]oxy}-2-(piperidin-4-yl)ethyl]carbamate

[1007] To a methanol (4.40 mL) solution of benzyl 4-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-5-yl)piperidine-1-carboxylate (0.24 g) obtained in step 4, after degassing, 10% Pd-C (24 mg) was added while stirring at room temperature under an argon atmosphere, and stirred at room temperature for 2 hours under a hydrogen atmosphere. After filtering the reaction solution through Celite (registered trademark), the solvent was distilled off under reduced pressure to obtain the title compound (0.16 g). MS (m / z): 359.4 [M+H] + .

[1008] Reference Example 3 Benzyl {1-[(1r,4r)-4-aminocyclohexyl]ethyl}carbamate

[1009] [Step 1] Preparation of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate

[1010] To a solution of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate (0.60g) in ether (8mL), methylmagnesium bromide (1M ether solution, 5.24mL) was added under ice cooling and stirred at room temperature. After confirming the disappearance of the raw material by TLC, the reaction solution was diluted with a saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was removed by reduced pressure distillation. The residue was purified by silica gel column chromatography to obtain the title compound (0.41g).

[1011] [Step 2] Preparation of tert-butyl [(1r,4r)-4-(1-aminoethyl)cyclohexyl]carbamate To a solution of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate (0.25 g) obtained in step 1 in methanol (5 mL), ammonium acetate (0.65 g) and sodium cyanoborohydride (80 mg) were added, and the mixture was stirred overnight at room temperature. A 2M aqueous sodium hydroxide solution was added to the reaction solution, and the mixture was adjusted to be alkaline, and then extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (0.38 g).

[1012] [Step 3] Preparation of benzyl (1-{(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl)carbamate To a solution of tert-butyl [(1r,4r)-4-(1-aminoethyl)cyclohexyl]carbamate (0.20 g) obtained in step 2 in dichloromethane (5 mL), DIPEA (0.29 mL) and benzyl chloroformate (0.15 mL) were added under ice cooling, and the mixture was stirred at room temperature for 3 hours and 30 minutes. Saturated aqueous sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure to obtain the title compound (0.30 g).

[1013] [Step 4] Preparation of benzyl {1-[(1r,4r)-4-aminocyclohexyl]ethyl}carbamate Hydrogen chloride (4M 1,4-dioxane solution, 3 mL) was added to benzyl (1-{(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl)carbamate (0.30 g) obtained in step 3, and the mixture was stirred at room temperature for 20 minutes. The reaction solution was made alkaline with a 2M aqueous sodium hydroxide solution and then extracted with chloroform. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (0.20 g).

[1014] Reference Example 4 Benzyl {2-[(1r,4r)-4-aminocyclohexyl]ethyl}carbamate

[1015] [Step 1] Preparation of benzyl (2-{(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl)carbamate

[1016] The title compound (0.21 g) was obtained by the method of Step 3 of Reference Example 3, except that tert-butyl [(1r,4r)-4-(2-aminoethyl)cyclohexyl]carbamate (0.20 g) was used instead of tert-butyl [(1r,4r)-4-(1-aminoethyl)cyclohexyl]carbamate.

[1017] [Step 2] Preparation of benzyl {2-[(1r,4r)-4-aminocyclohexyl]ethyl}carbamate The title compound (90 mg) was obtained by following the method of step 4 of reference example 3, except that benzyl (2-{(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl)carbamate (0.21 g) obtained in step 1 of reference example 4 was used instead of benzyl (1-{(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl)carbamate. MS (m / z): 277.2 [M+H] + .

[1018] Reference Example 5 (1S)-1-amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester

[1019] [Step 1] Preparation of tert-butyl (1E)-1-{[(S)-2-methylpropane-2-sulfinyl]imino}-7-azaspiro[3.5]nonane-7-carboxylate

[1020] A solution of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate (0.50 g) and (S)-(-)-2-methyl-2-propanesulfenamide (0.41 g) in tetraethyl orthotitanate (1.53 g) was stirred at 60° C. overnight. The reaction solution was diluted with ethyl acetate and water was added. The reaction solution was filtered through Celite (registered trademark) and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (0.60 g).

[1021] [Step 2] Preparation of (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester To a solution of (1E)-1-{[(S)-2-methylpropane-2-sulfinyl]imino}-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester (0.60 g) obtained in step 1 in THF (8.36 mL) and water (0.44 mL), sodium borohydride (0.13 g) was added at -80°C, and the mixture was stirred for 4 hours while warming from -80°C to room temperature. The reaction solution was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. After the organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to give the title compound (465 mg) and (1R)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester (23 mg). Stereochemistry was assigned based on physiological activity and similarity to the determined structure (arbitrarily).

[1022] [Step 3] Preparation of tert-butyl (1S)-1-amino-7-azaspiro [3.5] nonane-7-carboxylate To a solution of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro [3.5] nonane-7-carboxylate (465 mg) in methanol (2.7 mL) was added with hydrogen chloride (4M 1,4-dioxane solution, 0.354 mL) under ice cooling and stirred for 3 hours. A 2M aqueous sodium hydroxide solution was added to the reaction solution, adjusted to alkalinity, and then extracted with ethyl acetate. After drying the organic layer over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to obtain the title compound (311 mg).

[1023] Reference Example 6 (1R)-1-amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester

[1024] The title compound (14 mg) was obtained by following the method of Step 3 of Reference Example 5, using (1R)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester (23 mg) obtained in Step 2 of Reference Example 5 instead of (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester.

[1025] Reference Example 7 Tert-butyl {(1S,4r)-4-[(1S)-1-aminoethyl]cyclohexyl}carbamate

[1026] [Step 1] Preparation of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate The title compound (20.9 g) was obtained by following the method of Step 1 of Reference Example 5, using tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate (15.4 g) obtained in Step 1 of Reference Example 3 instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1027] [Step 2] Preparation of tert-butyl {(1S,4r)-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclohexyl}carbamate A suspension of dichloro(p-isopropylphenylmethane)ruthenium(II), dimer (3.72 g), 2-amino-2-methyl-1-propanol (1.16 mL), and molecular sieves 4A (20.9 g) in 2-propanol (140 mL) was degassed and stirred at 80°C for 30 minutes under an argon atmosphere. Next, potassium tert-butoxide (3.4 g) was added to a 2-propanol (70 mL) solution of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (20.9 g) obtained in step 1 while stirring at 50°C, and the mixture was stirred for 3 hours. The reaction solution was filtered through Celite (registered trademark), and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (17.4 g).

[1028] [Step 3] Preparation of tert-butyl {(1S,4r)-4-[(1S)-1-aminoethyl]cyclohexyl}carbamate The title compound (8.5 g) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl {(1S,4r)-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (17.4 g) obtained in Step 2 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclohexyl}carbamate.

[1029] Reference Example 8 Tert-butyl {(1R,4r)-4-[(1R)-1-aminoethyl]cyclohexyl}carbamate

[1030] [Step 1] Preparation of tert-butyl [(1r,4r)-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate

[1031] The title compound (6.0 g) was obtained by the method of Step 1 of Reference Example 7 except that (R)-(+)-2-methyl-2-propanesulfenamide was used instead of (S)-(-)-2-methyl-2-propanesulfenamide.

[1032] [Step 2] Preparation of tert-butyl {(1R,4r)-4-[(1R)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclohexyl}carbamate The title compound (4.8 g) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (6.0 g) obtained in Step 1 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate.

[1033] [Step 3] Preparation of tert-butyl {(1R,4r)-4-[(1R)-1-aminoethyl]cyclohexyl}carbamate The title compound (2.7 g) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl {(1R,4r)-4-[(1R)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (4.8 g) obtained in Step 2 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclohexyl}carbamate.

[1034] Reference Example 9 Benzyl 4-[(1R)-1-amino-2,2-difluoroethyl]piperidine-1-carboxylate

[1035] [Step 1] Preparation of benzyl 4-[(E)-{[(S)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate

[1036] The title compound (1.15 g) was obtained by the method of Step 1 of Reference Example 5 except that benzyl 4-formylpiperidine-1-carboxylate (1.0 g) was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1037] [Step 2] Preparation of benzyl 4-[(1R)-2,2-difluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1038] To a suspension of potassium tert-butoxide (0.74 g) in THF (10 mL), a solution of 4-[(E)-{[(S)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylic acid benzyl ester (1.15 g) obtained in step 1 and (difluoromethyl)trimethylsilane (0.90 mL) in THF (10 mL) was added dropwise at -78°C, and the mixture was stirred for 2 hours while warming to 0°C. The reaction solution was diluted with a saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (164 mg).

[1039] [Step 3] Preparation of benzyl 4-[(1R)-1-amino-2,2-difluoroethyl]piperidine-1-carboxylate The title compound (104 mg) was obtained by following the method of Step 3 of Reference Example 5, using benzyl 4-[(1R)-2,2-difluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (164 mg) obtained in Step 2 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate.

[1040] Reference Example 10 tert-Butyl 4-(1-aminoethyl)-4-methylpiperidine-1-carboxylate

[1041] The title compound (0.60 g) was obtained by following the method of step 2 of reference example 3, except that tert-butyl 4-acetyl-4-methylpiperidine-1-carboxylate (0.66 g) (synthesized, for example, by the method described in WO2013 / 182546) was used instead of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate.

[1042] Reference Example 11 Tert-butyl [(1r,4r)-4-(sulfanylmethyl)cyclohexyl]carbamate Potassium carbonate (96 mg) was added to a methanol (0.6 mL) solution of S-({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl)thioacetate (100 mg) (synthesized, for example, according to the method described in WO2013 / 007765), and the mixture was stirred at 50°C for 2 hours. 2M hydrochloric acid was added to the reaction solution, and the mixture was acidified and extracted with ether. After the organic layer was dried, the solvent was distilled off under reduced pressure to obtain the title compound (70 mg).

[1043] Reference Example 12 tert-Butyl 4-[(1S)-1-aminoethyl]-4-fluoropiperidine-1-carboxylate

[1044] [Step 1] Preparation of tert-butyl 4-fluoro-4-[(E)-{[(S)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate

[1045] The title compound (4.19 g) was obtained by the method of Step 1 of Reference Example 5, except that tert-butyl 4-fluoro-4-formylpiperidine-1-carboxylate (4.34 g) was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1046] [Step 2] Preparation of tert-butyl 4-fluoro-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1047] To a toluene (50 mL) solution of methyllithium (1.14 M ether solution, 10.5 mL), a toluene (10 mL) solution of tert-butyl 4-fluoro-4-[(E)-{[(S)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate (2.0 g) obtained in step 1 was added dropwise while stirring at -80°C, and the mixture was stirred at the same temperature for 1 hour. A saturated aqueous ammonium chloride solution was added to the reaction solution, and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (2.13 g).

[1048] [Step 3] Preparation of tert-butyl 4-[(1S)-1-aminoethyl]-4-fluoropiperidine-1-carboxylate The title compound (1.49 g) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl 4-fluoro-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (2.13 g) obtained in Step 2 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate.

[1049] Reference Example 13 Tert-butyl [(1r,4r)-4-(aminomethyl)cyclohexyl]methylcarbamate

[1050] [Step 1] Preparation of tert-butyl {(1r,4r)-4-[(dibenzylamino)methyl]cyclohexyl}carbamate A mixture of tert-butyl [(1r,4r)-4-(aminomethyl)cyclohexyl]carbamate hydrochloride (150 mg), potassium carbonate (235 mg), benzyl bromide (194 mg) and acetonitrile (5 mL) was stirred at 75°C for 17 hours. The reaction solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (208 mg).

[1051] [Step 2] Preparation of tert-butyl {(1r,4r)-4-[(dibenzylamino)methyl]cyclohexyl}methylcarbamate

[1052] To the DMF (3 mL) solution of tert-butyl {(1r,4r)-4-[(dibenzylamino)methyl]cyclohexyl}carbamate (205 mg) obtained in step 1, 60% sodium hydride (24 mg) was added under ice cooling, and after stirring at the same temperature for 30 minutes, iodomethane (214 mg) was added and stirred at the same temperature for 2.5 hours. 60% sodium hydride (120 mg) and iodomethane (456 mg) were added, and further stirred at room temperature for 1 hour. Water was added to the reaction solution under ice cooling, and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (192 mg).

[1053] [Step 3] Preparation of tert-butyl [(1r,4r)-4-(aminomethyl)cyclohexyl]methylcarbamate The title compound (101 mg) was obtained by following the method of Step 5 of Reference Example 2, using tert-butyl {(1r,4r)-4-[(dibenzylamino)methyl]cyclohexyl}methylcarbamate (185 mg) obtained in Step 2 instead of benzyl 4-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-5-yl)piperidine-1-carboxylate.

[1054] Reference Example 14 (3S)-3-(2-aminopropyl)pyrrolidine-1-carboxylic acid tert-butyl ester

[1055] [Step 1] Preparation of tert-butyl (3S)-3-{2-[methoxy(methyl)amino]-2-oxoethyl}pyrrolidine-1-carboxylate

[1056] HATU (915 mg), N,O-dimethylhydroxylamine hydrochloride (235 mg) and DIPEA (0.69 mL) were added to a solution of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid (460 mg) in DMF (4 mL), and the mixture was stirred at room temperature for 18 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with a saturated aqueous sodium bicarbonate solution and saturated brine, and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (545 mg).

[1057] [Step 2] Preparation of tert-butyl (3S)-3-(2-oxopropyl)pyrrolidine-1-carboxylate The title compound (340 mg) was obtained by following the method of Step 1 of Reference Example 3, except that tert-butyl (3S)-3-{2-[methoxy(methyl)amino]-2-oxoethyl}pyrrolidine-1-carboxylate (545 mg) obtained in Step 1 was used instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1058] [Step 3] Preparation of tert-butyl (3S)-3-(2-aminopropyl)pyrrolidine-1-carboxylate The title compound (300 mg) was obtained by following the method of Step 2 of Reference Example 3, except that tert-butyl (3S)-3-(2-oxopropyl)pyrrolidine-1-carboxylate (340 mg) obtained in Step 2 was used instead of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate.

[1059] Reference Example 15 (3R)-3-(2-aminopropyl)pyrrolidine-1-carboxylic acid tert-butyl ester

[1060] [Step 1] Preparation of tert-butyl (3R)-3-{2-[methoxy(methyl)amino]-2-oxoethyl}pyrrolidine-1-carboxylate

[1061] The title compound (545 mg) was obtained by the method of Step 1 of Reference Example 14, except that [(3R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid (460 mg) was used instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1062] [Step 2] Preparation of tert-butyl (3R)-3-(2-oxopropyl)pyrrolidine-1-carboxylate The title compound (380 mg) was obtained by following the method of Step 1 of Reference Example 3, except that (3R)-3-{2-[methoxy(methyl)amino]-2-oxoethyl}pyrrolidine-1-carboxylate (545 mg) obtained in Step 1 was used instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1063] [Step 3] Preparation of tert-butyl (3R)-3-(2-aminopropyl)pyrrolidine-1-carboxylate The title compound (190 mg) was obtained by following the method of Step 2 of Reference Example 3, using tert-butyl (3R)-3-(2-oxopropyl)pyrrolidine-1-carboxylate (380 mg) obtained in Step 2 instead of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate.

[1064] Reference Example 16 Tert-butyl {(1S,3R)-3-[(1S)-1-aminoethyl]-2,2-dimethylcyclobutyl}carbamate

[1065] [Step 1] Preparation of tert-butyl [(1S,3R)-3-acetyl-2,2-dimethylcyclobutyl]carbamate To a suspension of (1S,3R)-3-acetyl-2,2-dimethylcyclobutane-1-carboxylic acid (3.5 g) (synthesized, for example, according to the method described in Journal of Organic Chemistry, 2000, 65, 3934-3940.) in tert-butanol (40 mL), diphenylphosphoryl azide (5.3 mL) and TEA (4.3 mL) were added, and the mixture was stirred at 85°C for 15 hours. Saturated aqueous sodium bicarbonate solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (1.4 g).

[1066] [Step 2] Preparation of tert-butyl [(1S,3R)-2,2-dimethyl-3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclobutyl]carbamate

[1067] The title compound (700 mg) was obtained by following the method of Step 1 of Reference Example 5, except that tert-butyl [(1S,3R)-3-acetyl-2,2-dimethylcyclobutyl]carbamate (1.4 g) obtained in Step 1 was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1068] [Step 3] Preparation of tert-butyl {(1S,3R)-2,2-dimethyl-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclobutyl}carbamate

[1069] The title compound (450 mg) was obtained by following the method of Step 2 of Reference Example 7, except that tert-butyl [(1S,3R)-2,2-dimethyl-3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclobutyl]carbamate (500 mg) obtained in Step 2 was used instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclobutyl]carbamate.

[1070] [Step 4] Preparation of tert-butyl {(1S,3R)-3-[(1S)-1-aminoethyl]-2,2-dimethylcyclobutyl}carbamate

[1071] The title compound (300 mg) was obtained by following the method of Step 3 of Reference Example 5, except that tert-butyl {(1S,3R)-2,2-dimethyl-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (450 mg) was used instead of tert-butyl {(1S,3R)-2,2-dimethyl-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclobutyl}carbamate obtained in Step 3.

[1072] Reference Example 17 tert-Butyl 4-[(1S)-1-aminopropyl]piperidine-1-carboxylate

[1073] [Step 1] Preparation of tert-butyl 4-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate The title compound (5.0 g) was obtained by following the method of Step 1 of Reference Example 8, using tert-butyl 4-formylpiperidine-1-carboxylate (4.0 g) instead of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate.

[1074] [Step 2] Preparation of tert-butyl 4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}propyl]piperidine-1-carboxylate To a solution of tert-butyl 4-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate (5.0 g) obtained in step 1 in dichloromethane (64 mL) was added dropwise with ethylmagnesium bromide (3 M ether solution, 10.6 mL) at -78°C, and the mixture was stirred at the same temperature for 15 minutes. Then, the mixture was stirred for 2 hours while the temperature was raised from -78°C to 0°C. A saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (5.4 g).

[1075] [Step 3] Preparation of tert-butyl 4-[(1S)-1-aminopropyl]piperidine-1-carboxylate

[1076] The title compound (3.6 g) was obtained by following the method of step 3 of reference example 5, except that tert-butyl 4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (5.4 g) obtained in step 2 was used instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}propyl]piperidine-1-carboxylate.

[1077] Reference Example 18 tert-Butyl 4-[(1R)-1-amino-2,2-difluoroethyl]-4-fluoropiperidine-1-carboxylate

[1078] [Step 1] Preparation of tert-butyl 4-[(1R)-2,2-difluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]-4-fluoropiperidine-1-carboxylate The title compound (390 mg) was obtained by following the method of Step 2 of Reference Example 9, using tert-butyl 4-fluoro-4-[(E)-{[(S)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate (500 mg) obtained in Step 1 of Reference Example 12 instead of benzyl 4-[(E)-{[(S)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate (1.15 g) and (difluoromethyl)trimethylsilane.

[1079] [Step 2] Preparation of tert-butyl 4-[(1R)-1-amino-2,2-difluoroethyl]-4-fluoropiperidine-1-carboxylate The title compound (78 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl 4-[(1R)-2,2-difluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (320 mg) obtained in Step 1 of Reference Example 18 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]-4-fluoropiperidine-1-carboxylate.

[1080] Reference Example 19 Benzyl 4-(Aminomethyl)-3-methylpiperidine-1-carboxylate

[1081] [Step 1] Preparation of tert-butyl [(3-methylpyridin-4-yl)methyl]carbamate

[1082] The title compound (236 mg) was obtained by the method of Step 1 of Reference Example 1, except that 1-(3-methylpyridin-4-yl)methanamine (150 mg) was used instead of 2-methyl-2-(pyridin-4-yl)propan-1-amine.

[1083] [Step 2 Preparation of tert-butyl [(3-methylpiperidin-4-yl)methyl]carbamate The title compound (46 mg) was obtained by following the method of Step 2 of Reference Example 1, except that tert-butyl [(3-methylpyridin-4-yl)methyl]carbamate (220 mg) obtained in Step 1 was used instead of tert-butyl [2-methyl-2-(pyridin-4-yl)propyl]carbamate. MS (m / z): 229.3 [M+H] + .

[1084] [Step 3] Preparation of benzyl 4-{[(tert-butoxycarbonyl)amino]methyl}-3-methylpiperidine-1-carboxylate The title compound (186 mg) was obtained by following the method of Step 3 of Reference Example 3, using tert-butyl [(3-methylpiperidin-4-yl)methyl]carbamate (110 mg) obtained in Step 2 instead of tert-butyl [(1r,4r)-4-(1-aminoethyl)cyclohexyl]carbamate.

[1085] [Step 4] Preparation of 4-(aminomethyl)-3-methylpiperidine-1-carboxylic acid benzyl ester

[1086] The title compound (109 mg) was obtained by following the method of Step 4 of Reference Example 3, except that benzyl 4-{[(tert-butoxycarbonyl)amino]methyl}-3-methylpiperidine-1-carboxylate (186 g) obtained in Step 3 was used instead of benzyl (1-{(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl)carbamate.

[1087] Reference Example 20 tert-Butyl 2-[(1S)-1-aminoethyl]-7-azaspiro[3.5]nonane-7-carboxylate

[1088] [Step 1] Preparation of tert-butyl 2-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-7-azaspiro[3.5]nonane-7-carboxylate

[1089] The title compound (342 mg) was obtained by the method of Step 1 of Reference Example 8, except that tert-butyl 2-formyl-7-azaspiro[3.5]nonane-7-carboxylate (364 mg) was used instead of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate.

[1090] [Step 2] Preparation of tert-butyl 2-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-7-azaspiro[3.5]nonane-7-carboxylate

[1091] The title compound (341 mg) was obtained by the method of Step 2 of Reference Example 17 using tert-butyl 2-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-7-azaspiro[3.5]nonane-7-carboxylate (342 mg) obtained in Step 1 of Reference Example 20 and methylmagnesium bromide.

[1092] [Step 3] Preparation of tert-butyl 2-[(1S)-1-aminoethyl]-7-azaspiro[3.5]nonane-7-carboxylate The title compound (249 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl 2-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-7-azaspiro[3.5]nonane-7-carboxylate (341 mg) obtained in Step 2 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate.

[1093] Reference Example 21 Benzyl 4-(Aminomethyl)-2-methylpiperidine-1-carboxylate

[1094] [Step 1] Preparation of tert-butyl [(2-methylpyridin-4-yl)methyl]carbamate

[1095] The title compound (256 mg) was obtained by following the method of Step 1 of Reference Example 1, except that 1-(2-methylpyridin-4-yl)methanamine (150 mg) was used instead of 2-methyl-2-(pyridin-4-yl)propan-1-amine. MS (m / z): 223.2 [M+H] + .

[1096] [Step 2 Preparation of tert-butyl [(2-methylpiperidin-4-yl)methyl]carbamate The title compound (252 mg) was obtained by following the method of Step 2 of Reference Example 1, except that tert-butyl [(2-methylpyridin-4-yl)methyl]carbamate (256 mg) obtained in Step 1 was used instead of tert-butyl [2-methyl-2-(pyridin-4-yl)propyl]carbamate. MS (m / z): 229.3 [M+H] + .

[1097] [Step 3] Preparation of benzyl 4-{[(tert-butoxycarbonyl)amino]methyl}-2-methylpiperidine-1-carboxylate The title compound (248 mg) was obtained by following the method of Step 3 of Reference Example 3, using tert-butyl [(2-methylpiperidin-4-yl)methyl]carbamate (252 mg) obtained in Step 2 instead of tert-butyl [(1r,4r)-4-(1-aminoethyl)cyclohexyl]carbamate.

[1098] [Step 4] Preparation of 4-(aminomethyl)-2-methylpiperidine-1-carboxylic acid benzyl ester

[1099] The title compound (209 mg) was obtained by following the method of Step 4 of Reference Example 3, except that benzyl 4-{[(tert-butoxycarbonyl)amino]methyl}-2-methylpiperidine-1-carboxylate (248 g) obtained in Step 3 was used instead of benzyl (1-{(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl)carbamate.

[1100] Reference Example 22 tert-Butyl 4-[(1S)-1-aminoethyl]-4-methylpiperidine-1-carboxylate

[1101] [Step 1] Preparation of tert-butyl 4-methyl-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate The title compound (320 mg) was obtained by following the method of Step 1 of Reference Example 5, using tert-butyl 4-acetyl-4-methylpiperidine-1-carboxylate (580 mg) instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1102] [Step 2] Preparation of tert-butyl 4-methyl-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1103] The title compound (180 mg) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl 4-methyl-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (320 mg) obtained in Step 1 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate.

[1104] [Step 3] Preparation of tert-butyl 4-[(1S)-1-aminoethyl]-4-methylpiperidine-1-carboxylate The title compound (107 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl 4-methyl-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (180 mg) obtained in Step 2 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate.

[1105] Reference Example 23 Tert-butyl {(1R,3s)-3-[(1S)-1-aminoethyl]cyclobutyl}carbamate

[1106] [Step 1] Preparation of tert-butyl {(1s,3s)-3-[methoxy(methyl)carbamoyl]cyclobutyl}carbamate The title compound (44.7 g) was obtained by following the method of Step 1 of Reference Example 14, except that (1s,3s)-3-[(tert-butoxycarbonyl)amino]cyclobutane-1-carboxylic acid (36.3 g) was used instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid. MS (m / z): 259.6 [M+H] + .

[1107] [Step 2] Preparation of tert-butyl [(1s,3s)-3-acetylcyclobutyl]carbamate The title compound (33.8 g) was obtained by following the method of Step 1 of Reference Example 3, except that tert-butyl {(1s,3s)-3-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate (44.7 g) obtained in Step 1 was used instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclobutyl}carbamate.

[1108] [Step 3] Preparation of tert-butyl [(1s, 3s)-3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclobutyl]carbamate

[1109] The title compound (24 g) was obtained by following the method of Step 1 of Reference Example 5, except that tert-butyl [(1s,3s)-3-acetylcyclobutyl]carbamate (32.8 g) obtained in Step 2 was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1110] [Step 4] Preparation of tert-butyl {(1R,3s)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclobutyl}carbamate The title compound (11.2 g) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl [(1s,3s)-3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (23.4 g) obtained in Step 3 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclobutyl]carbamate.

[1111] [Step 5] Preparation of tert-butyl {(1R,3s)-3-[(1S)-1-aminoethyl]cyclobutyl}carbamate The title compound (7.2 g) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl {(1R,3s)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (11.2 g) obtained in Step 4 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclobutyl}carbamate.

[1112] Reference Example 24 tert-Butyl 4-[(1R)-1-amino-2,2,2-trifluoroethyl]piperidine-1-carboxylate

[1113] [Step 1] Preparation of tert-butyl 4-{(1E)-2,2,2-trifluoro-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate

[1114] The title compound (640 mg) was obtained by the method of Step 1 of Reference Example 5, except that tert-butyl 4-(trifluoroacetyl)piperidine-1-carboxylate (1.26 g) was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1115] [Step 2] Preparation of tert-butyl 4-[(1R)-2,2,2-trifluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1116] To the solution of tert-butyl 4-{(1E)-2,2,2-trifluoro-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate (300 mg) in THF (8 mL) obtained in step 1, lithium tri-sec-butylborohydride (1M THF solution, 1.6 mL) was added under ice cooling and stirred at the same temperature for 2 hours. Saturated aqueous ammonium chloride solution was added to the reaction solution and extracted with ethyl acetate. After drying the organic layer with anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (133 mg).

[1117] [Step 3] Preparation of tert-butyl 4-[(1R)-1-amino-2,2,2-trifluoroethyl]piperidine-1-carboxylate The title compound (76 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl 4-[(1R)-2,2,2-trifluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (133 mg) obtained in Step 2 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate.

[1118] Reference Example 25 tert-Butyl 4-[(1S)-1-amino-2,2,2-trifluoroethyl]piperidine-1-carboxylate

[1119] [Step 1] Preparation of tert-butyl 4-[(1S)-2,2,2-trifluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1120] To a solution of tert-butyl 4-{(1E)-2,2,2-trifluoro-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate (300 mg) in THF (8 mL) and water (0.16 mL) obtained in step 1 of reference example 24, sodium borohydride (30 mg) was added at -50°C and stirred at the same temperature for 2 hours. A saturated aqueous solution of ammonium chloride was added to the reaction solution, and extraction was performed with ethyl acetate. After drying the organic layer over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (111 mg).

[1121] [Step 2] Preparation of tert-butyl 4-[(1S)-1-amino-2,2,2-trifluoroethyl]piperidine-1-carboxylate The title compound (67 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl 4-[(1S)-2,2,2-trifluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (111 mg) obtained in Step 1 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate.

[1122] Reference Example 26 tert-Butyl 6-[(1S)-1-aminoethyl]-2-azaspiro[3.3]heptane-2-carboxylate

[1123] [Step 1] Preparation of tert-butyl 6-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-2-azaspiro[3.3]heptane-2-carboxylate

[1124] The title compound (371 mg) was obtained by following the method of step 1 of reference example 8, except that tert-butyl 6-formyl-2-azaspiro[3.3]heptane-2-carboxylate (400 mg) was used instead of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate. MS (m / z): 329.6 [M+H] + .

[1125] [Step 2] Preparation of tert-butyl 6-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-2-azaspiro[3.3]heptane-2-carboxylate

[1126] The title compound (364 mg) was obtained by following the method of Step 2 of Reference Example 20, except that tert-butyl 6-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-2-azaspiro[3.3]heptane-2-carboxylate (371 mg) obtained in Step 1 was used instead of tert-butyl 2-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-7-azaspiro[3.5]nonane-7-carboxylate.

[1127] [Step 3] Preparation of tert-butyl 6-[(1S)-1-aminoethyl]-2-azaspiro[3.3]heptane-2-carboxylate The title compound (239 mg) was obtained by following the method of Step 3 of Reference Example 5, except that tert-butyl 6-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-2-azaspiro[3.3]heptane-2-carboxylate (364 mg) obtained in Step 2 was used instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate. MS (m / z): 241.2 [M+H] + .

[1128] Reference Example 27 tert-Butyl 4-[(1R)-1-amino-2-fluoroethyl]piperidine-1-carboxylate

[1129] [Step 1] Preparation of tert-butyl 4-[(E)-{[(S)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate

[1130] The title compound (10.9 g) was obtained by the method of Step 1 of Reference Example 5 except that tert-butyl 4-formylpiperidine-1-carboxylate (10 g) was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1131] [Step 2] Preparation of tert-butyl 4-[(1R)-2-(benzenesulfonyl)-2-fluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate To a solution of tert-butyl 4-[(E)-{[(S)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate (800 mg) obtained in step 1 and fluoromethylphenyl sulfone (462 mg) in THF (13 mL) was added dropwise with lithium bis(trimethylsilyl)amide (1.1 M THF solution, 2.5 mL) at -80°C under an argon atmosphere, and the mixture was stirred at the same temperature for 1 hour. Saturated aqueous ammonium chloride solution was added to the reaction solution, and extraction was performed with ethyl acetate. After the organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to obtain the title compound (1.26 g). MS (m / z): 491.7 [M+H] + .

[1132] [Step 3] Preparation of tert-butyl 4-[(1R)-2-fluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1133] Magnesium (1.2 g) was added to a methanol (24 mL) solution of tert-butyl 4-[(1R)-2-(benzenesulfonyl)-2-fluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate (1.2 g) obtained in step 2, and the mixture was stirred at room temperature for 4 hours. Saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (283 mg).

[1134] [Step 4] Preparation of tert-butyl 4-[(1R)-1-amino-2-fluoroethyl]piperidine-1-carboxylate The title compound (201 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl 4-[(1R)-2-fluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (283 mg) obtained in Step 3 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate.

[1135] Reference Example 28 Tert-butyl {(1R,3S)-3-[(1S)-1-aminoethyl]-2,2-dimethylcyclobutyl}carbamate

[1136] [Step 1] Preparation of methyl (1S, 3R)-3-acetyl-2,2-dimethylcyclobutane-1-carboxylate

[1137] To a suspension of (1S,3R)-3-acetyl-2,2-dimethylcyclobutane-1-carboxylic acid (34.3 g) and cesium carbonate (78.8 g) in DMF (300 mL), add iodomethane (15.1 mL) and stir at room temperature for 20 hours. Add water to the reaction solution and extract with ethyl acetate. Wash the organic layer with saturated brine and remove the solvent by reduced pressure distillation. Purify the residue by silica gel column chromatography to obtain the title compound (37.2 g).

[1138] [Step 2] Preparation of (1S, 3R)-3-acetylamino-2,2-dimethylcyclobutane-1-carboxylic acid methyl ester The (1S, 3R)-3-acetyl-2,2-dimethylcyclobutane-1-carboxylic acid methyl ester (15.0 g) obtained in step 1 was dissolved in DME (250 mL), and sodium azide (15.9 g) was added while stirring at -78°C under an argon atmosphere. Methanesulfonic acid (63.4 mL) was then added dropwise, and the mixture was stirred for 15 hours while warming from -78°C to room temperature. Under ice cooling, 28% aqueous ammonia was added dropwise to the reaction solution for neutralization, and then extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (15.0 g).

[1139] [Step 3] Preparation of (1S,3R)-3-[(tert-butoxycarbonyl)amino]-2,2-dimethylcyclobutane-1-carboxylic acid 4M hydrochloric acid (164mL) was added to the (1S,3R)-3-acetylamino-2,2-dimethylcyclobutane-1-carboxylic acid methyl ester (32.7g) obtained in step 2, and the mixture was stirred at 100°C for 8 hours. Under ice cooling, 13M sodium hydroxide aqueous solution (50mL) was added to the reaction solution for neutralization, and then DMF (180mL), TEA (45.7mL), and Boc2O (41.4mL) were added, and the mixture was stirred at room temperature for 3 hours. 5% hydrochloric acid was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (39.4g).

[1140] [Step 4] Preparation of tert-butyl {(1R,3S)-3-[methoxy(methyl)carbamoyl]-2,2-dimethylcyclobutyl}carbamate

[1141] The title compound (33.4 g) was obtained by following the method of Step 1 of Reference Example 14, except that (1S,3R)-3-[(tert-butoxycarbonyl)amino]-2,2-dimethylcyclobutane-1-carboxylic acid (39.4 g) obtained in Step 3 was used instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1142] [Step 5] Preparation of tert-butyl [(1R,3S)-3-acetyl-2,2-dimethylcyclobutyl]carbamate The title compound (3.2 g) was obtained by following the method of Step 1 of Reference Example 3, using tert-butyl {(1R,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate (8.0 g) obtained in Step 4 instead of tert-butyl {(1R,3S)-3-[methoxy(methyl)carbamoyl]-2,2-dimethylcyclobutyl}carbamate to obtain.

[1143] [Step 6] Preparation of tert-butyl [(1R,3S)-2,2-dimethyl-3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclobutyl]carbamate

[1144] The title compound (2.2 g) was obtained by following the method of Step 1 of Reference Example 5, except that tert-butyl [(1R,3S)-3-acetyl-2,2-dimethylcyclobutyl]carbamate (3.2 g) obtained in Step 5 was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1145] [Step 7] Preparation of tert-butyl {(1R,3S)-2,2-dimethyl-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclobutyl}carbamate

[1146] The title compound (760 mg) was obtained by following the method of Step 2 of Reference Example 7, except that tert-butyl [(1R,3S)-2,2-dimethyl-3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclobutyl]carbamate (2.2 g) obtained in Step 6 was used instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclobutyl]carbamate.

[1147] [Step 8] Preparation of tert-butyl {(1R,3S)-3-[(1S)-1-aminoethyl]-2,2-dimethylcyclobutyl}carbamate

[1148] The title compound (520 mg) was obtained by following the method of Step 3 of Reference Example 5, except that tert-butyl {(1R,3S)-2,2-dimethyl-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (760 mg) obtained in Step 7 was used instead of tert-butyl {(1R,3S)-2,2-dimethyl-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclobutyl}carbamate.

[1149] Reference Example 29 (1S)-1-[(1R,5S,8r)-3-Benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethane-1- amine

[1150] [Step 1] Preparation of (R)-N-{(E)-[(1R,5S,8r)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]methylene}-2-methylpropane-2-sulfenamide The method of Step 1 of Reference Example 8 was followed except that 3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]methylene}-2-methylpropane-2-sulfenamide was used instead of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate. 8-carboxaldehyde (791 mg) (for example, synthesized according to the method described in WO2006035303), and the resulting residue was purified by silica gel column chromatography to obtain the title compound (133 mg) and (R)-N-{(E)-[(1R,5S,8s)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]methylene}-2-methylpropane-2-sulfenamide (397 mg). MS (m / z): 333.3 [M+H] + .

[1151] Title compound: 1 H-NMR (400MHz, CDCl3) δ: 7.92 (d, 1H), 7.34-7.19 (m, 5H), 3.50 (s, 2H), 2.79-2.71 (m, 2H), 2.49-2.45 (m, 1H), 2.44-2.35 (m, 2H), 1.84-1.72 (m, 2H), 1.68-1.55 (m, 3H), 1.17 (s, 9H).

[1152] (R)-N-{(E)-[(1R,5S,8s)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]methylene}-2-methylpropane-2-sulfenamide: 1 H-NMR (400MHz, CDCl3) δ: 8.42 (d, 1H), 7.32-7.17 (m, 5H), 3.47 (s, 2H), 2.64 (q, 1H), 2. 56-2.47 (m, 4H), 2.45-2.37 (m, 2H), 1.97-1.86 (m, 2H), 1.79-1.70 (m, 2H), 1.22 (s, 9H).

[1153] [Step 2] Preparation of (R)-N-{(1S)-1-[(1R,5S,8r)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethyl}-2-methylpropane-2-sulfinamide The title compound (124 mg) was obtained by following the method of Step 2 of Reference Example 20, using (R)-N-{(E)-[(1R,5S,8r)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]methylene}-2-methylpropane-2-sulfinamide (133 mg) obtained in Step 1 instead of tert-butyl 2-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-7-azaspiro[3.5]nonane-7-carboxylate.

[1154] [Step 3] Preparation of (1S)-1-[(1R,5S,8r)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethane-1-amine

[1155] The title compound (92 mg) was obtained by following the method of step 3 of reference example 5, except that (R)-N-{(1S)-1-[(1R,5S,8r)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethyl}-2-methylpropane-2-sulfinamide (124 mg) obtained in step 2 was used instead of (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester.

[1156] Reference Example 30 (1S)-1-[(1R,5S,8s)-3-Benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethane-1- amine

[1157] [Step 1] Preparation of (R)-N-{(1S)-1-[(1R,5S,8s)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethyl}-2-methylpropane-2-sulfinamide The title compound (280 mg) was obtained by following the method of Step 2 of Reference Example 20, using (R)-N-{(E)-[(1R,5S,8s)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]methylene}-2-methylpropane-2-sulfinamide (397 mg) obtained in Step 1 of Reference Example 29 instead of tert-butyl 2-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-7-azaspiro[3.5]nonane-7-carboxylate.

[1158] [Step 2] Preparation of (1S)-1-[(1R, 5S, 8s)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethane-1-amine

[1159] The title compound (201 mg) was obtained by following the method of step 3 of reference example 5, except that (R)-N-{(1S)-1-[(1R,5S,8s)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethyl}-2-methylpropane-2-sulfinamide (280 mg) obtained in step 1 was used instead of (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester.

[1160] Reference Example 31 tert-Butyl 4-[(1S)-1-aminoethyl]azepane-1-carboxylate

[1161] [Step 1] Preparation of tert-butyl 4-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]azepane-1-carboxylate The title compound (524 mg) was obtained by following the method of Step 1 of Reference Example 8, using tert-butyl 4-formylazepane-1-carboxylate (600 mg) instead of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate.

[1162] [Step 2] Preparation of tert-butyl 4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]azepane-1-carboxylate The title compound (450 mg) was obtained by following the method of Step 2 of Reference Example 20, using tert-butyl 4-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-7-azaspiro[3.5]nonane-7-carboxylate (524 mg) obtained in Step 1 instead of tert-butyl 2-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]azepane-1-carboxylate.

[1163] [Step 3] Preparation of tert-butyl 4-[(1S)-1-aminoethyl]azepane-1-carboxylate The title compound (281 mg) was obtained by following the method of Step 3 of Reference Example 5, except that tert-butyl 4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (450 mg) obtained in Step 2 was used instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]azepane-1-carboxylate. MS (m / z): 243.3 [M+H] + .

[1164] Reference Example 32 {(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl trifluoromethanesulfonateTrifluoromethanesulfonic anhydride (1.35 mL) was added dropwise to a solution of tert-butyl [(1r,4r)-4-(hydroxymethyl)cyclohexyl]carbamate (1.72 g) and pyridine (0.73 mL) in dichloromethane (75 mL) under ice cooling, and the mixture was stirred at the same temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (2.43 g).

[1165] Reference Example 33 tert-Butyl 5-[(1S)-1-aminoethyl]azocane-1-carboxylate

[1166] [Step 1] Preparation of tert-butyl 5-formylazacyclooctane-1-carboxylate

[1167] In a mixture of tert-butyl 5-oxoazacyclooctane-1-carboxylate (225 mg), (methoxymethyl)triphenylphosphonium chloride (679 mg) and THF (8 mL), potassium tert-butoxide (1M THF solution, 1.98 mL) was added under ice cooling and stirred at room temperature for 1 hour. Then, 1M hydrochloric acid (3.96 mL) was added and stirred at room temperature for 3 days. Saturated sodium bicarbonate aqueous solution was added to the reaction solution and extracted with ethyl acetate. After the organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (238 mg).

[1168] [Step 2] Preparation of tert-butyl 5-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]azocane-1-carboxylate The title compound (238 mg) was obtained by following the method of Step 1 of Reference Example 8, except that tert-butyl 5-formylazocane-1-carboxylate (238 mg) obtained in Step 1 was used instead of tert-butyl [(1r,4r)-4-acetylcyclohexyl]carbamate. MS (m / z): 345.6 [M+H] + .

[1169] [Step 3] Preparation of tert-butyl 5-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]azepane-1-carboxylate The title compound (255 mg) was obtained by following the method of Step 2 of Reference Example 20, using tert-butyl 5-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-7-azaspiro[3.5]nonane-7-carboxylate (238 mg) obtained in Step 2 instead of tert-butyl 2-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]azepane-1-carboxylate.

[1170] [Step 4] Preparation of tert-butyl 5-[(1S)-1-aminoethyl]azacyclooctane-1-carboxylate The title compound (140 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl 5-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]azacyclooctane-1-carboxylate (255 mg) obtained in Step 3 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate.

[1171] Reference Example 34 Tert-butyl [(1S,3R)-3-(Aminomethyl)-2,2-dimethylcyclobutyl]carbamate

[1172] [Step 1] Preparation of benzyl {[(1R,3S)-3-acetyl-2,2-dimethylcyclobutyl]methyl}carbamate To a suspension of [(1S,3S)-3-acetyl-2,2-dimethylcyclobutyl]acetic acid (5.80 g) in toluene (63 mL), TEA (6.6 mL) and diphenylphosphoryl azide (8.2 mL) were added, and the mixture was stirred at 70°C for 30 minutes, followed by benzyl alcohol (3.9 mL) and stirred at the same temperature for 5 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (7.20 g).

[1173] [Step 2] Preparation of benzyl {[(1R,3S)-3-acetylamino-2,2-dimethylcyclobutyl]methyl}carbamate

[1174] The title compound (5.28 g) was obtained by following the method of Step 2 of Reference Example 28, except that benzyl {[(1R,3S)-3-acetyl-2,2-dimethylcyclobutyl]methyl}carbamate (7.19 g) obtained in Step 1 was used instead of methyl (1S,3R)-3-acetyl-2,2-dimethylcyclobutane-1-carboxylate.

[1175] [Step 3] Preparation of N-[(1S,3R)-3-(aminomethyl)-2,2-dimethylcyclobutyl]acetamide The title compound (3.23 g) was obtained by following the method of Step 5 of Reference Example 2, using benzyl {[(1R,3S)-3-acetylamino-2,2-dimethylcyclobutyl]methyl}carbamate (5.28 g) obtained in Step 2 instead of benzyl 4-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-5-yl)piperidine-1-carboxylate.

[1176] [Step 4] Preparation of N-{(1S,3R)-3-[(dibenzylamino)methyl]-2,2-dimethylcyclobutyl}acetamide

[1177] The title compound (2.48 g) was obtained by following the method of Step 1 of Reference Example 13, except that N-[(1S,3R)-3-(aminomethyl)-2,2-dimethylcyclobutyl]acetamide (1.60 g) obtained in Step 3 was used instead of tert-butyl [(1r,4r)-4-(aminomethyl)cyclohexyl]carbamate hydrochloride.

[1178] [Step 5] Preparation of tert-butyl {(1S,3R)-3-[(dibenzylamino)methyl]-2,2-dimethylcyclobutyl}carbamate

[1179] The title compound (2.54 g) was obtained by following the method of Step 3 of Reference Example 28, except that N-{(1S,3R)-3-[(dibenzylamino)methyl]-2,2-dimethylcyclobutyl}acetamide (2.48 g) obtained in Step 4 was used instead of (1S,3R)-3-acetylamino-2,2-dimethylcyclobutane-1-carboxylic acid methyl ester.

[1180] [Step 6] Preparation of tert-butyl [(1S,3R)-3-(aminomethyl)-2,2-dimethylcyclobutyl]carbamate The title compound (1.29 g) was obtained by following the method of Step 5 of Reference Example 2, using tert-butyl {(1S,3R)-3-[(dibenzylamino)methyl]-2,2-dimethylcyclobutyl}carbamate (2.54 g) obtained in Step 5 instead of benzyl 4-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-5-yl)piperidine-1-carboxylate.

[1181] Reference Example 35 N-[(1R,3S)-3-(Aminomethyl)-2,2-dimethylcyclobutyl]acetamide

[1182] [Step 1] Preparation of benzyl {[(1S,3R)-3-acetyl-2,2-dimethylcyclobutyl]methyl}carbamate The title compound (13.6 g) was obtained by following the method of Step 1 of Reference Example 34, using [(1R,3R)-3-acetyl-2,2-dimethylcyclobutyl]acetic acid (10.0 g) instead of [(1S,3S)-3-acetyl-2,2-dimethylcyclobutyl]acetic acid.

[1183] [Step 2] Preparation of benzyl {[(1S,3R)-3-acetylamino-2,2-dimethylcyclobutyl]methyl}carbamate

[1184] The title compound (10.6 g) was obtained by following the method of Step 2 of Reference Example 28, except that benzyl {[(1S,3R)-3-acetyl-2,2-dimethylcyclobutyl]methyl}carbamate (13.6 g) obtained in Step 1 was used instead of methyl (1S,3R)-3-acetyl-2,2-dimethylcyclobutane-1-carboxylate.

[1185] [Step 3] Preparation of N-[(1R,3S)-3-(aminomethyl)-2,2-dimethylcyclobutyl]acetamide The title compound (6.5 g) was obtained by following the method of Step 5 of Reference Example 2, using benzyl {[(1S,3R)-3-acetylamino-2,2-dimethylcyclobutyl]methyl}carbamate (10.6 g) obtained in Step 2 instead of benzyl 4-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-5-yl)piperidine-1-carboxylate.

[1186] Reference Example 36 Tert-butyl {(1S,4r)-4-[(1S)-1-aminopropyl]cyclohexyl}carbamate

[1187] [Step 1] Preparation of tert-butyl [(1r,4r)-4-propionylcyclohexyl]carbamate

[1188] The title compound (450 mg) was obtained by following the procedure of Step 1 of Reference Example 3 except that ethylmagnesium bromide was used instead of methylmagnesium bromide.

[1189] [Step 2] Preparation of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]propaniminyl}cyclohexyl]carbamate

[1190] The title compound (300 mg) was obtained by following the method of Step 1 of Reference Example 5, except that tert-butyl [(1r,4r)-4-propionylcyclohexyl]carbamate (450 mg) obtained in Step 1 was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1191] [Step 3] Preparation of tert-butyl {(1S,4r)-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}propyl]cyclohexyl}carbamate The title compound (115 mg) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (300 mg) obtained in Step 2 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]propanimino}cyclohexyl]carbamate.

[1192] [Step 4] Preparation of tert-butyl {(1S,4r)-4-[(1S)-1-aminopropyl]cyclohexyl}carbamate The title compound (70 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl {(1S,4r)-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (112 mg) obtained in Step 3 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}propyl]cyclohexyl}carbamate.

[1193] Reference Example 37 Tert-butyl {3-[(1S)-1-aminoethyl]bicyclo[1.1.1]pentan-1-yl}carbamate

[1194] [Step 1] Preparation of tert-butyl {3-[methoxy(methyl)carbamoyl]bicyclo[1.1.1]pentan-1-yl}carbamate

[1195] The title compound (960 mg) was obtained by the method of Step 1 of Reference Example 14, except that 3-[(tert-butoxycarbonyl)amino]bicyclo[1.1.1]pentane-1-carboxylic acid (850 mg) was used instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1196] [Step 2] Preparation of tert-butyl (3-acetylbicyclo[1.1.1]pentan-1-yl)carbamate The title compound (790 mg) was obtained by following the method of Step 1 of Reference Example 3, using tert-butyl {3-[methoxy(methyl)carbamoyl]bicyclo[1.1.1]pentan-1-yl}carbamate (960 mg) obtained in Step 1 instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1197] [Step 3] Preparation of tert-butyl (3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}bicyclo[1.1.1]pentan-1-yl)carbamate

[1198] The title compound (493 mg) was obtained by the method of Step 1 of Reference Example 5, except that tert-butyl (3-acetylbicyclo[1.1.1]pentan-1-yl)carbamate (500 mg) obtained in Step 2 was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1199] [Step 4] Preparation of tert-butyl {3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]bicyclo[1.1.1]pentan-1-yl}carbamate

[1200] The title compound (444 mg) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl (3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (493 mg) obtained in Step 3 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}bicyclo[1.1.1]pentan-1-yl)carbamate.

[1201] [Step 5] Preparation of tert-butyl {3-[(1S)-1-aminoethyl]bicyclo[1.1.1]pentan-1-yl}carbamate

[1202] The title compound (302 mg) was obtained by following the method of step 3 of reference example 5, except that tert-butyl {3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (444 mg) obtained in step 4 was used instead of tert-butyl {3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]bicyclo[1.1.1]pentan-1-yl}carbamate (444 mg).

[1203] Reference Example 38 Tert-butyl {4-[(1S)-1-aminoethyl]cuban-1-yl}carbamate

[1204] [Step 1] Preparation of tert-butyl {4-[methoxy(methyl)carbamoyl]cubane-1-yl}carbamate The title compound (440 mg) was obtained by following the method of Step 1 of Reference Example 14, using 4-[(tert-butoxycarbonyl)amino]cubane-1-carboxylic acid instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1205] [Step 2] Preparation of tert-butyl [4-acetylcubane-1-yl]carbamate

[1206] The title compound (358 mg) was obtained by following the method of Step 1 of Reference Example 3, except that tert-butyl {4-[methoxy(methyl)carbamoyl]cuban-1-yl}carbamate (440 mg) obtained in Step 1 was used instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1207] [Step 3] Preparation of tert-butyl [4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cuban-1-yl]carbamate

[1208] The title compound (427 mg) was obtained by the method of Step 1 of Reference Example 5, except that tert-butyl [4-acetylcuban-1-yl]carbamate (358 mg) obtained in Step 2 was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1209] [Step 4] Preparation of tert-butyl {4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cuban-1-yl}carbamate The title compound (361 mg) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl [4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (427 mg) obtained in Step 3 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cuban-1-yl]carbamate.

[1210] [Step 5] Preparation of tert-butyl {4-[(1S)-1-aminoethyl]cuban-1-yl}carbamate The title compound (259 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl {4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (361 mg) obtained in Step 4 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cuban-1-yl}carbamate.

[1211] Reference Example 39 Tert-butyl {4-[(1S)-1-aminoethyl]bicyclo[2.2.1]heptane-1-yl}carbamate

[1212] [Step 1] Preparation of tert-butyl {4-[methoxy(methyl)carbamoyl]bicyclo[2.2.1]heptane-1-yl}carbamate

[1213] The title compound (231 mg) was obtained by the method of Step 1 of Reference Example 14, except that 4-[(tert-butoxycarbonyl)amino]bicyclo[2.2.1]heptane-1-carboxylic acid (255 mg) was used instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1214] [Step 2] Preparation of tert-butyl (4-acetylbicyclo[2.2.1]heptane-1-yl)carbamate The title compound (183 mg) was obtained by following the method of Step 1 of Reference Example 3, using tert-butyl {4-[methoxy(methyl)carbamoyl]bicyclo[2.2.1]heptane-1-yl}carbamate (231 mg) obtained in Step 1 instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1215] [Step 3] Preparation of tert-butyl {4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]bicyclo[2.2.1]heptane-1-yl}carbamate

[1216] To the tert-butyl (4-acetylbicyclo[2.2.1]heptane-1-yl)carbamate (183 mg) obtained in step 2, (S)-(-)-2-methyl-2-propanesulfenamide (219 mg) and tetraethyl orthotitanate (494 mg) were added, and the mixture was stirred at 60°C overnight. Then, THF (4 mL) was added, and sodium borohydride (55 mg) was added at -50°C, and the mixture was stirred for 4 hours while warming to room temperature. The reaction solution was diluted with ethyl acetate and water was added. The reaction solution was filtered through Celite (registered trademark), and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (130 mg).

[1217] [Step 4] Preparation of tert-butyl {4-[(1S)-1-aminoethyl]bicyclo[2.2.1]heptane-1-yl}carbamate

[1218] The title compound (90 mg) was obtained by following the method of Step 3 of Reference Example 5, except that tert-butyl {4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (130 mg) was used instead of tert-butyl {4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]bicyclo[2.2.1]heptane-1-yl}carbamate obtained in Step 3.

[1219] Reference Example 40 Tert-butyl {(1S,4r)-4-[(1S)-1-aminoethyl]cyclohexyl}methylcarbamate

[1220] [Step 1] Preparation of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}methylcarbamate

[1221] The title compound (1.68 g) was obtained by the method of Step 2 of Reference Example 13, except that tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate (2.0 g) was used instead of tert-butyl {(1r,4r)-4-[(dibenzylamino)methyl]cyclohexyl}carbamate.

[1222] [Step 2] Preparation of tert-butyl [(1r,4r)-4-acetylcyclohexyl]methylcarbamate The title compound (1.35 g) was obtained by following the method of Step 1 of Reference Example 3, using tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}methylcarbamate (1.68 g) obtained in Step 1 instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}methylcarbamate to obtain tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}methylcarbamate to obtain tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}methylcarbamate.

[1223] [Step 3] Preparation of tert-butyl methyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate The title compound (1.69 g) was obtained by following the method of Step 1 of Reference Example 5, using tert-butyl [(1r,4r)-4-acetylcyclohexyl]methylcarbamate (1.35 g) obtained in Step 2 instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1224] [Step 4] Preparation of tert-butyl methyl {(1S,4r)-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclohexyl}carbamate

[1225] The title compound (1.5 g) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl methyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (1.69 g) obtained in Step 3 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate.

[1226] [Step 5] Preparation of tert-butyl {(1S,4r)-4-[(1S)-1-aminoethyl]cyclohexyl}methylcarbamate

[1227] The title compound (880 mg) was obtained by following the method of step 3 of reference example 5, except that tert-butyl methyl {(1S,4r)-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (1.5 g) was used instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate.

[1228] Reference Example 41 Tert-butyl {(1S,3R)-3-[(1S)-1-aminoethyl]cyclohexyl}carbamate

[1229] [Step 1] Preparation of tert-butyl {(1S,3R)-3-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate The title compound (1.50 g) was obtained by following the method of Step 1 of Reference Example 14, using (1R,3S)-3-[(tert-butoxycarbonyl)amino]cyclohexane-1-carboxylic acid (1.23 g) instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1230] [Step 2] Preparation of tert-butyl [(1S,3R)-3-acetylcyclohexyl]carbamate The title compound (850 mg) was obtained by following the method of Step 1 of Reference Example 3, using tert-butyl {(1S,3R)-3-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate (1.50 g) obtained in Step 1 instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate to obtain.

[1231] [Step 3] Preparation of tert-butyl [(1S,3R)-3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate The title compound (700 mg) was obtained by following the method of Step 1 of Reference Example 5, using tert-butyl [(1S,3R)-3-acetylcyclohexyl]carbamate (850 mg) obtained in Step 2 instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1232] [Step 4] Preparation of tert-butyl {(1S,3R)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclohexyl}carbamate The title compound (555 mg) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl [(1S,3R)-3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (700 mg) obtained in Step 3 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate.

[1233] [Step 5] Preparation of tert-butyl {(1S,3R)-3-[(1S)-1-aminoethyl]cyclohexyl}carbamate The title compound (250 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl {(1S,3R)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (555 mg) obtained in Step 4 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclohexyl}carbamate.

[1234] Reference Example 42 Tert-butyl {(1S,4r)-4-[(1S)-1-aminoethyl]cyclohexyl}ethylcarbamate

[1235] [Step 1] Preparation of tert-butyl {(1S,4r)-4-[(1S)-1-(dibenzylamino)ethyl]cyclohexyl}carbamate

[1236] The title compound (1.72 g) was obtained by following the method of Step 1 of Reference Example 13, except that tert-butyl {(1S,4r)-4-[(1S)-1-aminoethyl]cyclohexyl}carbamate (1.0 g) obtained in Step 3 of Reference Example 7 was used instead of tert-butyl [(1r,4r)-4-(aminomethyl)cyclohexyl]carbamate hydrochloride.

[1237] [Step 2] Preparation of tert-butyl {(1S,4r)-4-[(1S)-1-(dibenzylamino)ethyl]cyclohexyl}ethylcarbamate The title compound (170 mg) was obtained by following the method of step 2 of reference example 13, using tert-butyl {(1S,4r)-4-[(1S)-1-(dibenzylamino)ethyl]cyclohexyl}carbamate (400 mg) obtained in step 1 instead of tert-butyl {(1r,4r)-4-[(dibenzylamino)methyl]cyclohexyl}carbamate and using iodoethane instead of iodomethane.

[1238] [Step 3] Preparation of tert-butyl {(1S,4r)-4-[(1S)-1-aminoethyl]cyclohexyl}ethylcarbamate

[1239] The title compound (95 mg) was obtained by following the method of step 5 of reference example 2, except that tert-butyl {(1S,4r)-4-[(1S)-1-(dibenzylamino)ethyl]cyclohexyl}ethylcarbamate (170 mg) obtained in step 2 was used instead of benzyl 4-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundecane-5-yl)piperidine-1-carboxylate.

[1240] Reference Example 43 Tert-butyl {(1R,3S)-3-[(1S)-1-aminoethyl]cyclohexyl}carbamate

[1241] [Step 1] Preparation of tert-butyl {(1R,3S)-3-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate The title compound (1.33 g) was obtained by following the method of Step 1 of Reference Example 14, using (1S,3R)-3-[(tert-butoxycarbonyl)amino]cyclohexane-1-carboxylic acid (1.1 g) instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1242] [Step 2] Preparation of tert-butyl [(1R,3S)-3-acetylcyclohexyl]carbamate The title compound (780 mg) was obtained by following the method of Step 1 of Reference Example 3, using tert-butyl {(1R,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate (1.33 g) obtained in Step 1 instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate to obtain tert-butyl {(1R,3S)-3-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1243] [Step 3: Preparation of tert-butyl [(1R,3S)-3-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate The title compound (883 mg) was obtained by following the method of Step 1 of Reference Example 5, using tert-butyl [(1R,3S)-3-acetylcyclohexyl]carbamate (777 mg) obtained in Step 2 instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1244] [Step 4] Preparation of tert-butyl {(1R,3S)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclohexyl}carbamate The title compound (630 mg) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl [(1R,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (883 mg) obtained in Step 3 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate.

[1245] [Step 5] Preparation of tert-butyl {(1R,3S)-3-[(1S)-1-aminoethyl]cyclohexyl}carbamate The title compound (375 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl {(1R,3S)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (630 mg) obtained in Step 4 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclohexyl}carbamate.

[1246] Reference Example 44 Tert-butyl {(1R,3S)-3-[(1S)-1-aminoethyl]cyclopentyl}carbamate

[1247] [Step 1] Preparation of tert-butyl {(1R,3S)-3-[methoxy(methyl)carbamoyl]cyclopentyl}carbamate The title compound was obtained by following the method of Step 1 of Reference Example 14, using (1S,3R)-3-[(tert-butoxycarbonyl)amino]cyclopentane-1-carboxylic acid instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1248] [Step 2] Preparation of tert-butyl [(1R,3S)-3-acetylcyclopentyl]carbamate The title compound is obtained by following the method of Step 1 of Reference Example 3, except that tert-butyl {(1R,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate is used instead of tert-butyl {(1R,3S)-3-[methoxy(methyl)carbamoyl]cyclopentyl}carbamate obtained in Step 1.

[1249] [Step 3] Preparation of tert-butyl {(1R,3S)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclopentyl}carbamate The title compound (336 mg) was obtained by following the method of Step 3 of Reference Example 39, using tert-butyl [(1R,3S)-3-acetylcyclopentyl]carbamate (368 mg) obtained in Step 2 instead of tert-butyl (4-acetylbicyclo[2.2.1]heptan-1-yl)carbamate.

[1250] [Step 4] Preparation of tert-butyl {(1R,3S)-3-[(1S)-1-aminoethyl]cyclopentyl}carbamate The title compound (225 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl {(1R,3S)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (336 mg) obtained in Step 3 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclopentyl}carbamate.

[1251] Reference Example 45 Tert-butyl {(1S,3R)-3-[(1S)-1-aminoethyl]cyclopentyl}carbamate

[1252] [Step 1] Preparation of tert-butyl {(1S,3R)-3-[methoxy(methyl)carbamoyl]cyclopentyl}carbamate The title compound was obtained by following the method of Step 1 of Reference Example 14, using (1R,3S)-3-[(tert-butoxycarbonyl)amino]cyclopentane-1-carboxylic acid instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1253] [Step 2] Preparation of tert-butyl [(1S,3R)-3-acetylcyclopentyl]carbamate The title compound is obtained by following the method of Step 1 of Reference Example 3, except that tert-butyl {(1S,3R)-3-[methoxy(methyl)carbamoyl]cyclopentyl}carbamate obtained in Step 1 is used instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1254] [Step 3] Preparation of tert-butyl {(1S,3R)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclopentyl}carbamate

[1255] The title compound (215 mg) was obtained by the method of Step 3 of Reference Example 39, except that tert-butyl [(1S,3R)-3-acetylcyclopentyl]carbamate (314 mg) obtained in Step 2 was used instead of tert-butyl (4-acetylbicyclo[2.2.1]heptan-1-yl)carbamate.

[1256] [Step 4] Preparation of tert-butyl {(1S,3R)-3-[(1S)-1-aminoethyl]cyclopentyl}carbamate The title compound (135 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl {(1S,3R)-3-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (215 mg) obtained in Step 3 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]cyclopentyl}carbamate.

[1257] Reference Example 46 tert-Butyl 4-[(1S)-1-amino-2-fluoroethyl]-4-fluoropiperidine-1-carboxylate

[1258] [Step 1] Preparation of tert-butyl 4-[(1R)-2-(benzenesulfonyl)-2-fluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]-4-fluoropiperidine-1-carboxylate The title compound (1.33 g) was obtained by following the method of Step 2 of Reference Example 27, using tert-butyl 4-fluoro-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate (900 mg) obtained in Step 2 of Reference Example 12 instead of tert-butyl 4-[(E)-{[(S)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate.

[1259] [Step 2] Preparation of tert-butyl 4-fluoro-4-[(1S)-2-fluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1260] The title compound (300 mg) was obtained by following the method of Step 3 of Reference Example 27, using tert-butyl 4-[(1R)-2-(benzenesulfonyl)-2-fluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate (1.33 g) obtained in Step 1 instead of tert-butyl 4-[(1R)-2-(benzenesulfonyl)-2-fluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]-4-fluoropiperidine-1-carboxylate.

[1261] [Step 3] Preparation of tert-butyl 4-[(1S)-1-amino-2-fluoroethyl]-4-fluoropiperidine-1-carboxylate The title compound (165 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl 4-fluoro-4-[(1S)-2-fluoro-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (300 mg) obtained in Step 2 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate.

[1262] Reference Example 47 (3S,4S)-4-[(1S)-1-aminoethyl]-3-methylpiperidine-1-carboxylic acid tert-butyl ester or (3R,4R)- tert-Butyl 4-[(1S)-1-aminoethyl]-3-methylpiperidine-1-carboxylate

[1263] [Step 1] Preparation of tert-butyl 4-[methoxy(methyl)carbamoyl]-3-methylpiperidine-1-carboxylate The title compound (4.62 g) was obtained by following the method of Step 1 of Reference Example 14, except that 1-(tert-butoxycarbonyl)-3-methylpiperidine-4-carboxylic acid (cis / trans=4 / 1, 4.1 g) was used instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid (for example, synthesized according to the method described in WO2010 / 013037).

[1264] [Step 2] Preparation of tert-butyl 4-acetyl-3-methylpiperidine-1-carboxylate

[1265] The title compound (3.98 g) was obtained by following the method of step 1 of reference example 3, except that tert-butyl 4-[methoxy(methyl)carbamoyl]-3-methylpiperidine-1-carboxylate (4.62 g) obtained in step 1 was used instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1266] [Step 3] Preparation of tert-butyl (3S, 4S)-3-methyl-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate or tert-butyl (3R, 4R)-3-methyl-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate A mixture of tert-butyl 4-acetyl-3-methylpiperidine-1-carboxylate (1.45 g) obtained in Step 2, (S)-(-)-2-methyl-2-propanesulfinamide (1.04 g) and tetraethyl orthotitanate (3.27 g) was stirred at 60°C overnight. The reaction solution was diluted with ethyl acetate and water was added. The reaction solution was filtered through Celite (registered trademark) and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to give the title compound (683 mg) and tert-butyl (3R,4R)-3-methyl-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate (609 mg). Stereochemistry was assigned based on physiological activity and similarity to the determined structure (arbitrarily).

[1267] [Step 4] Preparation of tert-butyl (3S,4S)-3-methyl-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate The title compound (426 mg) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl (3S,4S)-3-methyl-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate (683 mg) obtained in Step 3.

[1268] [Step 5] Preparation of tert-butyl (3S,4S)-4-[(1S)-1-aminoethyl]-3-methylpiperidine-1-carboxylate The title compound (291 mg) was obtained by following the method of Step 3 of Reference Example 5, using (3S,4S)-3-methyl-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate (426 mg) obtained in Step 4.

[1269] Reference Example 48 (3R, 4R)-4-[(1S)-1-aminoethyl]-3-methylpiperidine-1-carboxylic acid tert-butyl ester or (3S, 4S)- tert-Butyl 4-[(1S)-1-aminoethyl]-3-methylpiperidine-1-carboxylate

[1270] [Step 1] Preparation of tert-butyl (3R, 4R)-3-methyl-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1271] The title compound (350 mg) was obtained by following the method of Step 2 of Reference Example 7, except that tert-butyl (3R,4R)-3-methyl-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (609 mg) was used in Step 3 of Reference Example 47 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate.

[1272] [Step 2] Preparation of tert-butyl (3R,4R)-4-[(1S)-1-aminoethyl]-3-methylpiperidine-1-carboxylate The title compound (237 mg) was obtained by following the method of Step 3 of Reference Example 5, using (3R,4R)-3-methyl-4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate (350 mg) obtained in Step 1.

[1273] Reference Example 49 tert-Butyl 4-[(1S)-1-aminoethyl]-2-methylpiperidine-1-carboxylate

[1274] [Step 1] Preparation of tert-butyl 4-[methoxy(methyl)carbamoyl]-2-methylpiperidine-1-carboxylate The title compound (73.5 g) was obtained by following the method of Step 1 of Reference Example 14, using 1-(tert-butoxycarbonyl)-2-methylpiperidine-4-carboxylic acid (57.8 g) instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1275] [Step 2] Preparation of tert-butyl 4-acetyl-2-methylpiperidine-1-carboxylate

[1276] The title compound (54.7 g) was obtained by following the method of step 1 of reference example 3, except that tert-butyl 4-[methoxy(methyl)carbamoyl]-2-methylpiperidine-1-carboxylate (73.5 g) obtained in step 1 was used instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1277] [Step 3] Preparation of tert-butyl 2-methyl-4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1278] To the tert-butyl 4-acetyl-2-methylpiperidine-1-carboxylate (54.7 g) obtained in step 2, (R)-(+)-2-methyl-2-propanesulfenamide (35.7 g) and tetraisopropyl orthotitanate (193 g) were added in sequence, and stirred at 70°C for 12 hours. THF (453 mL) was then added, and lithium tri-sec-butylborohydride (1M THF solution, 453 mL) was added at -78°C, and stirred for 2 hours while warming from -78°C to room temperature. The reaction solution was diluted with ethyl acetate and water was added. The reaction solution was filtered through Celite (registered trademark) and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (85 g).

[1279] [Step 4] Preparation of tert-butyl 4-[(1S)-1-aminoethyl]-2-methylpiperidine-1-carboxylate The title compound (39.5 g) was obtained by following the method of Step 3 of Reference Example 5, except that tert-butyl 2-methyl-4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate (85 g) obtained in Step 3 was used instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate.

[1280] Reference Example 50 2-Amino-3,7-anhydro-6-[(tert-butoxycarbonyl)amino]-1,2,4,5,6-pentadeoxy-L-argan Rab-Heptitol

[1281] [Step 1] Preparation of tert-butyl {(3R,6S)-6-[methoxy(methyl)carbamoyl]oxan-3-yl}carbamate

[1282] The title compound was obtained by the method of Step 1 of Reference Example 14, except that 2,6-anhydro-5-[(tert-butoxycarbonyl)amino]-3,4,5-trideoxy-L-erythro-hexonic acid was used instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1283] [Step 2] Preparation of tert-butyl [(3R,6S)-6-acetyloxan-3-yl]carbamate The title compound (450 mg) was obtained by following the method of Step 1 of Reference Example 3, using tert-butyl {(3R,6S)-6-[methoxy(methyl)carbamoyl]oxan-3-yl}carbamate obtained in Step 1 instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1284] [Step 3] Preparation of 3,7-anhydro-6-[(tert-butoxycarbonyl)amino]-1,2,4,5,6-pentadeoxy-2-{[(R)-2-methylpropane-2-sulfinyl]amino}-L-arabino-heptanol The title compound (240 mg) was obtained by following the method of Step 3 of Reference Example 49, using tert-butyl [(3R,6S)-6-acetyloxan-3-yl]carbamate (450 mg) obtained in Step 2 instead of tert-butyl 4-acetyl-2-methylpiperidine-1-carboxylate.

[1285] [Step 4] Production of 2-amino-3,7-anhydro-6-[(tert-butoxycarbonyl)amino]-1,2,4,5,6-pentadeoxy-L-arabino-heptitol

[1286] The title compound (90 mg) was obtained by following the method of Step 3 of Reference Example 5, except that 3,7-anhydro-6-[(tert-butoxycarbonyl)amino]-1,2,4,5,6-pentadeoxy-2-{[(R)-2-methylpropane-2-sulfinyl]amino}-L-arabino-heptitol (240 mg) obtained in Step 3 was used instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate.

[1287] Reference Example 51 (3S,4R)-4-[(1S)-1-aminoethyl]-3-fluoropiperidine-1-carboxylic acid tert-butyl ester

[1288] [Step 1] Preparation of tert-butyl (3S, 4R)-3-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate To a solution of [(3S, 4R)-1-benzyl-3-fluoropiperidin-4-yl]methanol (1.2 g) (synthesized, for example, according to the method described in WO2006 / 069287) in methanol (20 mL), add hydrogen chloride (2 M methanol solution, 4 mL), degas, add 10% Pd-C (500 mg) while stirring at room temperature under an argon atmosphere, and stir overnight at room temperature under a medium-pressure hydrogen atmosphere (0.4 MPa). Saturated aqueous sodium bicarbonate solution and Boc2O (1.9 mL) were added to the reaction solution, and stirred at room temperature for 1 hour. After the insoluble matter was separated by filtration, it was diluted with ethyl acetate and the organic layer was washed with saturated brine. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (900 mg).

[1289] [Step 2] Preparation of tert-butyl (3S, 4R)-3-fluoro-4-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylate

[1290] 2-Hydroxy-2-azaadamantane (29 mg) and iodobenzene diacetate (2.46 g) were added to the dichloromethane (7.6 mL) solution of tert-butyl (3S, 4R)-3-fluoro-4-(hydroxymethyl)piperidine-1-carboxylate (890 mg) obtained in step 1, and stirred at room temperature. After confirming the disappearance of the raw material by TLC, a saturated aqueous sodium carbonate solution and a saturated aqueous sodium thiosulfate solution were added to the reaction solution, and stirred at room temperature for 10 minutes. After the reaction solution was extracted with dichloromethane, the solvent was distilled off under reduced pressure, and tetraisopropyl orthotitanate (3.3 mL) was added to the obtained residue under ice cooling in a dichloromethane (7.6 mL) solution of (R)-(+)-2-methyl-2-propanesulfenamide (694 mg), and stirred at room temperature for 2 hours. The reaction solution was diluted with ethyl acetate and water was added. The reaction solution was filtered through Celite (registered trademark) and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (575 mg).

[1291] [Step 3] Preparation of tert-butyl (3S, 4R)-3-fluoro-4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate

[1292] The title compound (353 mg) was obtained by following the method of Step 2 of Reference Example 20, except that (3S,4R)-3-fluoro-4-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]piperidine-1-carboxylic acid tert-butyl ester (575 mg) obtained in Step 2 was used instead of tert-butyl 2-[(E)-{[(R)-2-methylpropane-2-sulfinyl]imino}methyl]-7-azaspiro[3.5]nonane-7-carboxylate.

[1293] [Step 4] Preparation of tert-butyl (3S,4R)-4-[(1S)-1-aminoethyl]-3-fluoropiperidine-1-carboxylate The title compound (250 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl (3S,4R)-3-fluoro-4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (353 mg) obtained in Step 3 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate.

[1294] Reference Example 52 (3S,4S)-4-[(1S)-1-aminoethyl]-3-ethylpiperidine-1-carboxylic acid tert-butyl ester or (3R,4R)- tert-Butyl 4-[(1S)-1-aminoethyl]-3-ethylpiperidine-1-carboxylate

[1295] [Step 1] Production of 1-(tert-butoxycarbonyl)-3-ethylpiperidine-4-carboxylic acid

[1296] 3-Ethynylpyridine-4-carboxylic acid methyl ester (876 mg) was dissolved in methanol (10.9 mL). After degassing, 2M hydrochloric acid (4.1 mL) and platinum (IV) oxide (87.6 mg) were added while stirring at room temperature under an argon atmosphere, and stirred overnight at room temperature under a medium-pressure hydrogen atmosphere (0.4 MPa). After the reaction solution was filtered through Celite (registered trademark), the solvent was distilled off under reduced pressure. Boc2O (1.87 mL) and 2M aqueous sodium hydroxide solution (16.3 mL) were added to the residue in sequence, and stirred at 80°C for 1 hour. Hydrochloric acid was added to the reaction solution and extracted with ethyl acetate. After washing the organic layer with saturated brine, the solvent was distilled off under reduced pressure, hexane was added to the obtained residue, suspended, and filtered to obtain the precipitate to obtain the title compound (870 mg).

[1297] [Step 2] Preparation of tert-butyl 3-ethyl-4-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate The title compound (960 mg) was obtained by following the method of Step 1 of Reference Example 14, using 1-(tert-butoxycarbonyl)-3-ethylpiperidine-4-carboxylic acid (870 mg) obtained in Step 1 instead of [(3S)-1-(tert-butoxycarbonyl)pyrrolidin-3-yl]acetic acid.

[1298] [Step 3] Preparation of tert-butyl 4-acetyl-3-ethylpiperidine-1-carboxylate

[1299] The title compound was obtained by following the method of Step 1 of Reference Example 3 except that tert-butyl 3-ethyl-4-[methoxy(methyl)carbamoyl]piperidine-1-carboxylate obtained in Step 2 was used instead of tert-butyl {(1r,4r)-4-[methoxy(methyl)carbamoyl]cyclohexyl}carbamate.

[1300] [Step 4] Preparation of tert-butyl (3S,4S)-3-ethyl-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate or tert-butyl (3R,4R)-3-ethyl-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate The title compound (490 mg) and tert-butyl (3R,4R)-3-ethyl-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate were obtained by following the method of Step 3 of Reference Example 47, except that tert-butyl 4-acetyl-3-methylpiperidine-1-carboxylate was used instead of tert-butyl 4-acetyl-3-methylpiperidine-1-carboxylate. Stereochemistry is assigned (arbitrarily) based on physiological activity and similarity to defined structures.

[1301] [Step 5] Preparation of tert-butyl (3S,4S)-3-ethyl-4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate Tert-butyl (3S,4S)-3-ethyl-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate (490 mg) obtained in step 4 was dissolved in THF (6.8 mL), and lithium tri-sec-butylborohydride (1M THF solution, 2.7 mL) was added at -78°C, and the mixture was stirred while warming from -78°C to room temperature. After confirming the disappearance of the raw material by TLC, a saturated aqueous ammonium chloride solution was added to the reaction solution, and extraction was performed with ethyl acetate. After washing the organic layer with saturated brine, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (472 mg).

[1302] [Step 6] Preparation of tert-butyl (3S,4S)-4-[(1S)-1-aminoethyl]-3-ethylpiperidine-1-carboxylate The title compound (240 mg) was obtained by following the method of Step 3 of Reference Example 5, using (3S,4S)-3-ethyl-4-[(1S)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate (472 mg) obtained in Step 5 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate.

[1303] Reference Example 53 (3R, 4R)-4-[(1S)-1-aminoethyl]-3-ethylpiperidine-1-carboxylic acid tert-butyl or (3S, 4S)-4- [(1S)-1-Aminoethyl]-3-ethylpiperidine-1-carboxylic acid tert-butyl ester

[1304] [Step 1] Preparation of tert-butyl (3R,4R)-3-ethyl-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate The title compound (352 mg) was obtained by following the method of Step 5 of Reference Example 52, using tert-butyl (3R,4R)-3-ethyl-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate (430 mg) obtained in Step 4 of Reference Example 52 instead of tert-butyl (3S,4S)-3-ethyl-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate.

[1305] [Step 5] Preparation of tert-butyl (3R,4R)-4-[(1S)-1-aminoethyl]-3-ethylpiperidine-1-carboxylate The title compound (190 mg) was obtained by following the method of Step 3 of Reference Example 5, using tert-butyl (3R,4R)-3-ethyl-4-{(1E)-N-[(R)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate (352 mg) obtained in Step 1 instead of tert-butyl (1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}-7-azaspiro[3.5]nonane-7-carboxylate.

[1306] Reference Example 54 tert-Butyl 4-[(1s,3s)-3-(Hydroxymethyl)cyclobutyl]piperazine-1-carboxylate

[1307] [Step 1] Preparation of tert-butyl 4-[(1s,3s)-3-(methoxycarbonyl)cyclobutyl]piperazine-1-carboxylate Dissolve methyl 3-oxocyclobutane-1-carboxylate (1.0 g) in dichloromethane (31 mL), add 1-(tert-butoxycarbonyl)piperazine (1.7 g), add sodium triacetoxyborohydride (3.3 g) under ice cooling, and stir overnight at room temperature. Add saturated aqueous ammonium chloride to the reaction solution, and extract with ethyl acetate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (2.0 g). MS (m / z): 299.2 [M+H] + .

[1308] [Step 2] Preparation of tert-butyl 4-[(1s,3s)-3-(hydroxymethyl)cyclobutyl]piperazine-1-carboxylate To a solution of tert-butyl 4-[(1s,3s)-3-(methoxycarbonyl)cyclobutyl]piperazine-1-carboxylate (200 mg) obtained in step 1 in methanol (1.3 mL) was added sodium borohydride (101 mg), and the mixture was stirred overnight at room temperature. A saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (125 mg). MS (m / z): 271.2 [M+H] + .

[1309] Reference Example 55 4-{(1S)-1-[(2-hydroxyethyl)(2-nitrobenzene-1-sulfonyl)amino]ethyl}piperidin-1-carboxylic acid Tert-butyl ester

[1310] [Step 1] Preparation of tert-butyl 4-{(1S)-1-[(2-nitrobenzene-1-sulfonyl)amino]ethyl}piperidine-1-carboxylate 2-nitrobenzenesulfonyl chloride (1.07 g) was added to a mixture of tert-butyl 4-[(1S)-1-aminoethyl]piperidine-1-carboxylate (1.0 g), sodium bicarbonate (736 mg), water (9 mL) and THF (9 mL), and the mixture was stirred at room temperature for 1 hour. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with water and saturated brine. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (860 mg).

[1311] [Step 2] Preparation of tert-butyl 4-{(1S)-1-[(2-hydroxyethyl)(2-nitrobenzene-1-sulfonyl)amino]ethyl}piperidine-1-carboxylate

[1312] To a solution of tert-butyl 4-{(1S)-1-[(2-nitrobenzene-1-sulfonyl)amino]ethyl}piperidine-1-carboxylate (330 mg) obtained in step 1 in NMP (1.6 mL) were added 2-bromoethanol (598 mg) and potassium carbonate (662 mg), and the mixture was stirred at 80° C. After confirming the disappearance of the raw material by TLC, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (100 mg).

[1313] Reference Example 56 [(1S,4r)-4-{(1S)-1-[(2-hydroxyethyl)(2-nitrobenzene-1-sulfonyl)amino]ethyl} tert-Butyl]cyclohexylcarbamate

[1314] [Step 1] Preparation of tert-butyl [(1S,4r)-4-{(1S)-1-[(2-nitrobenzene-1-sulfonyl)amino]ethyl}cyclohexyl]carbamate The title compound (1.41 g) was obtained by following the method of Step 1 of Reference Example 55, using tert-butyl {(1S,4r)-4-[(1S)-1-aminoethyl]cyclohexyl}carbamate (1.0 g) obtained in Step 3 of Reference Example 7 instead of tert-butyl 4-[(1S)-1-aminoethyl]piperidine-1-carboxylate.

[1315] [Step 2] Preparation of tert-butyl [(1S,4r)-4-{(1S)-1-[(2-hydroxyethyl)(2-nitrobenzene-1-sulfonyl)amino]ethyl}cyclohexyl]carbamate

[1316] The title compound (140 mg) was obtained by following the method of step 2 of reference example 55, except that tert-butyl [(1S,4r)-4-{(1S)-1-[(2-nitrobenzene-1-sulfonyl)amino]ethyl}piperidine-1-carboxylate (200 mg) was used instead of tert-butyl 4-{(1S)-1-[(2-nitrobenzene-1-sulfonyl)amino]ethyl}cyclohexyl]carbamate obtained in step 1.

[1317] Reference Example 57 4-[(1S)-1-{(2-hydroxypropyl)[(S)-2-methylpropane-2-sulfinyl]amino}ethyl] Piperidine-1-carboxylic acid tert-butyl ester

[1318] [Step 1] Preparation of tert-butyl 4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate

[1319] The title compound (106 g) was obtained by the method of Step 1 of Reference Example 5, except that tert-butyl 4-acetylpiperidine-1-carboxylate (73.2 g) was used instead of tert-butyl 1-oxo-7-azaspiro[3.5]nonane-7-carboxylate.

[1320] [Step 2] Preparation of tert-butyl 4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate The title compound (91 g) was obtained by following the method of Step 2 of Reference Example 7, using tert-butyl 4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}cyclohexyl]carbamate (90 g) obtained in Step 1 instead of tert-butyl [(1r,4r)-4-{(1E)-N-[(S)-2-methylpropane-2-sulfinyl]ethaneimino}piperidine-1-carboxylate.

[1321] [Step 3] Preparation of tert-butyl 4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl](prop-2-en-1-yl)amino}ethyl]piperidine-1-carboxylate

[1322] The title compound (1.54 g) was obtained by the method of Step 2 of Reference Example 13 using tert-butyl 4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate (2.0 g) obtained in Step 2 of Reference Example 57 and allyl bromide.

[1323] [Step 4] Preparation of tert-butyl 4-[(1S)-1-{(2-hydroxypropyl)[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate To a solution of tert-butyl 4-[(1S)-1-{[(S)-2-methylpropane-2-sulfinyl](prop-2-en-1-yl)amino}ethyl]piperidine-1-carboxylate (500 mg) obtained in step 3 in THF (2.7 mL) was added BH3-THF (0.9 M THF solution, 3 mL) under ice cooling, and the mixture was stirred at the same temperature for 1 hour. Then, sodium perborate tetrahydrate (1.03 g) was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with saturated brine. The solvent was evaporated under reduced pressure and the obtained residue was purified by silica gel column chromatography to obtain the title compound (77 mg) and its isomer tert-butyl 4-[(1S)-1-{(3-hydroxypropyl)[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]piperidine-1-carboxylate (271 mg).

[1324] Reference Example 58 [(1S,4r)-4-{(1S)-1-[(2-hydroxypropyl)(2-nitrobenzene-1-sulfonyl)amino]ethyl} tert-Butyl]cyclohexylcarbamate Tert-butyl [(1S,4r)-4-{(1S)-1-[(2-hydroxyethyl)(2-nitrobenzene-1-sulfonyl)amino]ethyl}cyclohexyl]carbamate (240 mg) obtained in step 2 of reference example 56, propylene oxide (98 mg), potassium carbonate (155 mg) and DMF (1.1 mL) were stirred at 80°C for 24 hours. The reaction solution was diluted with water and extracted with ethyl acetate. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (71 mg).

[1325] Reference Example 59 Ethyl 3-({4-[(tert-butoxycarbonyl)amino]butyl}amino)-4-(trifluoromethyl)benzoate

[1326] Toluene (2 mL) was added to ethyl 3-iodo-4-(trifluoromethyl)benzoate (145 mg), tert-butyl (4-aminobutyl)carbamate (91 mg), BINAP (55 mg), cesium carbonate (286 mg), and Pd(OAc)2 (10 mg), and the mixture was degassed and stirred at 110° C. for 12 hours under an argon atmosphere. The reaction solution was cooled and purified by silica gel column chromatography to obtain the title compound (135 mg).

[1327] Reference Example 69 4-(4-{2-[(tert-Butyloxycarbonyl)amino]ethyl}piperidin-1-yl)-1-{[2-(trimethylsilyl) 1H-indazole-6-carboxylic acid methyl ester

[1328] [Step 1] Preparation of 4-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazole-6-carboxylic acid methyl ester In a mixture of 4-bromo-1H-indazole-6-carboxylic acid methyl ester (1.58 g), potassium carbonate (942 mg) and DMF (12 mL), 2-(chloromethoxy)ethyltrimethylsilane (1.1 mL) was added under ice cooling and stirred overnight at room temperature. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with water and saturated brine. After drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (1.01 g).

[1329] [Step 2] Preparation of methyl 4-(4-{2-[(tert-butoxycarbonyl)amino]ethyl}piperidin-1-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazole-6-carboxylate

[1330] The title compound (52 mg) was obtained by following the method of Reference Example 59, using 4-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-indazole-6-carboxylic acid methyl ester (80 mg) obtained in Step 1 instead of ethyl 3-iodo-4-(trifluoromethyl)benzoate, and using tert-butyl [2-(piperidin-4-yl)ethyl]carbamate instead of tert-butyl (4-aminobutyl)carbamate.

[1331] Reference Example 743'-{[(tert-Butyloxycarbonyl)amino]methyl}-6-chloro[1,1'-biphenyl]-3-carboxylic acid ethyl ester 1,4-dioxane (3 mL) was added to ethyl 4-chloro-3-iodobenzoate (150 mg), (3-{[(tert-butoxycarbonyl)amino]methyl}phenyl)boric acid (127 mg), Pd(PPh3)4 (56 mg) and saturated sodium bicarbonate aqueous solution (1 mL), and after degassing, the mixture was stirred at 100°C for 2 hours under an argon atmosphere. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with water and saturated brine. After drying over anhydrous magnesium sulfate, the solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (101 mg).

[1332] Reference Example 78 4-({[5'-(methoxycarbonyl)-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy}methyl) Piperidine-1-carboxylic acid tert-butyl ester

[1333] [Step 1] Production of 4'-hydroxy-6-(trifluoromethyl)[1,1'-biphenyl]-3-carboxylic acid

[1334] The title compound (414 mg) was obtained by following the method of Reference Example 74, using methyl 3-bromo-4-(trifluoromethyl)benzoate (500 mg) instead of ethyl 4-chloro-3-iodobenzoate and (4-hydroxyphenyl)boric acid instead of (3-{[(tert-butoxycarbonyl)amino]methyl}phenyl)boric acid.

[1335] [Step 2] Preparation of methyl 4'-hydroxy-6-(trifluoromethyl)[1,1'-biphenyl]-3-carboxylate Concentrated sulfuric acid (0.1 mL) was added to a methanol (4 mL) solution of 4'-hydroxy-6-(trifluoromethyl)[1,1'-biphenyl]-3-carboxylic acid (350 mg) obtained in step 1, and the mixture was stirred at 65°C for 4 hours. The reaction solution was concentrated under reduced pressure, water was added to the obtained residue, and the precipitate was filtered out and dried to obtain the title compound (320 mg).

[1336] [Step 3] Preparation of tert-butyl 4-({[5'-(methoxycarbonyl)-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy}methyl)piperidine-1-carboxylate To a THF (0.7 mL) solution of methyl 4'-hydroxy-6-(trifluoromethyl)[1,1'-biphenyl]-3-carboxylate (20 mg), tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (22 mg), and PPh3 (27 mg) obtained in step 2 was added di(2-methoxyethyl)azodicarboxylate (24 mg), and the mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (20 mg).

[1337] Reference Example 794'-({(2S)-1-[(tert-butoxycarbonyl)amino]propan-2-yl}oxy)-6-(trifluoromethyl) [1,1'-Biphenyl]-3-carboxylic acid methyl ester

[1338] The title compound (20 mg) was obtained by the method of Step 3 of Reference Example 78, except that tert-butyl [(2R)-2-hydroxypropyl]carbamate was used instead of tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate.

[1339] Reference Example 81 tert-Butyl 4-{2-[5-(methoxycarbonyl-2-(trifluoromethyl)phenyl]ethyl}piperidine-1-carboxylate

[1340] [Step 1] Preparation of tert-butyl 4-{[5-(methoxycarbonyl-2-(trifluoromethyl)phenyl]ethynyl}piperidine-1-carboxylate

[1341] DMF (2 mL) was added to methyl 3-bromo-4-(trifluoromethyl)benzoate (406 mg), tert-butyl 4-ethynylpiperidine-1-carboxylate (300 mg), copper iodide (20 mg), Pd(PPh3)4 (83 mg) and TEA (2 mL), and after degassing, the mixture was stirred at 50°C for 4 hours under an argon atmosphere. The reaction solution was diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The resulting residue was purified by silica gel column chromatography to obtain the title compound (180 mg). MS (m / z): 412.7 [M+H] + .

[1342] [Step 2] Preparation of tert-butyl 4-{2-[5-(methoxycarbonyl-2-(trifluoromethyl)phenyl]ethyl}piperidine-1-carboxylate The title compound was obtained by following the method of Step 5 of Reference Example 2, using tert-butyl 4-{[5-(methoxycarbonyl-2-(trifluoromethyl)phenyl]ethynyl}piperidine-1-carboxylate obtained in Step 1 instead of benzyl 4-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundec-5-yl)piperidine-1-carboxylate.

[1343] Reference Example 82 tert-Butyl 4-{[5-(methoxycarbonyl-2-(trifluoromethyl)phenyl]ethynyl}piperidine-1-carboxylate

[1344] The title compound (121 mg) was obtained by the method of Step 1 of Reference Example 81, except that tert-butyl [(1r,4r)-4-ethynylcyclohexyl]carbamate (300 mg) was used instead of tert-butyl 4-ethynylpiperidine-1-carboxylate.

[1345] Reference Example 833-(2-{(1r,4s)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl)-4-(trifluoromethyl) Methyl benzoate

[1346] The title compound (100 mg) was obtained by following the method of step 2 of reference example 1, except that methyl 3-({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethynyl)-4-(trifluoromethyl)benzoate (126 mg) obtained in reference example 82 was used instead of tert-butyl [2-methyl-2-(pyridin-4-yl)propyl]carbamate.

[1347] Reference Example 84 3-[(E)-2-{5-[(tert-butoxycarbonyl)amino]-1,3-dioxane-2-yl}vinyl]-4- Methyl (trifluoromethyl)benzoate

[1348] [Step 1] Preparation of methyl 3-[(1E)-3-oxoprop-1-en-1-yl]-4-(trifluoromethyl)benzoate To methyl 3-bromo-4-(trifluoromethyl)benzoate (500 mg), acrolein diethyl acetal (690 mg), potassium carbonate (366 mg), potassium chloride (132 mg), tetrabutylammonium acetate (1.07 g) and Pd(OAc)2 (20 mg), DMF (7.1 mL) was added, and after degassing, the mixture was stirred at 90°C for 3 hours under an argon atmosphere. The reaction solution was filtered through Celite (registered trademark), diluted with ethyl acetate, and the organic layer was washed with 2M hydrochloric acid and saturated brine. The solvent was distilled off under reduced pressure, and then purified by silica gel column chromatography to obtain the title compound (250 mg).

[1349] [Step 2] Preparation of methyl 3-{(E)-2-[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1,3-dioxan-2-yl]vinyl}-4-(trifluoromethyl)benzoate

[1350] 2-(1,3-dihydroxypropane-2-yl)-1H-isoindole-1,3(2H)-dione (321 mg) and p-toluenesulfonic acid monohydrate (92 mg) were added to a toluene (4.8 mL) solution of methyl 3-[(1E)-3-oxoprop-1-en-1-yl]-4-(trifluoromethyl)benzoate (250 mg) obtained in step 1, and the mixture was stirred at 140°C for 6 hours. After the reaction solution was cooled, sodium bicarbonate was added, and the reaction solution was filtered through Celite (registered trademark). After the solvent was distilled off under reduced pressure, the mixture was purified by silica gel column chromatography to obtain the title compound (291 mg).

[1351] [Step 3] Preparation of methyl 3-[(E)-2-{5-[(tert-butoxycarbonyl)amino]-1,3-dioxane-2-yl}vinyl]-4-(trifluoromethyl)benzoate To a solution of methyl 3-{(E)-2-[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1,3-dioxane-2-yl]vinyl}-4-(trifluoromethyl)benzoate (124 mg) obtained in step 2 in THF (1.3 mL) was added hydrazine monohydrate (13 mg), stirred at 60°C, and then hydrazine acetate (25 mg) was added, followed by stirring at the same temperature. After confirming the disappearance of the raw material by TLC, Boc2O (65 mg) was added, and stirred at the same temperature. After confirming the disappearance of the raw material by TLC, the reaction solution was diluted with ethyl acetate, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (71 mg).

[1352] Reference Example 85 4-{(E)-2-[5-(methoxycarbonyl)-2-(trifluoromethyl)phenyl]vinyl}piperidine-1-carboxylic acid Tert-butyl ester

[1353] [Step 1] Preparation of tert-butyl 4-[(E)-2-(tributylstannyl)vinyl]piperidine-1-carboxylate Tributyltin hydride (334 mg) was added to tert-butyl 4-ethynylpiperidine-1-carboxylate (200 mg), PdCl2(PPh3)2 (34 mg) and THF (4.8 mL), and after degassing, the mixture was stirred at room temperature for 2 hours under an argon atmosphere. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (440 mg).

[1354] [Step 2] Preparation of tert-butyl 4-{(E)-2-[5-(methoxycarbonyl)-2-(trifluoromethyl)phenyl]vinyl}piperidine-1-carboxylate

[1355] Toluene (4.8 mL) was added to tert-butyl 4-[(E)-2-(tributylstannyl)vinyl]piperidine-1-carboxylate (383 mg) obtained in step 1, methyl 3-bromo-4-(trifluoromethyl)benzoate (325 mg), lithium chloride (81 mg) and Pd(PPh3)4 (55 mg), and the mixture was degassed and stirred overnight at 110° C. under an argon atmosphere. The reaction solution was cooled and purified by silica gel column chromatography to obtain the title compound (150 mg).

[1356] Reference Example 90 4-Bromo-3-({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}amino)benzoic acid

[1357] [Step 1] Preparation of ethyl 4-bromo-3-({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}amino)benzoate

[1358] The title compound (127 mg) was obtained by following the method of Reference Example 59, using 4-bromo-3-iodobenzoic acid ethyl ester (200 mg) instead of 3-iodo-4-(trifluoromethyl)benzoic acid ethyl ester and [(1r,4r)-4-aminocyclohexyl]carbamic acid tert-butyl ester instead of (4-aminobutyl)carbamic acid tert-butyl ester. MS (m / z): 441.2 [M+H] + .

[1359] [Step 2] Production of 4-bromo-3-({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}amino)benzoic acid

[1360] To a solution of ethyl 4-bromo-3-({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}amino)benzoate (127 mg) obtained in step 1 in ethanol (2 mL), 2M aqueous sodium hydroxide solution (0.43 mL) was added, and the mixture was stirred at 70°C for 1 hour. The solvent was distilled off under reduced pressure, and after dilution with water, 1M hydrochloric acid was added for neutralization. The precipitate was filtered to obtain the title compound (52 mg). MS (m / z): 413.2 [M+H] + .

[1361] Reference Example 91 3-({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}amino)-5-fluoro-4-(trifluoromethyl)- methyl benzoate DMSO (3 mL) was added to methyl 3,5-difluoro-4-(trifluoromethyl)benzoate (160 mg), tert-butyl [(1r,4r)-4-aminocyclohexyl]carbamate (286 mg) and potassium carbonate (276 mg), and the mixture was stirred at 110°C for 2 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with water and saturated brine, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title compound (100 mg). MS (m / z): 435.3 [M+H] + .

[1362] Reference Example 126 2-[({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl)amino][1,1'-bicyclo[1,1'- Benzene]-4-carboxylic acid ethyl ester

[1363] The title compound (47 mg) was obtained by the method of Reference Example 74, using 4-bromo-3-[({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl)amino]benzoic acid ethyl ester (52 mg) obtained in Reference Example 123 instead of 4-chloro-3-iodobenzoic acid ethyl ester, and using phenylboronic acid instead of (3-{[(tert-butoxycarbonyl)amino]methyl}phenyl)boronic acid. MS (m / z): 453.4 [M+H] + .

[1364] Reference Example 130 3-({(1S)-1-[1-(tert-butoxycarbonyl)piperidin-4-yl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)- (fluoromethyl)benzoic acid

[1365] [Step 1] Preparation of tert-butyl 4-{(1S)-1-[5-bromo-3-fluoro-2-(trifluoromethyl)anilino]ethyl}piperidine-1-carboxylate

[1366] NMP (13 mL) was added to 5-bromo-1,3-difluoro-2-(trifluoromethyl)benzene (4.8 g), tert-butyl 4-[(1S)-1-aminoethyl]piperidine-1-carboxylate (3.0 g), and sodium bicarbonate (3.3 g), and stirred at 120°C for 5 hours. The reaction solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated brine, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (3.3 g).

[1367] [Step 2] Preparation of tert-butyl 4-{(1S)-1-[5-cyano-3-fluoro-2-(trifluoromethyl)anilino]ethyl}piperidine-1-carboxylate A mixture of tert-butyl 4-{(1S)-1-[5-bromo-3-fluoro-2-(trifluoromethyl)anilino]ethyl}piperidine-1-carboxylate (2.4 g), zinc cyanide (601 mg) and Pd(PPh3)4 (591 mg) in DMF (15 mL) obtained in Step 1 was degassed and stirred at 120°C for 2 hours under an argon atmosphere. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with saturated brine. The solvent was distilled off under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (2.0 g).

[1368] [Step 3] Production of 3-({(1S)-1-[1-(tert-butoxycarbonyl)piperidin-4-yl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)benzoic acid

[1369] To the ethanol (25 mL) solution of tert-butyl 4-{(1S)-1-[5-cyano-3-fluoro-2-(trifluoromethyl)anilino]ethyl}piperidine-1-carboxylate (2.0 g) obtained in step 2, 5.8 M aqueous sodium hydroxide solution (25 mL) was added, and the mixture was stirred at 70°C for 2 hours. The reaction solution was neutralized with hydrochloric acid under ice cooling and extracted with ethyl acetate. The organic layer was washed with saturated brine and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain the title compound (2.0 g).

[1370] Reference Example 137 tert-4-{(1S)-1-[2-methoxy-5-(methoxycarbonyl)anilino]ethyl}piperidine-1-carboxylic acid Butyl Ester

[1371] [Step 1] Preparation of methyl 4-methoxy-3-[(trifluoromethanesulfonyl)oxy]benzoate

[1372] The title compound (850 mg) was obtained by following the method of Reference Example 32, except that methyl 3-hydroxy-4-methoxybenzoate (515 mg) was used instead of tert-butyl [(1r,4r)-4-(hydroxymethyl)cyclohexyl]carbamate.

[1373] [Step 2] Preparation of tert-butyl 4-{(1S)-1-[2-methoxy-5-(methoxycarbonyl)anilino]ethyl}piperidine-1-carboxylate The title compound (41 mg) was obtained by the method of Reference Example 59, using methyl 4-methoxy-3-[(trifluoromethanesulfonyl)oxy]benzoate (100 mg) obtained in Step 1 of Reference Example 137 instead of ethyl 3-iodo-4-(trifluoromethyl)benzoate, and tert-butyl 4-[(1S)-1-aminoethyl]piperidine-1-carboxylate instead of tert-butyl (4-aminobutyl)carbamate. MS (m / z): 449.7 [M+H] + .

[1374] Reference Example 1424-{(1S)-1-[2,3-dichloro-6-fluoro-5-(methoxycarbonyl)anilino]ethyl}piperidin-1-yl Tert-butyl ester

[1375] [Step 1] Preparation of 4,5-dichloro-2-fluoro-3-iodobenzoic acid

[1376] 4,5-Dichloro-2-fluorobenzoic acid (500 mg) was dissolved in concentrated sulfuric acid (4 mL), N-iodosuccinimide (600 mg) was added under ice cooling, and the mixture was stirred at room temperature for 6 hours. The reaction solution was added to ice water, and the precipitate was filtered to obtain the title compound (750 mg).

[1377] [Step 2] Preparation of methyl 4,5-dichloro-2-fluoro-3-iodobenzoate

[1378] The title compound (734 mg) was obtained by the method of Step 2 of Reference Example 78, except that 4,5-dichloro-2-fluoro-3-iodobenzoic acid (750 mg) obtained in Step 1 was used instead of 4'-hydroxy-6-(trifluoromethyl)[1,1'-biphenyl]-3-carboxylic acid.

[1379] [Step 3] Preparation of tert-butyl 4-{(1S)-1-[2,3-dichloro-6-fluoro-5-(methoxycarbonyl)anilino]ethyl}piperidine-1-carboxylate

[1380] The title compound (23 mg) was obtained by the method of Reference Example 59 using methyl 4,5-dichloro-2-fluoro-3-iodobenzoate (50 mg) obtained in Step 2 of Reference Example 142 and tert-butyl 4-[(1S)-1-aminoethyl]piperidine-1-carboxylate. MS (m / z): 449.7 [M+H] + .

[1381] Reference Example 147 4-{(1S)-1-[3-amino-2-chloro-5-(methoxycarbonyl)anilino]ethyl}piperidine-1-carboxylic acid Tert-butyl ester

[1382] The title compound (16 mg) was obtained by following the method of Step 5 of Reference Example 2, using tert-butyl 4-{(1S)-1-[2-chloro-5-(methoxycarbonyl)-3-nitroanilino]ethyl}piperidine-1-carboxylate (30 mg) obtained in Reference Example 146 instead of benzyl 4-(2,2,3,3,10,10-hexamethyl-8-oxo-4,9-dioxa-7-aza-3-silaundec-5-yl)piperidine-1-carboxylate.

[1383] Reference Example 158 4-[(1S)-1-{3-chloro-5-(methoxycarbonyl)-2-[(propan-2-yl)oxy]anilino}ethyl tert-Butyl]piperidine-1-carboxylate

[1384] [Step 1] Preparation of methyl 3-chloro-4-hydroxy-5-iodobenzoate

[1385] Methyl 3-chloro-4-hydroxybenzoate (2.0 g) was dissolved in dichloromethane (50 mL), and N-iodosuccinimide (2.5 g) and titanium (IV) chloride (1.85 g) were added, and stirred at room temperature for 24 hours. The reaction solution was diluted with a saturated sodium bicarbonate aqueous solution and extracted with dichloromethane. After drying the organic layer with anhydrous magnesium sulfate, the solvent was removed by vacuum distillation. The residue was purified by silica gel column chromatography to obtain the title compound (1.65 g).

[1386] [Step 2] Preparation of methyl 3-chloro-5-iodo-4-[(propan-2-yl)oxy]benzoate 2-bromopropane (276 mg) was added to a solution of methyl 3-chloro-4-hydroxy-5-iodobenzoate (350 mg), potassium carbonate (310 mg) and DMF (3 mL) obtained in step 1, and the mixture was stirred at 100° C. for 9 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with water and saturated brine. After the solvent was distilled off under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (157 mg).

[1387] [Step 3] Preparation of tert-butyl 4-[(1S)-1-{3-chloro-5-(methoxycarbonyl)-2-[(propan-2-yl)oxy]anilino}ethyl]piperidine-1-carboxylate

[1388] The title compound (95 mg) was obtained by following the method of Reference Example 59, using methyl 3-chloro-5-iodo-4-[(propan-2-yl)oxy]benzoate (156 mg) obtained in Step 2 instead of ethyl 3-iodo-4-(trifluoromethyl)benzoate, and tert-butyl 4-[(1S)-1-aminoethyl]piperidine-1-carboxylate instead of tert-butyl (4-aminobutyl)carbamate.

[1389] Reference Example 165 4-{(1S)-1-[2-chloro-3-cyano-5-(methoxycarbonyl)anilino]ethyl}piperidine-1-carboxylic acid Tert-butyl ester

[1390] The title compound (20 mg) was obtained by following the method of Step 2 of Reference Example 130, using tert-butyl 4-{(1S)-1-[3-bromo-2-chloro-5-(methoxycarbonyl)anilino]ethyl}piperidine-1-carboxylate (160 mg) obtained in Reference Example 152 instead of tert-butyl 4-{(1S)-1-[5-bromo-3-fluoro-2-(trifluoromethyl)anilino]ethyl}piperidine-1-carboxylate.

[1391] Reference Example 176 4-bromo-1-{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}-1H-indazole-6-carboxylic acid methyl ester The title compound (122 mg) was obtained by the method of Step 3 of Reference Example 78, except that methyl 4-bromo-1H-indazole-6-carboxylate (150 mg) was used instead of methyl 4'-hydroxy-6-(trifluoromethyl)[1,1'-biphenyl]-3-carboxylate.

[1392] Reference Example 1814-{[5-(ethoxycarbonyl)-3-fluoro-2-(trifluoromethyl)anilino]methyl}-4-fluoropiperidin-1- Tert-Butyl Formate

[1393] [Step 1] Preparation of ethyl 3,5-difluoro-4-(trifluoromethyl)benzoate

[1394] DMF (0.1 mL) was added to a solution of 3,5-difluoro-4-(trifluoromethyl)benzoic acid (2.0 g) in dichloromethane (40 mL). Oxalyl chloride (1.12 mL) was added dropwise under ice cooling and stirred for 1 hour. Ethanol (20 mL) was then added dropwise and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography to obtain the title compound (1.95 g).

[1395] [Step 2] Preparation of tert-butyl 4-{[5-(ethoxycarbonyl)-3-fluoro-2-(trifluoromethyl)anilino]methyl}-4-fluoropiperidine-1-carboxylate

[1396] The title compound (73 mg) was obtained according to the method of Reference Example 91 using ethyl 3,5-difluoro-4-(trifluoromethyl)benzoate (150 mg) obtained in Step 1 of Reference Example 181 and tert-butyl 4-(aminomethyl)-4-fluoropiperidine-1-carboxylate.

[1397] Reference Example 182 3-[({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl)(methyl)amino]- Methyl 4-(trifluoromethyl)benzoate

[1398] [Step 1] Preparation of methyl 3-[({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl)amino]-4-(trifluoromethyl)benzoate

[1399] The title compound (56 mg) was obtained by the method of Reference Example 59 using methyl 3-bromo-4-(trifluoromethyl)benzoate (65 mg) and tert-butyl [(1r,4r)-4-(aminomethyl)cyclohexyl]carbamate. MS (m / z): 431.7 [M+H] + .

[1400] [Step 2] Preparation of methyl 3-[({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl)(methyl)amino]-4-(trifluoromethyl)benzoate A mixture of methyl 3-[({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl)amino]-4-(trifluoromethyl)benzoate (56 mg), formaldehyde (37% aqueous solution, 0.63 mL), acetic acid (0.5 mL) and acetonitrile (3 mL) was stirred at room temperature for 15 minutes. Then, sodium cyanoborohydride (522 mg) was added and stirred overnight at the same temperature. Saturated aqueous sodium bicarbonate solution was added to the reaction solution, and extraction was performed with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (22 mg). MS (m / z): 445.7 [M+H] + .

[1401] Reference Example 184 3-[({(1r,4r)-4-[(tert-butoxycarbonyl)(methyl)amino]cyclohexyl}methyl)(methyl) [amino]-4-(trifluoromethyl)benzoic acid methyl ester

[1402] The title compound (82 mg) was obtained by following the method of Step 2 of Reference Example 13, except that methyl 3-[({(1r,4r)-4-[(tert-butoxycarbonyl)(methyl)amino]cyclohexyl}methyl)amino]-4-(trifluoromethyl)benzoate (70 mg) obtained in Reference Example 183 was used instead of tert-butyl {(1r,4r)-4-[(dibenzylamino)methyl]cyclohexyl}carbamate. MS (m / z): 459.7 [M+H] + .

[1403] Reference Example 207 (1R, 5S, 8r)-8-{(1S)-1-[5-(methoxycarbonyl)-2-(trifluoromethyl)anilino]ethyl tert-Butyl}-3-azabicyclo[3.2.1]octane-3-carboxylate

[1404] [Step 1] Preparation of methyl 3-({(1S)-1-[(1R,5S,8r)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethyl}amino)-4-(trifluoromethyl)benzoate

[1405] The title compound (54 mg) was obtained by the method of Reference Example 59 using methyl 3-iodo-4-(trifluoromethyl)benzoate (110 mg) and (1S)-1-[(1R,5S,8r)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethan-1-amine obtained in Reference Example 29. MS (m / z): 447.7 [M+H] + .

[1406] [Step 2] Preparation of tert-butyl (1R, 5S, 8r)-8-{(1S)-1-[5-(methoxycarbonyl)-2-(trifluoromethyl)anilino]ethyl}-3-azabicyclo[3.2.1]octane-3-carboxylate The title compound (734 mg) was obtained by following the method of Step 1 of Reference Example 51, except that methyl 3-({(1S)-1-[(1R, 5S, 8r)-3-benzyl-3-azabicyclo[3.2.1]octan-8-yl]ethyl}amino)-4-(trifluoromethyl)benzoate (750 mg) obtained in Step 1 was used instead of [(3S, 4R)-1-benzyl-3-fluoropiperidin-4-yl]methanol. MS (m / z): 357.2 [M+H] + .

[1407] Reference Example 2113-({(1S)-1-[1-(tert-butoxycarbonyl)-4-fluoropiperidin-4-yl]ethyl}amino)-5-fluoro- 4-(Trifluoromethyl)benzoic acid

[1408] [Step 1] Preparation of 3-bromo-5-fluoro-4-(trifluoromethyl)benzonitrile

[1409] In a mixture of 3-amino-5-fluoro-4-(trifluoromethyl)benzonitrile (480 mg), copper (II) bromide (630 mg), and acetonitrile (10 mL), isoamyl nitrite (0.41 mL) was added at room temperature and stirred at 60°C for 8 hours. Hydrochloric acid was added to the reaction solution and extracted with ethyl acetate. After washing the organic layer with saturated brine, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (580 mg).

[1410] [Step 2] Preparation of tert-butyl 4-{(1S)-1-[5-cyano-3-fluoro-2-(trifluoromethyl)anilino]ethyl}-4-fluoropiperidine-1-carboxylate

[1411] The title compound (135 mg) was obtained by the method of Reference Example 59 using 3-bromo-5-fluoro-4-(trifluoromethyl)benzonitrile (117 mg) obtained in Step 1 of Reference Example 211 and tert-butyl 4-[(1S)-1-aminoethyl]-4-fluoropiperidine-1-carboxylate obtained in Reference Example 12.

[1412] [Step 3] Preparation of 3-({(1S)-1-[1-(tert-butoxycarbonyl)-4-fluoropiperidin-4-yl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)benzoic acid The title compound (140 mg) was obtained by following the method of Step 3 of Reference Example 73, using 4-{(1S)-1-[5-cyano-3-fluoro-2-(trifluoromethyl)anilino]ethyl}piperidine-1-carboxylic acid tert-butyl ester (133 mg) obtained in Step 2 instead of tert-butyl 4-{(1S)-1-[5-cyano-3-fluoro-2-(trifluoromethyl)anilino]ethyl}piperidine-1-carboxylate.

[1413] Reference Example 2133-(2-{(2r,5r)-5-[(tert-butoxycarbonyl)amino]-1,3-dioxane-2-yl}cyclopropane 4-(Trifluoromethyl)benzoic acid methyl ester

[1414] [Step 1] Preparation of methyl 3-[(1E)-3-hydroxyprop-1-en-1-yl]-4-(trifluoromethyl)benzoate To a solution of methyl 3-[(1E)-3-oxoprop-1-en-1-yl]-4-(trifluoromethyl)benzoate (500 mg) in ethanol (9.7 mL) obtained in step 1 of reference example 84, sodium borohydride (73 mg) was added and stirred at room temperature for 30 minutes. The reaction solution was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. After the organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (600 mg).

[1415] [Step 2] Preparation of 3-[2-(hydroxymethyl)cyclopropyl]-4-(trifluoromethyl)benzoic acid methyl ester In a dichloromethane (5.8mL) solution of diethylzinc (1M hexane solution, 5.8mL), a dichloromethane (5.8mL) solution of TFA (0.44mL) was added dropwise under ice cooling, and then diiodomethane (1.54g) was added and stirred at the same temperature for 30 minutes. 3-[(1E)-3-hydroxyprop-1-ene-1-yl]-4-(trifluoromethyl)benzoic acid methyl ester (300mg) obtained in step 1 of reference example 213 was added to the reaction solution and stirred overnight at room temperature. Water was added to the reaction solution, and the reaction solution was filtered through Celite (registered trademark). The filtrate was extracted with ethyl acetate, and the organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (160mg).

[1416] [Step 3] Preparation of methyl 3-(2-formylcyclopropyl)-4-(trifluoromethyl)benzoate To a solution of methyl 3-[2-(hydroxymethyl)cyclopropyl]-4-(trifluoromethyl)benzoate (160 mg) in dichloromethane (5 mL) obtained in step 2 of reference example 213, 1,1,1-triacetoxy-1,1-dihydro-1,2-benzoiodooxolan-3-(1H)-one (Dess-Martin reagent) (495 mg) was added and stirred at room temperature. After confirming the disappearance of the raw material by TLC, the reaction solution was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. After drying the organic layer over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (159 mg).

[1417] [Step 4] Production of methyl 3-{2-[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1,3-dioxan-2-yl]cyclopropyl}-4-(trifluoromethyl)benzoate

[1418] The title compound (235 mg) was obtained by following the method of Step 2 of Reference Example 84, using methyl 3-(2-formylcyclopropyl)-4-(trifluoromethyl)benzoate (159 mg) obtained in Step 3 instead of methyl 3-[(1E)-3-oxoprop-1-en-1-yl]-4-(trifluoromethyl)benzoate.

[1419] [Step 5] Production of methyl 3-(2-{5-[(tert-butoxycarbonyl)amino]-1,3-dioxan-2-yl}cyclopropyl}-4-(trifluoromethyl)benzoate

[1420] To a solution of methyl 3-{2-[5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1,3-dioxane-2-yl]cyclopropyl}-4-(trifluoromethyl)benzoate (215 mg) obtained in step 4 in 2-propanol (1.92 mL) and water (0.32 mL), sodium borohydride (34 mg) was added, and the mixture was stirred for 2 hours under ice cooling. Acetic acid (2.26 mL) was added to the reaction solution, and the mixture was stirred at 60°C for 30 minutes. The reaction solution was concentrated under reduced pressure, and THF (2.3 mL), sodium bicarbonate (190 mg), and Boc2O (296 mg) were added to the obtained residue, and the mixture was stirred at room temperature. After confirming the disappearance of the raw material by TLC, the reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography to obtain the title compound (14 mg).

[1421] Reference Example 215 4-{(1R)-2,2-difluoro-1-[3-fluoro-5-(methoxycarbonyl)-2-(trifluoromethyl)anilino] tert-Butyl}-4-fluoropiperidin-1-carboxylate

[1422] [Step 1] Preparation of methyl 3-bromo-5-fluoro-4-(trifluoromethyl)benzoate

[1423] The title compound (500 mg) was obtained by the method of Step 1 of Reference Example 211, using methyl 3-amino-5-fluoro-4-(trifluoromethyl)benzoate (1.12 g) instead of 3-amino-5-fluoro-4-(trifluoromethyl)benzonitrile.

[1424] [Step 2] Preparation of tert-butyl 4-{(1R)-2,2-difluoro-1-[3-fluoro-5-(methoxycarbonyl)-2-(trifluoromethyl)anilino]ethyl}-4-fluoropiperidine-1-carboxylate

[1425] The title compound (171 mg) was obtained by the method of Reference Example 59 using methyl 3-bromo-5-fluoro-4-(trifluoromethyl)benzoate obtained in Step 1 of Reference Example 215 and tert-butyl 4-[(1R)-1-amino-2,2-difluoroethyl]-4-fluoropiperidine-1-carboxylate (125 mg) obtained in Reference Example 18.

[1426] Reference Example 228 3-[({(1S,3R)-3-[acetyl(tert-butoxycarbonyl)amino]-2,2-dimethylcyclobutyl} [methyl]amino]-4-(trifluoromethyl)benzoic acid methyl ester

[1427] [Step 1] Preparation of methyl 3-({[(1S,3R)-3-acetylamino-2,2-dimethylcyclobutyl]methyl}amino)-4-(trifluoromethyl)benzoate

[1428] The title compound (298 mg) was obtained by the method of Reference Example 59 using methyl 3-bromo-5-fluoro-4-(trifluoromethyl)benzoate (399 mg) and N-[(1R,3S)-3-(aminomethyl)-2,2-dimethylcyclobutyl]acetamide obtained in Reference Example 35. MS (m / z): 373.2 [M+H] + .

[1429] [Step 2] Preparation of methyl 3-[({(1S,3R)-3-[acetyl(tert-butoxycarbonyl)amino]-2,2-dimethylcyclobutyl}methyl)amino]-4-(trifluoromethyl)benzoate

[1430] The title compound (200 mg) was obtained by following the method of Step 1 of Reference Example 1, except that methyl 3-({[(1S,3R)-3-acetylamino-2,2-dimethylcyclobutyl]methyl}amino)-4-(trifluoromethyl)benzoate (298 mg) obtained in Step 1 was used instead of 2-methyl-2-(pyridin-4-yl)propan-1-amine.

[1431] Reference Example 2443-{[(1S)-1-{(1s,3R)-3-[(tert-butoxycarbonyl)(methyl)amino]cyclobutyl}ethyl] Amino}-4-(trifluoromethyl)benzoic acid methyl ester

[1432] [Step 1] Preparation of methyl 3-{[(1S)-1-{(1s,3R)-3-[(2-nitrobenzene-1-sulfonyl)amino]cyclobutyl}ethyl]amino}-4-(trifluoromethyl)benzoate To methyl 3-{[(1S)-1-{(1s,3R)-3-[(tert-butoxycarbonyl)amino]cyclobutyl}ethyl]amino}-4-(trifluoromethyl)benzoate (100 mg) obtained in Reference Example 197 was added hydrogen chloride (2M methanol solution, 2 mL), and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and THF (2 mL), sodium bicarbonate (61 mg) and 2-nitrobenzenesulfonyl chloride (80 mg) were added to the resulting residue, and the mixture was stirred at room temperature for 1 hour. The reaction solution was diluted with water and extracted with ethyl acetate. After the organic layer was dried over anhydrous sodium sulfate, the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography to give the title compound (98 mg).

[1433] [Step 2] Preparation of methyl 3-{[(1S)-1-{(1s,3R)-3-[methyl(2-nitrobenzene-1-sulfonyl)amino]cyclobutyl}ethyl]amino}-4-(trifluoromethyl)benzoate

[1434] To a solution of 3-{[(1S)-1-{(1s,3R)-3-[(2-nitrobenzene-1-sulfonyl)amino]cyclobutyl}ethyl]amino}-4-(trifluoromethyl)benzoic acid methyl ester (30 mg) obtained in step 1 of reference example 244 in DMF (0.3 mL), iodomethane (13 mg) and cesium carbonate (97 mg) were added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with water and saturated brine. After the solvent was distilled off under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (31 mg).

[1435] [Step 3] Preparation of methyl 3-{[(1S)-1-{(1s,3R)-3-[(tert-butoxycarbonyl)(methyl)amino]cyclobutyl}ethyl]amino}-4-(trifluoromethyl)benzoate

[1436] To the DMF (0.12 mL) solution of methyl 3-{[(1S)-1-{(1s,3R)-3-[methyl(2-nitrobenzene-1-sulfonyl)amino]cyclobutyl}ethyl]amino}-4-(trifluoromethyl)benzoate (31 mg) obtained in step 2, 4-mercaptobenzoic acid (19 mg) and potassium carbonate (33 mg) were added, and the mixture was stirred at 90°C. After confirming the disappearance of the raw material by TLC, the reaction solution was diluted with water, Boc2O (66 mg) was added, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added to the reaction solution, the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (15 mg).

[1437] Reference Example 249 3-{[(1S)-1-{(1r,4S)-4-[(2,2,2-trifluoroethyl)amino]cyclohexyl}ethyl]amino 4-(Trifluoromethyl)benzoic acid methyl ester

[1438] To a methanol (2 mL) solution of methyl 3-{[(1S)-1-{(1r,4S)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl]amino}-4-(trifluoromethyl)benzoate (200 mg) obtained in Reference Example 161, hydrogen chloride (4M 1,4-dioxane solution, 2 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and THF (3 mL), TEA (0.36 mL) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (274 mg) were added to the obtained residue, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography to obtain the title compound (160 mg).

[1439] Reference Example 2533-{[(1S)-1-{(1r,4S)-4-[(tert-butoxycarbonyl)(2-hydroxyethyl)amino]cyclohexane 4-(trifluoromethyl)benzoic acid methyl ester

[1440] To a methanol (1 mL) solution of methyl 3-{[(1S)-1-{(1r,4S)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}ethyl]amino}-4-(trifluoromethyl)benzoate (100 mg) obtained in Reference Example 161, hydrogen chloride (4M 1,4-dioxane solution, 1 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and THF (2 mL), TEA (0.16 mL) and 2-iodoethanol (39 mg) were added to the obtained residue, and the mixture was stirred at 60°C for 30 hours. Next, Boc2O (491 mg) was added to the reaction solution, and the mixture was stirred at the same temperature for 12 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography to obtain the title compound (70 mg).

[1441] Reference Example 2553-{[(1S)-1-{(1s,3R)-3-[(tert-butoxycarbonyl)(methyl)amino]cyclobutyl}ethyl] Amino}-5-fluoro-4-(trifluoromethyl)benzoic acid

[1442] [Step 1] Preparation of N-[(1R,3s)-3-{(1S)-1-[5-bromo-3-fluoro-2-(trifluoromethyl)anilino]ethyl}cyclobutyl]-2-nitrobenzene-1-sulfonamide

[1443] The title compound (1.08 g) was obtained by following the method of Step 1 of Reference Example 244, using tert-butyl [(1R,3s)-3-{(1S)-1-[5-bromo-3-fluoro-2-(trifluoromethyl)anilino]ethyl}cyclobutyl]carbamate (767 mg) obtained in Reference Example 217 instead of methyl 3-{[(1S)-1-{(1s,3R)-3-[(tert-butoxycarbonyl)amino]cyclobutyl}ethyl]amino}-4-(trifluoromethyl)benzoate.

[1444] [Step 2] Preparation of tert-butyl [(1R,3s)-3-{(1S)-1-[5-bromo-3-fluoro-2-(trifluoromethyl)anilino]ethyl}cyclobutyl]methylcarbamate

[1445] To a DMF (11 mL) solution of N-[(1R,3s)-3-{(1S)-1-[5-bromo-3-fluoro-2-(trifluoromethyl)anilino]ethyl}cyclobutyl]-2-nitrobenzene-1-sulfonamide (600 mg) obtained in step 1, iodomethane (236 mg) and potassium carbonate (921 mg) were added, and the mixture was stirred at room temperature. After confirming the disappearance of the raw material by TLC, 4-mercaptobenzoic acid (428 mg) was added to the reaction solution, and the mixture was stirred at 80°C. After confirming the disappearance of the raw material by TLC, the reaction solution was diluted with water, and Boc2O (1.21 g) was added, and the mixture was stirred at room temperature. After confirming the disappearance of the raw material by TLC, ethyl acetate was added to the reaction solution, and the organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title compound (396 mg).

[1446] [Step 3] Preparation of tert-butyl [(1R,3s)-3-{(1S)-1-[5-cyano-3-fluoro-2-(trifluoromethyl)anilino]ethyl}cyclobutyl]methylcarbamate

[1447] The title compound (352 mg) was obtained by following the method of Step 2 of Reference Example 130, except that tert-butyl [(1R,3s)-3-{(1S)-1-[5-bromo-3-fluoro-2-(trifluoromethyl)anilino]ethyl}piperidine-1-carboxylate (396 mg) was used instead of tert-butyl 4-{(1S)-1-[5-bromo-3-fluoro-2-(trifluoromethyl)anilino]ethyl}cyclobutyl]methylcarbamate obtained in Step 2.

[1448] [Step 4] Production of 3-{[(1S)-1-{(1s,3R)-3-[(tert-butoxycarbonyl)(methyl)amino]cyclobutyl}ethyl]amino}-5-fluoro-4-(trifluoromethyl)benzoic acid

[1449] The title compound was obtained by following the method of Step 3 of Reference Example 130, except that tert-butyl 4-{(1S)-1-[5-cyano-3-fluoro-2-(trifluoromethyl)anilino]ethyl}piperidine-1-carboxylate was replaced with tert-butyl [(1R,3s)-3-{(1S)-1-[5-cyano-3-fluoro-2-(trifluoromethyl)anilino]ethyl}cyclobutyl]methylcarbamate (352 mg) obtained in Step 3. MS (m / z): 435.6 [M+H] + .

[1450] Reference Example 257 tert-Butyl 4-[{[2-chloro-5-(methoxycarbonyl)phenyl]methyl}(methyl)amino]piperidine-1-carboxylate ester

[1451] Methyl 3-(bromomethyl)-4-chlorobenzoate (400 mg) was dissolved in 2-propanol (7 mL), tert-butyl 4-(methylamino)piperidine-1-carboxylate (423 mg) and DIPEA (0.39 mL) were added, and stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the title compound (447 mg).

[1452] Reference Example 2644-{(1S)-1-[2-(difluoromethoxy)-3-fluoro-5-(methoxycarbonyl)anilino]ethyl}piperidin Tert-Butylpyridine-1-carboxylate

[1453] [Step 1] Preparation of methyl 3-bromo-4-(difluoromethoxy)-5-fluorobenzoate

[1454] To a solution of methyl 3-bromo-5-fluoro-4-hydroxybenzoate (500 mg) in DMF (4 mL), sodium chlorodifluoroacetate (612 mg) and potassium carbonate (416 mg) were added, and the mixture was stirred at 100° C. for 4 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with water and saturated brine. After the solvent was distilled off under reduced pressure, the residue was purified by silica gel column chromatography to obtain the title compound (500 mg).

[1455] [Step 2] Preparation of tert-butyl 4-{(1S)-1-[2-(difluoromethoxy)-3-fluoro-5-(methoxycarbonyl)anilino]ethyl}piperidine-1-carboxylate The title compound (200 mg) was obtained by the method of Reference Example 59 using methyl 3-bromo-4-(difluoromethoxy)-5-fluorobenzoate (200 mg) obtained in Step 1 of Reference Example 277 and tert-butyl 4-[(1S)-1-aminoethyl]piperidine-1-carboxylate.

[1456] Reference Example 280 3-[({(1r,4r)-4-[(tert-butoxycarbonyl)amino]cyclohexyl}methyl)sulfanyl]-4-(tri Methyl fluoromethylbenzoate A mixture of methyl 3-bromo-4-(trifluoromethyl)benzoate (58 mg), tert-butyl [(1r, 4r)-4-(sulfanylmethyl)cyclohexyl]carbamate (50 mg), Xantphos (5.9 mg), DIPEA (0.07 mL), Pd2(dba)3 (4.7 mg), and 1,4-dioxane (1.2 mL) was degassed and stirred at 90°C for 2 hours under an argon atmosphere. The reaction solution was filtered through Celite (registered tradem...

Claims

1. A 1,3,4-oxadiazolinone compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof, [Chemical formula 1] In the formula, X 1 is a carbon atom or a nitrogen atom, X 1 When it is a carbon atom, R 1 is a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, a monocyclic non-aromatic carbocyclic group having 3 to 8 carbon atoms, a dihaloalkyl group having 1 to 6 carbon atoms, a trihaloalkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a dihaloalkoxy group having 1 to 6 carbon atoms, a trihaloalkoxy group having 1 to 6 carbon atoms, an alkylsulfonyl group having 1 to 6 carbon atoms, a cyano group, an aromatic carbocyclic group selected from phenyl, or an aromatic heterocyclic group selected from pyridyl, X 1 When it is a nitrogen atom, R 1 does not exist, R 2 is a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, a monocyclic non-aromatic carbocyclic group having 3 to 8 carbon atoms, a trihaloalkyl group having 1 to 6 carbon atoms, a pentafluorosulfanyl group (SF5), a cyano group, an amino group, or a nitro group, R 1 , and R 2 Together with adjacent atoms, they can form an indazole ring. R 3 is a hydrogen atom, a halogen atom, or an alkyl group having 1 to 6 carbon atoms, X 4 is a carbon atom or a nitrogen atom, X 4 When it is a carbon atom, R 4 is a hydrogen atom, a halogen atom, or an alkyl group having 1 to 6 carbon atoms, X 4 When it is a nitrogen atom, R 4 does not exist, Where X 1 and X 4 These two are not nitrogen atoms. L is a linking bond, an alkylene group having 1 to 6 carbon atoms, an alkenylene group having 2 to 6 carbon atoms, an alkynylene group having 2 to 6 carbon atoms, or a group represented by L-1, L-2, L-3, or L-4 below, [Chemical formula 2] The left-side connecting bond of each group is connected to A of formula [1], and the right-side connecting bond is connected to ring B of formula [1]; R 11 , R 13 , and R 14 are hydrogen atoms or alkyl groups having 1 to 6 carbon atoms, R 12 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a monohalogenated alkyl group having 1 to 6 carbon atoms, a dihalogenated alkyl group having 1 to 6 carbon atoms, or a trihalogenated alkyl group having 1 to 6 carbon atoms, and Y is O, S, or -NR 15 -,in, R 15 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, m is 0, 1 or 2, L is L-2, and Y is -NR 15 -, R 1 and R 15 Together with the adjacent atoms, they are the following groups represented by z-1, z-2, and z-3, [Chemical formula 3] R 21 is a hydrogen atom, an oxo group (=O), or an alkoxyimino group (=NOR 23 ), R 23 is an alkyl group having 1 to 6 carbon atoms, n is 1 or 2, R 22 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, A means aminoalkylamino having 1 to 8 carbon atoms, a non-aromatic heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, azocanyl, 1,3-dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, and 2-azaspiro[3.3]heptyl, a non-aromatic carbocyclic group selected from cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[1.1.1]pentyl, cuban-1-yl, and spiro[3.3]heptyl, An aromatic carbocyclic group selected from phenyl, or an aromatic heterocyclic group selected from pyridyl, The non-aromatic heterocyclic group involved in A may be substituted by one or two groups selected from the following (1) to (7): (1) Amino group (-NH2), (2) an alkyl group having 1 to 6 carbon atoms, (3) an aminoalkyl group having 1 to 6 carbon atoms, (4) an alkyl group having 1 to 6 carbon atoms substituted with an amino group or a hydroxy group, (5) Halogen, (6) alkylcarbonyl, the alkyl portion of which is an alkyl group having 1 to 6 carbon atoms, (7) alkoxycarbonyl, the alkoxy moiety is an alkoxy group having 1 to 6 carbon atoms, The non-aromatic carbocyclic group involved in A may be substituted by 1 to 3 groups selected from the following (1) to (15): (1) Amino group, (2) an alkyl group having 1 to 6 carbon atoms, (3) an alkylamino group having 1 to 6 carbon atoms substituted by a non-aromatic carbocyclic group having 3 to 8 carbon atoms (4) trihaloalkylamino groups having 1 to 6 carbon atoms (5) a hydroxyalkyl group having 1 to 6 carbon atoms, (6) aminoalkyl groups having 1 to 6 carbon atoms, (7) Hydroxyl, (8) a monoalkylamino group having 1 to 6 carbon atoms, (9) a hydroxyalkylamino group having 1 to 6 carbon atoms, (10) alkoxycarbonyl, the alkoxy moiety is an alkoxy group having 1 to 6 carbon atoms, (11) Carboxyl, (12) Carbamoyl, (13) acetylamino (Me-C(=O)-NH-), (14) piperazinyl, and (15) an alkylamino group having 1 to 6 carbon atoms, The aromatic carbocyclic group related to A may be substituted by one group selected from the following (1) to (4): (1) an aminoalkyl group having 1 to 6 carbon atoms, (2) an aminoalkoxy group having 1 to 6 carbon atoms, (3) an alkoxy group having 1 to 6 carbon atoms substituted by a piperidinyl group, (4) an alkoxycarbonylaminoalkyl group, wherein the alkoxy moiety is an alkoxy group having 1 to 6 carbon atoms, and the alkyl moiety is an alkyl group having 1 to 6 carbon atoms, The aromatic heterocyclic group involved in A may be substituted by a piperazinyl group, A and L are selected from any of the following (a) to (h), (a) When L is a connecting key A is an aminoalkylamino group, a non-aromatic heterocyclic group, an aromatic carbocyclic group, or an aromatic heterocyclic group, (b) When L is an alkylene group A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group, (c) When L is alkenylene A is a non-aromatic heterocyclic group, (d) When L is an alkynylene group A is a non-aromatic heterocyclic group, (e) When L is L-1 A is a non-aromatic heterocyclic group, a non-aromatic carbocyclic group, or an aromatic carbocyclic group, (f) When L is L-2 A is a non-aromatic heterocyclic group or a non-aromatic carbocyclic group, (g) When L is L-3 A is a non-aromatic heterocyclic group, (h) When L is L-4 A is a non-aromatic heterocyclic group, Among them, the compound represented by the following formula is not included, 2. The 1,3,4-oxadiazolinone compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: X 1 is a carbon atom, X 4 For carbon atoms.

3. The 1,3,4-oxadiazolinone compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: L is a linking bond, an alkylene group having 1 to 6 carbon atoms, an alkenylene group having 2 to 6 carbon atoms, an alkynylene group having 2 to 6 carbon atoms, L-1, or L-2.

4. The 1,3,4-oxadiazolinone compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: A is an aminoalkylamino group having 1 to 8 carbon atoms, a non-aromatic heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, azocanyl, 1,3-dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, and 2-azaspiro[3.3]heptyl, a non-aromatic carbocyclic group selected from cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[1.1.1]pentyl, cuban-1-yl, and spiro[3.3]heptyl, An aromatic carbocyclic group selected from phenyl, or An aromatic heterocyclic group selected from pyridyl.

5. The 1,3,4-oxadiazolinone compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: L is a linking bond, L-1, or L-2.

6. The 1,3,4-oxadiazolinone compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: A and L are any of the following groups (aa), (ee), (ff), (aa) When L is a linking bond, A is an aminoalkylamino group having 1 to 8 carbon atoms, a non-aromatic heterocyclic group selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, azocanyl, 1,3-dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, and 2-azaspiro[3.3]heptyl, An aromatic carbocyclic group selected from phenyl, or an aromatic heterocyclic group selected from pyridyl, (ee) when L is L-1, A is a non-aromatic heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, azocanyl, 1,3-dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, and 2-azaspiro[3.3]heptyl, or a non-aromatic carbocyclic group selected from cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[1.1.1]pentyl, cuban-1-yl, and spiro[3.3]heptyl, or (ff) when L is L-2, A is a non-aromatic heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, azocanyl, 1,3-dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, and 2-azaspiro[3.3]heptyl, or A non-aromatic carbocyclic group selected from cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[1.1.1]pentyl, cuban-1-yl, and spiro[3.3]heptyl.

7. The 1,3,4-oxadiazolinone compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: L is L-2, A is a non-aromatic heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, azocanyl, 1,3-dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, and 2-azaspiro[3.3]heptyl, or A non-aromatic carbocyclic group selected from cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[1.1.1]pentyl, cuban-1-yl, and spiro[3.3]heptyl.

8. The 1,3,4-oxadiazolinone compound or its pharmaceutically acceptable salt or solvate thereof according to claim 7, wherein: L is L-2, m is 0, and Y is -NR 15 -, A is a non-aromatic heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, azocanyl, 1,3-dioxanyl, tetrahydrofuranyl, tetrahydropyranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, and 2-azaspiro[3.3]heptyl, or A non-aromatic carbocyclic group selected from cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[1.1.1]pentyl, cuban-1-yl, and spiro[3.3]heptyl.

9. The 1,3,4-oxadiazolinone compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: The non-aromatic heterocyclic group involved in A is piperidinyl, piperazinyl, pyrrolidinyl, azepanyl, azacyclooctanyl, 1,3-dioxanyl, tetrahydrofuranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonan-7-yl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, or 2-azaspiro[3.3]heptan-6-yl, The non-aromatic carbocyclic group of A is cyclohexyl, cyclopentyl, cyclobutenyl, bicyclo[2.2.1]heptyl, bicyclo[1.1.1]pentyl, or cuban-1-yl, The aromatic carbocyclic group of A is phenyl, The aromatic heterocyclic group referred to as A is pyridyl.

10. The 1,3,4-oxadiazolinone compound or a pharmaceutically acceptable salt thereof, or a solvate thereof according to claim 9, wherein: X 1 is a carbon atom, R 1 is a halogen atom, a dihaloalkyl group having 1 to 6 carbon atoms, a trihaloalkyl group having 1 to 6 carbon atoms, a dihaloalkoxy group having 1 to 6 carbon atoms, or a trihaloalkoxy group having 1 to 6 carbon atoms, R 2 is a halogen atom or a trihaloalkyl group having 1 to 6 carbon atoms, R 3 is a hydrogen atom, X 4 is a carbon atom, R 4 is a hydrogen atom, L is L-2, m is 0, Y is NR 15 , R 15 is a hydrogen atom, R 12 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, A is piperidinyl, piperazinyl, pyrrolidinyl, azepanyl, azacyclooctanyl, 1,3-dioxanyl, tetrahydrofuranyl, 6-azaspiro[2.5]octyl, 3,9-diazaspiro[5.5]undecyl, 2,7-diazaspiro[3.5]nonan-7-yl, 7-azaspiro[3.5]nonyl, 3-azabicyclo[3.2.1]octyl, or 2-azaspiro[3.3]heptan-6-yl.

11. The 1,3,4-oxadiazolinone compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein: The 1,3,4-oxadiazolinone compound is a compound described in any one of the following (1) to (74), (76) to (201), (203) to (227), (229), and (232) to (254), (1) 5-{3-[(4-aminobutyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (2) 5-{3-[(3-aminopropyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (3) 5-{3-[(5-aminopentyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (4) 5-{3-[(6-aminohexyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (5) 5-{3-[(6-aminohexane-2-yl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (6) 5-{3-[4-(aminomethyl)piperidin-1-yl]-4-chlorophenyl}-1,3,4-oxadiazol-2(3H)-one, (7) tert-butyl 4-[2-chloro-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]piperazine-1-carboxylate, (8) 5-[4-chloro-3-(piperazin-1-yl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (9) 5-[3-(4-aminopiperidin-1-yl)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (10) 5-{3-[4-(2-aminoethyl)piperidin-1-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (11) 5-{3-[3-(2-aminoethyl)piperidin-1-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (12) 5-{4-[4-(2-aminoethyl)piperidin-1-yl]-1H-indazol-6-yl}-1,3,4-oxadiazol-2(3H)-one, (13) 5-{3-[4-(1-amino-2-methylpropane-2-yl)piperidin-1-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (14) 5-{3-[4-(2-amino-1-hydroxyethyl)piperidin-1-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (15) 5-[3-(3,9-diazaspiro[5.5]undecane-3-yl)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (16) 5-[3-(2,7-diazaspiro[3.5]nonan-7-yl)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (17) tert-butyl {[2'-chloro-5'-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-3-yl]methyl}carbamate, (18) 5-[3'-(aminomethyl)-6-chloro[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one, (19) tert-butyl {[5'-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl}carbamate, (20) 5-[4'-(aminomethyl)-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one, (21) 5-[3'-(aminomethyl)-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one, (22) 5-[4'-(2-aminoethyl)-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one, (23) 5-{4'-[(piperidin-4-yl)methoxy]-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl}-1,3,4-oxadiazol-2(3H)-one, (24) 5-[4'-{[(2S)-1-aminopropane-2-yl]oxy}-6-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-1,3,4-oxadiazol-2(3H)-one, (25) 5-{3-[5-(piperazin-1-yl)pyridin-3-yl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (26) 5-{3-[2-(piperidin-4-yl)ethyl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (27) 5-[3-{2-[(1r,4s)-4-aminocyclohexyl]ethyl}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (28) 5-[3-{2-[(2r,5r)-5-amino-1,3-dioxane-2-yl]ethyl}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (29) 5-{3-[(piperidin-4-yl)ethynyl]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (30) 5-{3-[(E)-2-(piperidin-4-yl)vinyl]-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (31) 5-{4-chloro-3-[(piperidin-4-yl)amino]phenyl}-1,3,4-oxadiazol-2(3H)-one, (32) 5-(3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one, (33) 5-(3-{[(1s,4s)-4-aminocyclohexyl]amino}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one, (34) 5-[3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (35) 5-(3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-bromophenyl)-1,3,4-oxadiazol-2(3H)-one, (36) 5-[3-{[(1r,4r)-4-aminocyclohexyl]amino}-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (37) 5-[3-{[(1r,4r)-4-(aminomethyl)cyclohexyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (38) 5-[3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, (39) 5-[3-{[(1r,4r)-4-(1-aminoethyl)cyclohexyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (40) 5-(3-{[(1r,4r)-4-aminocyclohexyl]amino}-4-chloro-5-fluorophenyl)-1,3,4-oxadiazol-2(3H)-one, (41) 5-{3-[4-(aminomethyl)anilino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (42) 5-{3-[(6-azaspiro[2.5]octan-1-yl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (43) 5-{3-[(6-aminospiro[3.3]heptane-2-yl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (44) 5-[3-{[(1r,4r)-4-(2-aminoethyl)cyclohexyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (45) 5-[3-{[(1S)-7-azaspiro[3.5]nonan-1-yl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (46) 5-[3-{[(1R)-7-azaspiro[3.5]nonan-1-yl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (47) 5-(4-chloro-3-{[(piperidin-4-yl)methyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (48) 5-[3-{[(piperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (49) 5-[4-chloro-3-({[(3R)-pyrrolidin-3-yl]methyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one, (50) 5-(4-bromo-3-{[(piperidin-4-yl)methyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (51) 5-[3-{methyl[(piperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (52) 5-[3-{[1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (53) 5-[3-({[(3S)-piperidin-3-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (54) 5-[3-({[(3R)-piperidin-3-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (55) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (56) 5-[3-{[1-(piperidin-4-yl)propyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (57) 5-[3-{[(4-methylpiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (58) 5-[3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (59) 5-[3-{[(1R)-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (60) 5-[3-{[2-(piperidin-3-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (61) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one, (62) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one, (63) 5-[3-({1-[(1r,4r)-4-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (64) 5-[3-{[2-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (65) 5-[3-{[2-(piperazin-1-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (66) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, (67) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-methylphenyl]-1,3,4-oxadiazol-2(3H)-one, (68) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-bromophenyl]-1,3,4-oxadiazol-2(3H)-one, (69) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (70) 5-[3-{[2-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (71) 5-[2-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)[1,1'-biphenyl]-4-yl]-1,3,4-oxadiazol-2(3H)-one, (72) 5-[3-({2-[(3R)-3-aminopiperidin-1-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (73) 5-[3-({2-[(3S)-3-aminopiperidin-1-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (74) 5-[3-({[(1s,4s)-4-aminocyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (76) 5-(4-chloro-3-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (77) 5-(4-chloro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (78) 5-(4-bromo-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (79) 5-(3,4-dichloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (80) 5-(4-fluoro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (81) 5-[3-{[1-(piperidin-4-yl)propan-2-yl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (82) 5-(4-methoxy-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (83) 5-(4-bromo-3-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (84) 5-(4-chloro-3-methyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (85) 4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-{[(1S)-1-(piperidin-4-yl)ethyl]amino}benzonitrile, (86) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}amino)-4-chloro-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one, (87) 5-(4,5-dichloro-2-fluoro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (88) 5-(4-chloro-2,5-difluoro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (89) 5-(3,4-difluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (90) 5-[4-(difluoromethyl)-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one, (91) 5-(4-chloro-3-nitro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (92) 5-(3-amino-4-chloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (93) 5-(4,5-dichloro-2-methyl-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (94) 5-(4-chloro-2-methyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (95) 5-(4-chloro-2-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (96) 5-(2,4-dichloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (97) 5-(3-bromo-4-chloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (98) 5-(3-chloro-4-methyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (99) 5-(3-fluoro-4-methyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (100) 5-(4-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-1H-indazol-6-yl)-1,3,4-oxadiazol-2(3H)-one, (101) 5-[4-chloro-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-5-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (102) 5-(4-chloro-3-cyclopropyl-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (103) 5-(3-chloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-4-[(propan-2-yl)oxy]phenyl)-1,3,4-oxadiazol-2(3H)-one, (104) 5-(3-chloro-4-methoxy-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (105) 5-(3-chloro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (106) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (107)5-[3-(pentafluoro-λ 6 -sulfanyl)-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one, (108) 5-[3-{[(4-fluoropiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (109) 5-[3-{[(3-fluoropiperidin-3-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (110) 2-chloro-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}benzonitrile, (111) 5-[3-({(1R)-1-[(1r,4R)-4-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (112) 5-(2-{[(1S)-1-(piperidin-4-yl)ethyl]amino}pyridin-4-yl)-1,3,4-oxadiazol-2(3H)-one, (113) 5-[3-{[(1R)-2,2-difluoro-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (114) 5-[6-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2(3H)-one, (115) 5-[3-{[1-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (116) 5-(4-{[(4-fluoropiperidin-4-yl)methyl]amino}-1H-indazol-6-yl)-1,3,4-oxadiazol-2(3H)-one, (117) 5-[3-({2-[(1r,4r)-4-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (118) (1r,4r)-4-{[5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)anilino]methyl}cyclohexane-1-carboxylic acid tert-butyl ester, (119) (1r,4r)-4-{[5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)anilino]methyl}cyclohexane-1-carboxylic acid, (120) 5-[3-({[(1r,4r)-4-(hydroxymethyl)cyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (121) (1r, 4r)-4-{[5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)anilino]methyl}cyclohexane-1-carboxamide, (122) 5-[3-{[(4-ethylpiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (123) 5-(4-chloro-3-fluoro-5-{[(4-fluoropiperidin-4-yl)methyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (124) 5-{4-bromo-1-[(piperidin-4-yl)methyl]-1H-indazol-6-yl}-1,3,4-oxadiazol-2(3H)-one, (125) 5-[3-{[(1S)-1-(4-fluoropiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (126) 5-[3-({[(3S,4R)-3-fluoropiperidin-4-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (127) 5-[3-({[(3S,4S)-3-fluoropiperidin-4-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (128) 5-[4-(methylsulfonyl)-3-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one, (129) 5-[3-fluoro-5-{[(4-fluoropiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (130) 5-{3-[{[(1r,4r)-4-aminocyclohexyl]methyl}(methyl)amino]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (131) 5-[3-({[(1r,4r)-4-(methylamino)cyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (132) 5-[3-(methyl{[(1r,4r)-4-(methylamino)cyclohexyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (133) 5-[3-{[(3-azabicyclo[3.2.1]octan-8-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (134) 5-[3-({1-[(3S)-pyrrolidin-3-yl]propan-2-yl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (135) 5-[3-({[(1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (136) 5-[3-({1-[(3R)-pyrrolidin-3-yl]propan-2-yl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (137) 5-[3-({(1S)-1-[(1R,3S)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (138) 5-[3-{[(1S)-1-(piperidin-4-yl)propyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one (139) 5-(4-chloro-3-fluoro-5-{[(1S)-1-(piperidin-4-yl)propyl]amino}phenyl)-1,3,4-oxadiazol-2(3H)-one, (140) 5-[3-{[(1R)-2,2-difluoro-1-(4-fluoropiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (141) 5-[3-({[(3R,4R)3-methylpiperidin-4-yl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (142) 5-[3-{[(1S)-1-(7-azaspiro[3.5]nonan-2-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (143) 5-[3-{[(2-methylpiperidin-4-yl)methyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (144) 5-[3-{[(1S)-1-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (145) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (146) 5-[4-(trifluoromethyl)-3-{[(1R)-2,2,2-trifluoro-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one, (147) 5-[4-(trifluoromethyl)-3-{[(1S)-2,2,2-trifluoro-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one, (148) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one, (149) 5-[3-{[(1S)-1-(2-azaspiro[3.3]heptane-6-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (150) 5-[3-({(1S)-1-[(1R,3S)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (151) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (152) 5-[3-{[(1R)-2-fluoro-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (153) 5-[3-({(1S)-1-[(1S,3R)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (154) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-bromophenyl]-1,3,4-oxadiazol-2(3H)-one, (155) 5-[3-({(1S)-1-[(1R,5S,8r)-3-azabicyclo[3.2.1]octan-8-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (156) 5-[3-({(1S)-1-[(1R,5S,8s)-3-azabicyclo[3.2.1]octan-8-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (157) 5-[3-{[(1S)-1-(azepan-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (158) 5-[3-({(1S)-1-[(1R,3S)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one, (159) 5-[3-fluoro-5-{[(1S)-1-(4-fluoropiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (160) 5-[3-fluoro-5-{[(1R)-2-fluoro-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (161) 5-[3-{2-[(2r,5r)-5-amino-1,3-dioxane-2-yl]cyclopropyl}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (162) 5-[3-{[(1S)-1-(azoctan-5-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (163) 5-[3-{[(1R)-2,2-difluoro-1-(4-fluoropiperidin-4-yl)ethyl]amino}-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (164) 5-[3-({(1S)-1-[(1S,3R)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (165) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (166) 5-[3-({[(1R,3S)-3-amino-2,2-dimethylcyclobutyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (167) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-methoxyphenyl]-1,3,4-oxadiazol-2(3H)-one, (168) 5-[3-({(1S)-1-[(1S,3R)-3-amino-2,2-dimethylcyclobutyl]ethyl}amino)-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one, (169) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-chloro-2,5-difluorophenyl]-1,3,4-oxadiazol-2(3H)-one, (170) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (171) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-bromo-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one, (172) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-methylphenyl]-1,3,4-oxadiazol-2(3H)-one, (173) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-ethoxy-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one, (174) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4,5-dichlorophenyl]-1,3,4-oxadiazol-2(3H)-one, (175) 5-{3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-[(propan-2-yl)oxy]phenyl}-1,3,4-oxadiazol-2(3H)-one, (176) 5-[3-({[(1S,3R)-3-amino-2,2-dimethylcyclobutyl]methyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (177) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-chloro-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one, (178) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-4-chloro-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one, (179) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-4,5-dichlorophenyl]-1,3,4-oxadiazol-2(3H)-one, (180) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-5-fluoro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, (181) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]propyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (182) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-5-bromo-4-chlorophenyl]-1,3,4-oxadiazol-2(3H)-one, (183) 5-[3-({(1S)-1-[(1s,3R)-3-aminocyclobutyl]ethyl}amino)-4-chloro-5-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (184) N-[(1S,3R)-2,2-dimethyl-3-{[5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-(trifluoromethyl)anilino]methyl}cyclobutyl]acetamide, (185) 5-[3-{[(1S)-1-(3-aminobicyclo[ 1.1.1]pentan-1-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (186) 5-[3-({(1S)-1-[(2S,3R)-4-aminocuban-1-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (187) 5-[3-{[(1S)-1-(4-aminobicyclo[2.2.1]heptane-1-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (188) 5-[3-({(S)-1-[(2S,5R)-5-aminotetrahydro-2H-pyran-2-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (189) 5-[3-({(1S)-1-[(1r,4S)-4-(methylamino)cyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (190) 5-[3-fluoro-5-({(1S)-1-[(1r,4S)-4-(methylamino)cyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (191) 5-[3-({(1S)-1-[(1R,3S)-3-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (192) 5-[3-({(1S)-1-[(1s,3R)-3-(methylamino)cyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (193) 5-[3-({(1S)-1-[(1r,4S)-4-(ethylamino)cyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (194) 5-[3-({(1S)-1-[(1S,3R)-3-aminocyclohexyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (195) 5-[3-({(1S)-1-[(1s,3R)-3-(ethylamino)cyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (196) 5-[3-{[(1S)-1-{(1s,3R)-3-[(cyclopropylmethyl)amino]cyclobutyl}ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (197) 5-[3-{[(1S)-1-{(1r,4S)-4-[(2,2,2-trifluoroethyl)amino]cyclohexyl}ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (198) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]propyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (199) 5-[3-({(1S)-1-[(1S,3R)-3-aminocyclopentyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (200) 5-[3-({(1S)-1-[(1R,3S)-3-aminocyclopentyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (201) 5-[3-{[(1S)-1-{(1r,4S)-4-[(2-hydroxyethyl)amino]cyclohexyl}ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (203) 5-[3-fluoro-5-({(1S)-1-[(1s,3R)-3-(methylamino)cyclobutyl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (204) 5-[3-fluoro-5-({(1S)-1-[(1r,4S)-4-(methylamino)cyclohexyl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, (205) 5-(4-chloro-3-{[methyl(piperidin-4-yl)amino]methyl}phenyl)-1,3,4-oxadiazol-2(3H)-one, (206) 5-[3-fluoro-5-{[(1S)-1-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (207) 5-[3-fluoro-5-{[(1S)-1-(4-methylpiperidin-4-yl)ethyl]amino}-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, (208) 5-[3-fluoro-5-({(1S)-1-[(1s,3R)-3-(methylamino)cyclobutyl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, (209) 5-[3-{[(1S)-2-fluoro-1-(4-fluoropiperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (210) 5-[3-fluoro-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (211) 5-[3-fluoro-5-({(1S)-1-[(3R,4R)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (212) 5-[4-(difluoromethoxy)-3-fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one, (213) 5-[4-(difluoromethoxy)-3-fluoro-5-{[(1S)-1-(4-methylpiperidin-4-yl)ethyl]amino}phenyl]-1,3,4-oxadiazol-2(3H)-one, (214) 5-[4-(difluoromethoxy)-3-fluoro-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one, (215) 5-(3-{[(1-acetylpiperidin-4-yl)(methyl)amino]methyl}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one, (216) 5-[4-(difluoromethoxy)-3-fluoro-5-({(1S)-1-[(2R,4R)-2-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one, (217) 5-[3-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (218) 5-[3-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, (219) 5-[3-fluoro-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, (220) 5-[4-(difluoromethoxy)-3-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl-1,3,4-oxadiazol-2(3H)-one, (221) 5-[4-chloro-3-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one, (222) 5-[4-chloro-3-fluoro-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one, (223) 5-[3-fluoro-5-({(1S)-1-[(3S,4R)-3-fluoropiperidin-4-yl]ethyl}amino)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (224) 5-[3-fluoro-5-({(1S)-1-[(3S,4R)-3-fluoropiperidin-4-yl]ethyl}amino)-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, (225) 5-[3-({(1S)-1-[(3S,4S)-3-ethylpiperidin-4-yl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (226) 5-[3-({(1S)-1-[(3R,4R)-3-ethylpiperidin-4-yl]ethyl}amino)-5-fluoro-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (227) 5-[3-fluoro-5-({(1S)-1-[(3S,4R)-3-fluoropiperidin-4-yl]ethyl}amino)-4-methylphenyl]-1,3,4-oxadiazol-2(3H)-one, (229) 5-[3-({(1S)-1-[(3S,4S)-3-ethylpiperidin-4-yl]ethyl}amino)-5-fluoro-4-methylphenyl]-1,3,4-oxadiazol-2(3H)-one, (232) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-(prop-1-en-2-yl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (233) 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-5-fluoro-4-(propan-2-yl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (234) 5-[3-({[(1r,4r)-4-aminocyclohexyl]methyl}sulfanyl)-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (235) 5-{4-bromo-3-[(piperidin-4-yl)methoxy]phenyl}-1,3,4-oxadiazol-2(3H)-one, (236) 5-{4-bromo-3-[1-(piperidin-4-yl)ethoxy]phenyl}-1,3,4-oxadiazol-2(3H)-one, (237) 5-(3-{1-[(1r,4r)-4-aminocyclohexyl]ethoxy}-4-bromophenyl)-1,3,4-oxadiazol-2(3H)-one, (238) 5-(3-{[(1r,4r)-4-aminocyclohexyl]methoxy}-4-bromophenyl)-1,3,4-oxadiazol-2(3H)-one, (239) 5-{3-[1-(piperidin-4-yl)ethoxy]-4-(trifluoromethyl)phenyl}-1,3,4-oxadiazol-2(3H)-one, (240) 5-[3-{[(1r,4r)-4-aminocyclohexyl]methoxy}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, (241) 5-(3-{[(1r,4r)-4-aminocyclohexyl]methoxy}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one, (242) 5-(4-chloro-3-{[(1s,3s)-3-(piperazin-1-yl)cyclobutyl]methoxy}phenyl)-1,3,4-oxadiazol-2(3H)-one, (243) 5-(3-{[(1s,4s)-4-aminocyclohexyl]methoxy}-4-chlorophenyl)-1,3,4-oxadiazol-2(3H)-one, (244) 5-(1-{[(1r,4r)-4-aminocyclohexyl]methyl}-1,2,3,4-tetrahydroquinolin-7-yl)-1,3,4-oxadiazol-2(3H)-one, (245) 5-fluoro-1-{(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}-7-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2,3-dihydroquinolin-4(1H)-one, (246) 5-[(4E)-5-fluoro-4-(methoxyimino)-1-{(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}-1,2,3,4-tetrahydroquinolin-7-yl]-1,3,4-oxadiazol-2(3H)-one, (247) 5-(4-{(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3,4-oxadiazol-2(3H)-one, (248) 5-{8-fluoro-4-[(1S)-1-(piperidin-4-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl}-1,3,4-oxadiazol-2(3H)-one, (249) 5-(4-{(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}-8-fluoro-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-1,3,4-oxadiazol-2(3H)-one, (250) 5-{(2R)-8-fluoro-2-methyl-4-[(1S)-1-(piperidin-4-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl}-1,3,4-oxadiazol-2(3H)-one, (251) 5-{(2S)-8-fluoro-2-methyl-4-[(1S)-1-(piperidin-4-yl)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-6-yl}-1,3,4-oxadiazol-2(3H)-one, (252) 5-[(2S)-4-{(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}-8-fluoro-2-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-1,3,4-oxadiazol-2(3H)-one, (253) 5-[(2R)-4-{(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}-8-fluoro-2-methyl-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-1,3,4-oxadiazol-2(3H)-one, (254) 5-{9-fluoro-5-[(1S)-1-(piperidin-4-yl)ethyl]-2,3,4,5-tetrahydro-1,5-benzoxazepine -7-yl}-1,3,4-oxadiazol-2(3H)-one.

12. 5-[3-Fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

13. 5-[3-Fluoro-5-{[(1S)-1-(piperidin-4-yl)ethyl]amino}-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

14. 5-[3-Fluoro-4-methyl-5-({(1S)-1-[(3S,4S)-3-methylpiperidin-4-yl]ethyl}amino)phenyl]-1,3,4-oxadiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

15. 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-cyclopropyl-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

16. 5-[3-({(1S)-1-[(1r,4S)-4-aminocyclohexyl]ethyl}amino)-4-ethyl-5-fluorophenyl]-1,3,4-oxadiazol-2(3H)-one, or a pharmaceutically acceptable salt thereof, or a solvate thereof.

17. A pharmaceutical composition comprising the 1,3,4-oxadiazolinone compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient.

18. A PIM kinase inhibitor comprising the 1,3,4-oxadiazolinone compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient.

19. PIM kinases are involved in multiple sclerosis, rheumatoid arthritis, food allergies, asthma, systemic lupus erythematosus, lupus nephritis, inflammatory bowel disease, ulcerative colitis, atopic dermatitis, autoimmune lymphoproliferative syndrome, chronic obstructive pulmonary disease, allergic respiratory disease, eosinophilic granulomatosis with polyangiitis, eosinophilic syndrome, chorioamnionitis, ankylosing spondylitis, myasthenia gravis, psoriasis, prostate cancer, colorectal cancer, esophageal cancer, ovarian cancer, uterine cancer, kidney cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, glioma, osteosarcoma, bladder cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia disease, B-cell lymphoma, multiple myeloma, T-cell lymphoma, skin cancer, Kaposi's sarcoma, Hodgkin's lymphoma, myeloproliferative neoplasms, adenoid cystic carcinoma, Ewing's sarcoma, adult T-cell leukemia, mesothelioma, acute promyelocytic leukemia, choriocarcinoma, liposarcoma, neuroblastoma, seminoma, lymphoblastic lymphoma, Epstein-Barr virus infection or hemophagocytic syndrome known to involve Epstein-Barr virus, influenza, hepatitis C, salmonella infection, herpes virus infection, vaginal Trichomonas infection, human granulocytic ehrlichiosis, aplastic anemia, atherosclerosis, pulmonary hypertension, diabetes, prostatic hypertrophy or Alzheimer's disease, wherein The composition comprises the 1,3,4-oxadiazolinone compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient.

Citation Information

Patent Citations

  • Process for isolating rubbers

    EP0002015A1

  • Anodes for electrochemical purposes

    EP0002017A1

  • Muscarinic receptor antagonists

    WO2006035303A1

  • Process for making substituted piperidines

    WO2006069287A1

  • 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as SMO antagonists

    WO2010013037A1